summary,text
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by another illness they have or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 86 out of 93 patients (93%) had at least 1 medical problem, including 35 out of 38 patients (92%) with val30met who received tafamidis only in their previous study, 33 out of 37 patients (89%) with val30met who received placebo followed by tafamidis in their previous study, and 18 out of 18 patients (100%) without val30met who received tafamidis in their previous study. a total of 6 patients (7%) left the study due to medical problems, including 3 patients (8%) with val30met who received tafamidis in their previous study, 1 patient (3%) with val30met who received placebo followed by tafamidis in their previous study, and 2 patients (11%) without val30met who received tafamidis in their previous study. the most common medical problems are listed below. ","  safety results: brief summary and incidence of treatment-emergent adverse events a total of 692 all-causality teaes were reported during the study (table s4), of which 40 were treatment-related teaes (table s5). a total of 86 (92.5%) participants experienced at least 1 all-causality teae, and 25 (26.9%) participants experienced at least 1 all-causality treatment-emergent serious adverse event (sae). however, a lower proportion of participants experienced treatment-related teaes (23 [24.7%] participants), and 1 (1.1%) participant experienced at least 1 treatment-related sae. a total of 21 (22.6%) participants experienced at least 1 all-causality severe teae; the incidence of treatment-related severe teaes was low (2 [2.2%] participants). a total of 6 (6.5%) participants discontinued study drug due to all-causality teaes, of which 1 (1.1%) participant discontinued study drug due to treatment-related teae. a total of 8 (8.6%) participants required temporary discontinuation of study drug due to all-causality teaes, of which 2 (2.2%) participants temporarily discontinued study drug due to treatment-related teaes. subjects with temporary discontinuation due to adverse events imply those subjects that had study drug interrupted.treatment-emergent adverse event is defined as an event which began after enrollment in b3461023 (fx1a-303) or which worsened during the course of b3461023 (fx1a-303). of note, the teae of fall was reported in 12 (66.7%) non-val30met participants and 1 (2.6%) t-t val30met participant. the most frequently reported treatment-related teaes in participants were oedema peripheral (1 [2.6%] t-t val30met and 1 [5.6%] non-val30met group) and urinary tract infection (1 [2.6%] t-t val30met and 1 [2.7%] p-t val30met group). permanent discontinuations due to adverse events a total of 6 (6.5%) participants discontinued study drug due to all-causality aes, of which 1 (1.1%) participant in the t-t val30met group discontinued study drug due to treatment- related teae. deaths the 8 deaths during the study or within 28 days after the last dose of tafamidis were cardiac failure (1 t-t val30met), ileus (1 p-t val30met), cardiac arrest (1 non-val30met), sepsis (1 non-val30met), and amyloidosis (2 non-val30met). in addition, 1 t-t val30met participant died from lymphoma 10 days after last dose of tafamidis, and 1 non-val30met participant died after heart transplant 18 days after the last dose of tafamidis. one t-t val30met participant died from central nervous system lymphoma approximately 4.5 months after the last dose of tafamidis, 1 non-val30met participant completed suicide approximately 1.5 years after the study reporting period, and 1 non-val30met participant died from an unknown cause approximately 2 years after the study reporting period."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. to do this, the researchers looked to see what medical problems occurred in the 127 participants originally treated in study b1801014 and the medical problems that were seen in the 109 participants who continued in this long-term study during the entire 10-year study period (up to 2 years in study b1801014 and up to 8 years in study b1801023). there were 106 out of the 127 (84%) participants who had at least 1 medical problem if infections and injection site reactions were not counted. the most common medical problems  those reported by 10% or more participants overall and excluding infections and injection site reactions  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 10% or more participants are listed.  the 2nd column tells how many of the 127 participants taking etanercept reported each medical problem. next to this number is the percentage of the 127 participants taking the study medication who reported the medical problem.  using these instructions, you can see that 19 out of the 127 (15%) participants taking etanercept reported joint pain. the researchers also grouped medical problems together to see what different types of medical problems were commonly seen in this study. this showed 111 out of 127 (87%) participants had infections, 45 out of 127 (35%) had problems with their tummy or intestines, 21 out of 127 (17%) participants had infections considered preventable by vaccination in participants not previously vaccinated, and 16 out of 127 (13%) participants had injection site reactions (eg, pain, redness, swelling, and/or itching). a total of 14 participants left the study because of medical problems (11%) if infections and injection site reactions were not counted. ","  safety results: safety data were cumulative and included combined data for all participants collected in the parent study (2 years) and extension study (8 years), over a period of approximately 10 years. primary analysis: the primary endpoint in this extension study was the occurrence of malignancy over the course of the study. up to the database release date of 03 march 2021, 1 malignancy was reported. participant with eojia, who started etanercept treatment on study experienced an sae of hodgkins disease during the active treatment period of the extension study. there were no relevant risk factors for malignancy, and the participant had on (day 132 of the extension study), the participant presented with a mediastinal mass and a swollen lymph node at the side of neck. d. in study b1801014, 1 additional event of crohns disease was reported but was not considered treatment-emergent based on missing data for the last dose. the majority of the ip-related teaes were of mild (9.4% participants) or moderate (10.2% participants) severity. ip-related severe disease in 1 participant; uveitis in another participant; and colitis, crohns disease, intestinal perforation, and pneumoperitoneum in the third participant. injection site reactions overall, at least 1 isr was reported in 16 (12.60%) participants comprising of 8 (13.33%) eojia participants, 6 (15.79%) era participants, and 2 (6.90%) psa participants. infections at least 1 treatment-emergent infection was reported in 108 (85.0%) participants in the overall population, comprising of 53 (88.3%) eojia participants, 31 (81.6%) era participants, and 24 (82.8%) psa participants. the highest exposure-adjusted rate (by pt) of treatment-emergent infections reported in this category was for upper respiratory tract infections at 24.59 ep100py with 168 events. treatment-emergent infections considered ip-related were reported in 29 (22.8%) participants, including severe infections of appendicitis and peritonitis in 1 eojia participant, and septic shock in another eojia participant. infections causing ip withdrawal were bronchopneumonia, pyelocystitis, and sepsis that were reported in 1 participant each. at least 1 treatment-emergent sae (excluding infections and isrs) was reported in 30 (23.6%) participants corresponding to an exposure-adjusted rate of 40 (5.85 ep100py) events. at least 1 treatment-emergent serious infection was reported in 11 (8.7%) participants. infections considered preventable by vaccination among the participants with a prior history of vaccination, 1 eojia participant experienced a rubella infection in year 1 in the parent study. among the participants with no history of vaccination, 21 (16.5%) participants experienced an infection considered preventable by vaccination, including influenza and varicella infection that were reported in 11 (8.7%) participants and 8 (6.3%) participants, respectively."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. a total of 66% (402 out of 605) of participants had at least 1 medical problem, including 68% (336 out of 491) of participants under 17 years old, and 58% (66 out of 114) of participants 17 years or older. a total of 18 (3%) participants left the study because of medical problems. the most common medical problems are listed on the following page.  ","  safety results: the overall median daily dose was 204.64 mg/day (range 21.9 mg/day to 562.7 mg/day). the median daily dose was lowest in the youngest subjects (1 month to <2 years of age, 115.60 mg/day), and was highest in subjects 10 to 16 years of age (308.90 mg/day). treatment-emergent adverse events (all causalities) - safety analysis set source: table 14.3.1.2.1 a. one of these subjects died due to this event. includes data up to 999 days after last dose of study drug. except for the number of adverse events subjects are counted only once per treatment in each row. serious adverse events - according to the investigators assessment. severity counts are based on the maximum severity or grade of events. in the overall population, aes reported in at least 10% of subjects were upper respiratory tract infection and pyrexia. upper respiratory tract infection and pyrexia were the most frequently reported aes (reported in at least 10% of subjects) in subjects 1 month to 16 years of age; the most frequently reported aes (reported in at least 10% of subjects) in subjects  17 years of age were headache, dizziness, and somnolence. in total, 18 (3.0%) subjects discontinued due to aes: 12 (2.4%) subjects 1 month to 16 years of age and 6 (5.3%) subjects 17 years of age. seventeen of these subjects discontinued due to treatment-emergent aes. the soc with the most aes leading to discontinuation was the nervous system disorders soc (8 aes for 8 subjects), of which the majority were due to a seizure- or epilepsy-related event. there were a total of 7 deaths; 6 deaths occurred during the study and 1 death occurred approximately 9 months after the subject had completed the study. no deaths were considered related to study drug by the investigator. pneumonia was the most frequently reported sae, with 32 events during the study in 23 subjects. two subjects had saes of suicide attempt and were permanently discontinued from the study, one due to the outcome of an mhra and one due to ongoing psychological and behavioral issues. one additional subject was discontinued from the study due to an ae of suicidal ideation. pregabalin treatment resulted in an overall reduction in median 28-day seizure rate for pos and pgtc seizures. there were no clinically significant findings for laboratory results, physical and neurological examinations, cognitive function, vital signs (blood pressure and pulse rate), and ecgs. conclusion(s): long-term use of pregabalin in this study was generally safe and well tolerated and consistent with the well-established safety profile of pregabalin for patients with pos."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. 780 out of 944 (83%) participants in this study had at least 1 medical problem.  154 out of 175 (88%) participants who received tofacitinib 5 mg had a medical problem.  626 out of 769 (81%) participants who received tofacitinib 10 mg had a medical problem. a total of 196 out of 944 (21%) participants left the study because of medical problems.  30 out of 175 (17%) participants who received tofacitinib 5 mg left the study because of a medical problem.  166 out of 769 (22%) participants who received tofacitinib 10 mg left the study because of a medical problem. the most common medical problems  those reported by at least 10% of participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 10% of participants are listed.  the 2nd column tells how many of the 175 participants taking tofacitinib 5 mg reported each medical problem. next to this number is the percentage of the 175 participants taking tofacitinib 5 mg who reported the medical problem.  the 3rd column tells how many of the 769 participants taking tofacitinib 10 mg reported each medical problem. next to this number is the percentage of the 769 participants taking tofacitinib 10 mg who reported the medical problem.  using these instructions, you can see that 41 out of the 175 (23%) participants taking tofacitinib reported a common cold. a total of 157 out of 769 (20%) participants taking tofacitinib 10 mg reported common cold. ","  safety results:  the proportion of participants who experienced all-causality treatment-emergent adverse events (teaes) was similar between the treatment groups (table s4).  the majority of reported all-causality teaes mild to moderate in both treatment groups, and the proportion of participants with severe teaes was similar between treatment groups.  the proportion of participants with serious adverse events (saes) in each treatment group were similar.  the proportion of participants who discontinued the study due to aes in the tofacitinib was similar between treatment groups.  the proportion of participants with temporary discontinuations was similar between treatment groups.  the proportions of participants with dosage of lipid-lowering agents increased during the study were similar between the two treatment groups.  the mean duration of treatment was approximately 1305 days for the tofacitinib 5 mg bid group and approximately 823 days for the tofacitinib 10 mg bid group.  most aes were mild to moderate in severity.  the most frequent ae leading to discontinuation was colitis ulcerative (worsening of uc).  six (6) participant deaths occurred during the study, all in the tofacitinib 10 mg bid group.  the most frequent saes were colitis ulcerative and condition aggravated (worsening of uc).  proportions of infection teaes were similar in both treatment groups.  proportions of serious infection aes and treatment-emergent herpes zoster aes were similar in both treatment groups.  proportions of adjudicated ois, cardiovascular/neurovascular events, and gi perforations (all cases) were similar between the two treatment groups. proportions of mace and malignancy events were slightly higher in the tofacitinib 5 mg bid group, while the proportion of te events was slightly higher in the tofacitinib 10 mg bid group. regarding adjudicated hepatic injury events, proportions of mild events were similar between the two treatment groups, while proportions of moderate events were slightly higher in the tofacitinib 5 mg bid group and proportions of severe events were slightly higher in the tofacitinib 10 mg bid group.  the proportions of participants with dosage of lipid-lowering agents increased during the study were similar between the two treatment groups. participants in the maintenance remission and other maintenance completers subpopulations maintained hrqol, while those participants in the maintenance treatment failures and induction non-responders subpopulations experienced an improvement in hrqol. safety this study demonstrated that tofacitinib administered as 5 mg bid or 10 mg bid had an acceptable safety profile and was well tolerated during long-term therapy for uc.  most aes were mild to moderate in severity. the proportions of participants with aes, saes, and serious infection aes were similar between the tofacitinib 5 mg bid and tofacitinib 10 mg bid dose groups.  proportions of adjudicated ois, cardiovascular/neurovascular events, and gi perforations (all cases) were similar between the two treatment groups.  six deaths were reported in this study, all in the tofacitinib 10 mg bid group."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. during phase 1, all patients in this study had at least 1 medical problem. a total of 20 patients left the study because of medical problems. the most common medical problems during phase 1 are listed below. to view the full list of medical problems reported by 5% or more of patients, please visit www.clinicaltrials.gov or www.clinicaltrialsregister.eu and use the study identifier information found at the end of this summary.  during phase 2, all of the patients in this study had at least 1 medical problem. a total of 65 patients left the study because of medical problems. the most common medical problems during phase 2 are listed below. to view the full list of medical problems reported by 5% or more of patients, please visit www.clinicaltrials.gov or www.clinicaltrialsregister.eu and use the study identifier information found at the end of this summary. "," methods study design: this was a phase 1b/2, open-label, international, multi-center, safety and efficacy study of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin), low dose ara-c (ldac), or decitabine in previously untreated patients with acute myeloid leukemia (aml) or high-risk myelodysplastic syndrome (mds). newly diagnosed and previously untreated patients were eligible, as well as those who may have had 1 prior regimen with commercially available agent(s) for their antecedent hematologic disease (ahd). results subject disposition and demography: phase 1b the patient disposition for phase 1b portion is summarized in table s1. nine (9) patients completed the phase 1b portion of the study. treated: patients received at least 1 non-zero dose of glasdegib or backbone chemotherapy. treatment completed: unfit patients who completed treatment for 1 year (12 cycles) with ldac or decitabine, or fit patients who completed induction, consolidation (cytarabine/daunorubicin), and 6 cycles of maintenance therapy and no other reason for discontinuation applied. abbreviations: ae=adverse event; ldac=low dose ara-c. a. in march 2013, all active patients receiving glasdegib 200 mg were required to reduce dose to 100 mg. patients who had glasdegib dose reduction were reported as the starting glasdegib dose level received. phase 2 unfit (non-intensive) the patient disposition for the phase 2 unfit arms is summarized in table s2. two (2 [2.4%]) patients in the glasdegib 100 mg+ldac arm completed study treatments. the main reasons for discontinuations from study treatments (glasdegib 100 mg and ldac for the glasdegib 100 mg+ldac arm and ldac for the ldac alone arm) were insufficient clinical response, adverse events (aes, regardless of causality) and deaths. four (4 [4.5%]) and 1 (2.3%) patients completed the study in the glasdegib 100 mg+ldac arm and ldac alone arm, respectively. treated: patients received at least 1 non-zero dose of glasdegib or ldac. phase 2 fit (intensive) the patient disposition for the phase 2 fit arm by age (55 versus <55 years) is summarized in table s3. eighteen (18) patients completed the phase 2 fit portion of the study. treated: patients received at least 1 non-zero dose of glasdegib or cytarabine/daunorubicin. efficacy results: phase 1b overall survival (os; secondary endpoint): twenty-one (21 [91.3%]) deaths were reported in arm a, the estimated median os was 4.4 (80% confidence interval [ci]: 2.5, 6.6) months. the lower bound of 80% ci was 14.5 months and the upper bound of 80% ci was not estimable, as 10 (45.5%) patients were censored for no longer being followed for survival. phase 2 unfit (non-intensive) all the p-values reported in the supplemental csr were 1-sided unless specified otherwise."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. during the efficacy phase (first 12 weeks of treatment), a total of 76 out of 124patients in group 1 (61%) had at least 1 medical problem. in the fesoterodine 4 mg tablet group, 26 out of 42 patients (62%) had a medical problem. in the fesoterodine 8 mg tablet group, 20 out of 42 patients (48%) had a medical problem. in the oxybutynin xl group, 30 out of 40 patients (75%) had a medical problem. three out of 42 patients in the fesoterodine 4 mg tablet group (7%) left the study because of medical problems. a total of 67 patients in group 1 received fesoterodine during both the efficacy phase and the safety extension phase. 46 of these patients (69%) had at least 1 medical problem. one of these patients (1%) left the study because of medical problems. the most common medical problems are listed below.  during the efficacy phase (first 12 weeks of treatment), a total of 37 out of 57patients in group 2 (65%) had at least 1 medical problem. in the fesoterodine 2 mg capsule group, 19 out of 28 patients (68%) had a medical problem. in the fesoterodine 4 mg capsule group, 18 out of 29 patients (62%) had a medical problem. three out of 28 patients in the fesoterodine 2 mg capsule group (11%) left the study because of medical problems. a total of 57 patients in group 2 received fesoterodine during either the efficacy phase or the safety extension phase. 44 of these patients (77%) had at least 1 medical problem. three of these patients (5%) left the study because of medical problems. the most common medical problems are listed below.  ","  safety results: for cohort 1 during the active comparator phase, teaes were reported for 61.9% of subjects in the fesoterodine 4 mg arm, 47.6% of subjects in the fesoterodine 8 mg arm, and 75.0% of subjects in the oxybutynin arm (table s6). during the active comparator phase, treatment-related teaes were reported for 28.6% of subjects in the fesoterodine 4 mg arm, 23.8% of subjects in the fesoterodine 8 mg arm, and 37.5% of subjects in the oxybutynin arm. there were no treatment-related saes, and treatment-related severe teaes were reported for 1 subject (2.4%) in the fesoterodine 4 mg arm, no subjects in the fesoterodine 8 mg arm, and 2 subjects (5.0%) in the oxybutynin arm. among subjects who received at least 1 dose of fesoterodine in both the active comparator and safety extension phases of cohort 1, teaes were reported for 76.7% of subjects in the fesoterodine 4 mg arm and 62.2% of subjects in the fesoterodine 8 mg arm (table s7). among subjects who received at least 1 dose of fesoterodine in both the active comparator and safety extension phases of cohort 1, treatment-related teaes were reported for 33.3% of subjects in the fesoterodine 4 mg arm and 29.7% of subjects in the fesoterodine 8 mg arm. for cohort 2 during the efficacy phase, teaes were reported for 67.9% of subjects in the fesoterodine 2 mg bic arm and 62.1% of subjects in the fesoterodine 4 mg bic arm (table s8). for cohort 2 during the overall study, teaes were reported for 75.0% of subjects in the fesoterodine 2 mg bic arm and 79.3% of subjects in the fesoterodine 4 mg bic arm (table s9). the incidence of dose reduction or temporary discontinuations (interruption) of study drug due to teaes was low in the 2 arms in cohort 2. during the overall study, treatment-related teaes were reported for 32.1% of subjects in the fesoterodine 2 mg bic arm and 10.3% of subjects in the fesoterodine 4 mg bic arm.  tier 1 treatment-emergent adverse events: for subjects in cohort 1 during the active comparator phase, the incidence of dry mouth was significantly higher in the oxybutynin arm (11 subjects [27.5%]) than in the fesoterodine 4 mg (3 subjects [7.1%]) and fesoterodine 8 mg arms (4 subjects [9.5%]) (p=0.0155 and p=0.0406, respectively).  tier 2 treatment-emergent adverse events: for subjects in cohort 1 during the active comparator phase, the incidence of dry mouth was numerically higher in the oxybutynin arm (11 subjects [27.5%]) than in the fesoterodine 4 mg (3 subjects [7.1%]) and fesoterodine 8 mg arms (4 subjects [9.5%]) (upper limit of the 95% ci for the risk difference was <0)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. a total of 41 out of the 59 patients in this study had at least 1 medical problem and 8 patients did not finish the study treatment because of medical problems. this included 14%, or 4 out of 29 patients in the sildenafil group and 13%, or 4 out of 30 patients in the placebo group. the most common medical problems are listed in the following table. ","  safety results: teaes of all causalities, serious teaes, severe teaes and discontinuations due to aes were reported in the iv sildenafil group in 22 (75.9%) subjects, 7 (24.1%) subjects, 9 (31.0%) subjects, and 4 (13.8%) subjects, respectively. teaes of all causalities, serious teaes, severe teaes and discontinuations due to aes were reported in the placebo group in 19 (63.3%) subjects, 2 (6.7%) subjects, 7 (23.3%) subjects), and 4 (13.3%) subjects, respectively. in the iv sildenafil group, the most common teaes of all causalities by preferred term were hypotension (8 [27.6%] subjects), hypokalaemia (7 [24.1%] subjects), anaemia and drug withdrawal syndrome (4 [13.8%] subjects each), and bradycardia (3 [10.3%] subjects). in the placebo group, the most common teaes by preferred term were pneumothorax (4 [13.3%] subjects), anaemia, oedema, hyperbilirubinaemia, c-reactive protein increased, and hypotension (3 [10.0%] subjects each). treatment-related teaes were reported in 9 (31.0%) subjects in the iv sildenafil group and in 4 (13.3%) subjects in the placebo group. a treatment-related sae was reported for 1 (3.4%) subject and severe treatment-related aes were reported for 2 (6.9%) subjects in the iv sildenafil group; no treatment-related saes and severe treatment-related aes were reported for the placebo group. the incidence of all causalities teae of hypotension was higher in the iv sildenafil group compared to the placebo group (8 [27.6%] out of 29 subjects versus 3 [10.0%] out of 30 subjects). the teae of hypotension occurred during the first 24 hours of study treatment for all the 8 subjects in the iv sildenafil group and 1 out of 3 subjects in the placebo group. teaes of tier-2 events were reported for some subjects in the study, and the 95% cis for all risk differences include 0. three (3) deaths were reported during the study, 2 subjects died in the iv sildenafil group and 1 subject died in the placebo group. over the study duration, treatment-emergent saes of all causalities were reported in 7 (24.1%) subjects in the iv sildenafil group and in 2 (6.7%) subjects in the placebo group. of these, a treatment-related sae was reported in 1 (3.4%) subject in the iv sildenafil group (sae of hypotension, leading to permanent discontinuation from study drug treatment); no treatment related saes were reported in the placebo group (table s6). aes leading to permanent discontinuations from study treatment were reported for 8 subjects, the incidence was comparable between the treatment groups with 4 (13.8%) in the iv sildenafil group and 4 (13.3%) in the placebo group (table s6)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. one-hundred and twenty-seven (127) out of 127 patients in this study had at least 1 medical problem. a total of 11 patients (9%) stopped treatment because of medical problems. the most common medical problems are listed below. "," a total of 30 (23.6%) patients had at least 1 dose reduction. adverse events all patients had at least 1 all-causality ae during the study. most patients (97.6%) had at (sae), of which 11 were considered treatment-related. grade 5 aes were reported in 15 (11.8%) patients, and 1 of them was considered treatment-related. all-causality aes leading to permanent discontinuation of crizotinib, dosing interruptions, or dose reductions were reported in 8.7%, 44.1%, and 18.9% of patients, respectively (table s5). one patient experienced an adverse event (diarrhoea, relationship = reasonable possibility) which had been entered into the database in error as leading to permanent treatment discontinuation. a total of 10 (7.9%) patients had aes leading to permanent discontinuation of crizotinib, and a total of 2 patients had treatment-related aes leading to permanent discontinuation of crizotinib, and the aes were chronic kidney disease and hepatotoxicity (1 each). the most frequently reported (2%) treatment-related aes leading to dose reductions were the same as all-causality aes, and the aes were elevated transaminases, decreased appetite, fatigue neutropenia, and renal cyst. treatment-related aes associated with dosing interruptions were reported for 39 (30.7%) patients, including all 15 patients with neutropenia, 9 of the 10 patients with elevated transaminases and 2 of the 8 patients with pneumonia. deaths overall, 65 (51.2%) patients died during the study, and 1 death occurred within 30 days after the first dose. there were in total 15 patients with grade 5 aes (disease progression [n=7], respiratory failure [n=4], pneumonia [n=2], lung neoplasm malignant [n=1] ,and road traffic accident [n=1]), of which 1 (respiratory failure) was considered treatment-related. treatment-related saes were reported in 11 (8.7%) patients. shifts in blood chemistry parameters from grade 2 at baseline to grade 3 or grade 4 postbaseline (2% of patients) were observed for hyperuricemia (26.2%), hypophosphatemia (11.1%), alt increased (7.0%), hyponatremia (9.4%), hypokalemia (4.7%), ast increased (4.7%), and hypoalbuminemia (2.4%). vital signs overall, 1 (0.8%) patient had a pulse rate 120 bpm and 7 (5.5%) patients had a pulse rate 50 bpm while on treatment. decreases of 40 mmhg in dbp from baseline were reported for 2 (1.6%) patients and decreases of 60 mmhg in sbp from baseline were reported for 2 (1.6%) patients. electrocardiogram most patients (90.3%) had a maximum qtcf of 450 msec during the study, a maximum qtcf 500 msec was reported for 3 (2.4%) patients, and qtcf 60 msec increase from baseline were reported for 7 (5.6%) patients."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems over time, doctors may be able to understand what the side effects of an experimental drug might be. a total of 405 out of 412 patients in this study who received at least 1 dose of study medication had at least 1 medical problem (282 out of 286 on talazoparib and 123 out of 126 on chemotherapy). most medical problems were manageable by lowering the dose of talazoparib or chemotherapy medications. the most common medical problems reported by patients in this study are listed below.  "," among the reported aes associated with myelosuppression, anaemia was the most frequently reported preferred term in the talazoparib arm, occurring in 54.2% of patients compared with 19.0% of patients in the pct arm. neutropenia was the most frequently reported preferred term in the pct arm (30.2% of patients versus 27.3% of patients in the talazoparib arm). grade 3 or 4 aes were reported for 70.3% of patients in the talazoparib arm and 64.3% of patients in the pct arm. aes related to mds identified by the broad search of the standardized medical dictionary for regulatory activities (meddra) query (smq) myelodysplastic syndrome were reported for 3 (1.0%) patients in the talazoparib arm and no events were reported by patients in the pct arm. in the talazoparib arm, 11.5% of patients had at least 1 hepatotoxicity-related ae, versus 21.4% of patients in the pct arm. as of the lslv date in the safety population, 320 patients (77.7%) had died, 220 patients (76.9%) in the talazoparib arm and 100 patients (79.4%) in the pct arm. five additional deaths in the talazoparib arm and 1 additional death in the pct arm were reported since the data cutoff date of the os supplemental csr. of these fatal aes, 2 events were considered by the investigator to be related to study drug, including venoocclusive liver disease (1 patient in the talazoparib arm) and sepsis (1 patient in the pct arm who received capecitabine). three additional saes were reported since the data cutoff date of the os supplemental csr: cellulitis in 1 patient, and pancytopenia and myelodysplastic syndrome in another patient who was subsequently diagnosed with aml after the safety reporting period of 30 days after last dose. anaemia was the most frequently reported sae in the talazoparib arm (18 patients [6.3%]), whereas pleural effusion was the most frequently reported sae in the pct arm (7 patients [5.6%]). study drug-related saes were reported for 31 patients (10.8%) in the talazoparib arm and 11 patients (8.7%) in the pct arm. an additional ae of pancytopenia was reported in 1 (0.3%) patient in the talazoparib arm since the data cutoff date of the os supplemental csr. aes associated with permanent study drug discontinuation in more than 1 patient in either treatment arm were anaemia (3 patients [1.0%]) and metastases to the central nervous system (cns) (2 patients [0.7%]), both in the talazoparib arm. a total of 20.3% of patients in the talazoparib arm and 23.8% of patients in the pct arm were reported to have aes associated with dose reduction."
" the researchers recorded medical problems the children had during the study. children could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study vaccine, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. out of 243 children who participated in the persistence phase, 2 children (less than 1%) left the study because of medical problem. the study doctors determined that these medical problems were not related to the study vaccines. during the booster phase, the researchers recorded medical problems that occurred within 31 days of receiving the booster vaccine. out of 181 children who participated in this phase, 59 children (33%) had a medical problem that the study doctors determined was related to the vaccine. this included 16 children (24%) in group 1, 5 children (31%) in group 2, 27 children (35%) in group 3, and 11 children (52%) in group 4. the most common medical problems during the booster phase are listed on the following page. ","  safety results: in the total enrolled cohort, 2 aes leading to study withdrawal were reported by 2 subjects in the acwy2 group. one (1) subject each withdrew because of an ae of juvenile idiopathic arthritis (moderate severity) and depression (severe); both aes were considered to be unrelated to the investigational vaccine by the investigator. following the booster vaccination, 23.9% of subjects in the acwy<2 group, 31.3% of subjects in the menccrm group, 35.1% of subjects in the acwy2 group, and 52.4% of subjects in the menps group reported at least 1 ae during the 31-day postbooster vaccination period. aes occurring in 5% of subjects and >1 subject in any given vaccine group included: pyrexia (12.5% [2 subjects] of the menccrm group), upper respiratory tract infection (9.1% [7 subjects] of the acwy2 group; 9.5% [2 subjects] of the menps group), and headache (6% [4 subjects] of the acwy<2 group). the proportion of subjects with at least 1 ae considered to be related to the investigational vaccine by the investigator was <10% for all vaccine groups except in the acwy2 group (15.6%). for the acwy 2 group, the only related ae reported in more than 1 subject was upper respiratory tract reported in the acwy2 group and was considered to be unrelated to the investigational vaccine by the investigator. no subjects were withdrawn from the study for safety-related reasons following booster vaccination. most solicited local and general events were mild to moderate in severity and none led to study withdrawal. conclusion(s): antibody persistence was demonstrated 6 to 10 years after primary vaccination with menacwy-tt, meningitec, or mencevax acwy. regardless of the primary vaccination received, booster responses were robust with higher proportions of subjects achieving protective titers 1 month after the booster vaccination than before the booster vaccination. no new safety concerns were identified in this extended follow-up study in children who received a primary vaccination of menacwy-tt, meningitec, or mencevax acwy. the booster vaccination was well tolerated in this cohort and the safety profile was acceptable."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. during phase 1 of the study, all 54 patients (100%) had at least 1 non-serious medical problem (that means a medical problem that is not life-threatening, does not cause lasting problems, or does not need hospital care). a total of 5 patients (9%) in phase 1 left the study due to medical problems. the most common non-serious medical problems reported during phase 1 are listed below.  during phase 2 of the study, 273 out of 275 patients (99%) had at least 1 non-serious medical problem. a total of 20 patients (7%) in phase 2 left the study due to medical problems. the most common non-serious medical problems reported during phase 2 are listed below.  ","  safety results: dose-limiting toxicity (phase 1 only) and rp2d one (1) patient treated at 200 mg qd met the criteria for dlt. this patient failed to receive 16 of the planned 21 doses of lorlatinib during cycle 1 due to toxicities attributed to lorlatinib, which met the protocol definition of a dlt. this patient experienced grade 1 and grade 2 cns effects during cycle 1, including grade 2 aphasia and cognitive disorder, and grade 1 visual impairment and abnormal dreams. as a result, lorlatinib was temporarily discontinued and the patient did not receive at least 16 of the planned 21 doses in cycle 1. the cns effects resolved within 7 days. lorlatinib was reduced to dose of 150 mg qd during cycle 2. additionally, at the 150 and 200 mg qd cohorts, the majority of patients had treatment-related aes resulting in dose interruption and/or dose reduction. as a result, it was agreed upon by the sponsor and the phase 1 investigators to evaluate doses lower than 200 mg qd and consider an alternative dosing regimen. bid dosing was evaluated to potentially modulate these aes, but the patients did not tolerate the 75 mg or 100 mg bid dosing. at the time of the rp2d selection, none of the patients at 100 mg qd required a dose reduction. additionally, based on the pk data observed, simulated patient exposure suggested that the 100 mg qd dose was the lowest dose that would exceed the lorlatinib minimum efficacious concentration (c ) of 150 ng/ml eff to inhibit alk g1202, during the majority of the 24 hour dosing interval, once steady-state was reached. therefore, while the mtd was not formally identified, 100 mg qd was chosen as the rp2d based on the entirety of the safety, efficacy, and clinical pharmacology data. serious adverse event phase 1 incidences of treatment-emergent all-causality and treatment-related saes (phase 1) were 9 (52.9%) patients had saes and 1 (5.9%) patient had treatment-related saes. incidences of treatment-emergent all-causality and treatment-related saes (phase 2) were summarized in table 9 and table 10, respectively. overall, 89 (32.4%) patients had saes and 19 (6.9%) patients had treatment-related saes. phase 1 incidence of treatment-emergent all-causality non-saes in >5% of patients (phase 1) was summarized in table 11. overall, all 54 phase 1 patients had treatment-emergent all-causality non-saes. incidence of treatment-emergent all-causality non-saes in >5% of patients (phase 2) was summarized in table 12. overall, in phase 2, 273 out of 275 patients had treatment-emergent all-causality non-saes. phase 1 the incidence of patients permanently discontinuing from treatment due to aes (phase 1) was summarized in table 13. lorlatinib was permanently discontinued for 5 patients, which was associated with aes."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 685 out of 702 patients (98%) had at least 1 medical problem, including 344 out of 349 patients (99%) in the pf-05280014 group and 341 out of 353 patients (97%) in the herceptin group. a total of 109 patients (16%) stopped study treatment due to medical problems, including 57 out of 349 patients (16%) in the pf-05280014 group and 52 out of 353 patients (15%) in the herceptin group. the most common medical problems are listed in the table below.  ","  safety results:  the incidence for all categories of treatment-emergent adverse events (teaes) and serious teaes was comparable across the 2 treatment groups. of the total of 85 deaths, the majority were due to the disease under study (70 [10.0%] patients, with 38 [10.9%] patients in the pf-05280014 group and 32 [9.1%] patients in the trastuzumab-eu group). overall, there were 70 (20.1%) patients in the pf-05280014 group and 73 (20.7%) patients in the trastuzumab-eu group who experienced at least 1 sae.  there were no statistically significant differences in the incidences of any of the events of special interest (tier-1) between the 2 treatment groups, including irrs and cardiac disorders.  the analysis of the primary efficacy endpoint, orr, demonstrated similarity between the 2 treatment groups as presented in the previous csr (data cutoff on 24 august 2016).  a reanalysis of the orr endpoint incorporating new information that resulted in updates to the central radiology assessments, for the data cutoff of 11 january 2017, provided results that were consistent with the primary analysis from the previous csr. the week 33 csr (dated 16 february 2017) presented the data as of the cutoff date of 24 august 2016, when all patients had either completed the week 33 tumor assessment (for the primary efficacy analysis) or discontinued study drug earlier than the week 33 visit, and included data for up to 378 days post-randomization for some patients. the week 53 csr (dated 21 july 2017) presented data from the study with a cutoff date of 11 january 2017 when all patients had either completed the week 53 tumor assessment or discontinued study drug earlier than the week 53 visit. after the data cutoff for the week 53 analysis, the study protocol was amended to delineate 2 treatment periods (treatment period 1 and treatment period 2). the study elements required to achieve study objectives and endpoints (ie, through week 53 visit assessments) (table 1) were contained within treatment period 1. treatment period 2 was intended solely to provide access to study treatment for patients who continued to receive clinical benefit beyond treatment period 1, with limited protocol-required assessments. the results reported in this synopsis study report are limited to a summary of the study population, treatment exposure, cumulative safety (adverse events [aes], left ventricular ejection fraction [lvef]) and overall survival (os). this was an international, double-blind, randomized, phase 3 clinical trial evaluating the efficacy, safety, pk and immunogenicity of pf-05280014 in combination with paclitaxel versus trastuzumab-eu with paclitaxel in patients with her2-positive, metastatic breast cancer in the first-line treatment setting. it was the responsibility of the investigator to perform tests and procedures necessary to ensure the safety and well-being of the patient."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 412 out of 441 patients (93%) in this study had at least 1 medical problem. in this study, the percentage of patients with medical problems was similar in each group:  tafamidis 20 mg: 99% (87 out of 88 patients)  tafamidis 80 mg: 98% (173 out of 176 patients)  placebo: 99% (175 out of 177 patients) some of the medical problems were determined to be related to the study drug. in this study, more patients in the placebo group had medical problems that were determined to be related to the study drug, compared to patients in the tafamidis groups.  tafamidis 20 mg: 39% (34 out of 88 patients)  tafamidis 80 mg: 45% (79 out of 176 patients)  placebo: 51% (90 out of 177 patients) the most common medical problems are listed on the following page.  ","  safety results: all-causality non-serious adverse events: all-causality non-serious treatment-emergent adverse events (teaes) that occurred in >5% of subjects are summarized by system organ class (soc) and preferred term (pt) in table 12. the most frequently reported non-serious ae by pt was fall in the tafamidis 20 mg and 80 mg treatment groups and dyspnea in the placebo group. there were 3 saes in the tafamidis 20 mg group, 3 saes in the tafamidis 80 mg group, and 6 saes in the placebo group that were considered by the investigator to be treatment-related. discontinuations from the study are summarized in table 14. a greater proportion of subjects in the placebo group (52.0%) discontinued from the study compared with the tafamidis 20 mg and 80 mg treatment groups (31.8% and 35.8%, respectively). b. relationship is determined by investigators assessment of relationship to study treatment on the adverse event case report form page. deaths: a total of 144 subjects died; 77 occurred during the study period (14 [15.9%], 25 [14.2%], and 38 [21.5%] subjects in the tafamidis 20 mg, tafamidis 80 mg, and placebo groups, respectively) and 67 occurred during the follow-up period (9 [10.2%], 24 [13.6%], and 34 [19.2%] subjects in the tafamidis 20 mg, tafamidis 80 mg, and placebo groups, respectively). the majority of deaths in the study were considered the result of underlying disease. conclusion(s):  this phase 3 study demonstrated the efficacy of tafamidis as therapy for subjects with ttr-cm, with statistically significant reduction at month 30 in on all-cause mortality and the frequency of cardiovascular-related hospitalizations.  in addition to a positive primary analysis, this study demonstrated significant and clinically meaningful effects of tafamidis on the individual components of the primary analysis (all-cause mortality and frequency of cardiovascular-related hospitalizations).  the efficacy of tafamidis was supported by all other secondary efficacy endpoints (cardiovascular-related mortality, frequency of cardiovascular-related hospitalization, all-cause mortality, and ttr stabilization at month 1).  significant treatment effects were observed for both the 20 mg and 80 mg tafamidis doses in the primary, key secondary, and secondary analyses when compared with placebo.  tafamidis treatment was generally safe and well tolerated in the study subject population, with few dose reductions and a similar frequency of teaes and serious teaes between the treatment groups. a greater proportion of deaths were observed in the placebo group compared with the tafamidis group. none of the deaths were related to study treatment, and most were considered as a result of the disease under study.  the demonstrated efficacy and safety profile of tafamidis in this study population supports tafamidis as a treatment option for ttr-cm."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another drug the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. a total of 21 patients left the study due to medical problems (16 in the bococizumab group and 5 in the placebo group). more than half of all patients in this study had at least 1 non-serious medical problem (62% in the bococizumab group and 56% in the placebo group). a non-serious medical problem means a medical problem that is not life-threatening, does not cause lasting problems, or needs hospital care. the most common are listed below. 13% of patients in the bococizumab group (67 out of 499) had a non-serious injection site reaction (pain, stinging, redness, or swelling where the shot was given). less than 1% in the placebo group (2 out of 247) had a non-serious injection site reaction. ","  safety results: all-causality non-serious adverse events: all-causality non-serious teaes (>2% of subjects) by system organ class (soc) and pt are summarized in table 12. overall, the percentage of subjects with aes was similar in the bococizumab group (63.3%) and the placebo group (59.5%). the most frequently reported non-serious ae in the bococizumab group was coded to the pt of injection site reaction. the incidence of saes by soc and pt are summarized in table 13. the percentage of subjects reporting saes was higher in the placebo group compared with the bococizumab group (8.8% in bococizumab group; 13.0% in placebo group). withdrawals of subjects from the study: discontinuations from the study are summarized in table 14. the overall rate of discontinuations from the study was slightly higher in the bococizumab group compared with the placebo group (14.8% in bococizumab group; 11.7% in placebo group). deaths: a total of 4 subjects died during the study (2 [0.4%] subjects in the bococizumab group and 2 [0.8%] subjects in the placebo group). conclusions:  this phase 3 study demonstrated a superior ldl-c lowering effect of bococizumab 150 mg administered sc q2w compared with placebo at week 12, with an adjusted mean treatment group difference of -49.9% (95% ci: 54.0, 45.8) at week 12 (p <0.001).  a superior effect for bococizumab compared with placebo was also demonstrated at week 12 for all key secondary endpoints (percent cfb in fasting tc, apob, non-hdl-c, ldl-c in subjects with primary hyperlipidemia, ldl-c in subjects with mixed dyslipidemia, lp[a], and hdl-c) for which type i error was controlled.  bococizumab treatment resulted in greater reductions in tg, vldl-c, tc/hdl-c and apob/apoa-i ratios, and greater elevations in apoa-i compared with placebo.  in subjects treated with bococizumab, trough plasma concentrations of 5.37  5.327, 5.28  5.888, and 4.01  4.652 g/ml were achieved at weeks 12, 24, and 52, respectively. the most frequently reported non-serious ae in the bococizumab group was coded to the pt of injection site reaction (13.4% bococizumab and 0.8 % placebo group).  the incidence of saes was lower in the bococizumab group compared with the placebo group (8.8% and 13.0%, respectively). four (4) deaths occurred during the study, 2 (0.4%) in the bococizumab group and 2 (0.8%) in the placebo group. none of the deaths were considered by the investigator to be due to study drug.  the overall rate of discontinuations from the study was slightly higher in the bococizumab group compared with the placebo group (14.8% in bococizumab group; 11.7% in placebo group).  the overall incidence of adas and nabs in bococizumab-treated subjects was 54.8% and 37.9%, respectively."
" 527 participants out of 533 (99%; 99 out of 100) participants in this study had at least 1 medical problem. 496 participants out of 533 (93%; 93 out of 100) participants had medical problems that the researchers thought were caused by one of the study drugs. of the 268 participants treated with bosutinib, 265 participants (99%; 99 out of 100) had medical problems. of the 265 participants treated with imatinib, 262 of the 265 (99%; 99 out of 100) participants had medical problems. of the 533 participants, 106 participants (20%; 20 out of 100) stopped taking study treatment because of medical problems. of the participants treated with bosutinib, 68 of the 268 participants (25%; 25 out of 100) stopped taking bosutinib because of medical problems. of the participants treated with imatinib, 38 of the 265 participants (14%; 14 out of 100) stopped taking study treatment because of medical problems. the most common medical problems  those reported by at least 10% of participants  are described below. below are instructions on how to read table 1 most common medical problems. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 10% of participants are listed.  the 2nd column tells how many of the 268 participants taking bosutinib reported each medical problem. next to this number is the percentage of the 268 participants taking bosutinib who reported the medical problem.  the 3rd column tells how many of the 265 participants taking imatinib reported each medical problem. next to this number is the percentage of the 265 participants taking imatinib who reported the medical problem.  using these instructions, you can see that 10 participants out of the 268 (4%) participants taking bosutinib reported muscle cramps. a total of 81 participants out of the 265 (31%) participants taking imatinib reported muscle cramps.    ","  safety results: extent of exposure the median duration of study treatment was 55.10 months (range: 0.3 to 60.1 months) for patients receiving bosutinib compared with 55.03 months (range: 0.7 to 56.8 months) for patients receiving imatinib in the safety population. in patients receiving bosutinib, 68.7% had at least 1 dose delay, compared with 45.7% of patients receiving imatinib, 45.5% had at least 1 dose reductions, compared with 24.5% of patients receiving imatinib. the proportion of patients with at least 1 dose escalation in the bosutinib arm was 21.6% compared with 31.3% in the imatinib arm. adverse events the proportion of patients reporting at least 1 teae was the same in the bosutinib arm (98.9%) as in the imatinib (98.9%) arm, most teaes were treatment related, 95.1% and 90.1% respectively. the number of patients (bosutinib vs imatinib) with grade 3 or 4 teaes (73.5% vs 57.0%), teaes leading to dose reduction (45.1% vs 24.5%) or temporary stop (68.7 vs 45.7%), treatment-emergent saes (36.6% vs 25.7%) and aes leading to discontinuation (25.4% vs 14.3%) was higher in the bosutinib arm. the most common (10%) grade 3 or 4 teaes in patients receiving bosutinib were alt increased (20.9%), thrombocytopenia (14.2%), lipase increased (13.4%) and ast increased (10.4%), while the most common grade 3 or 4 teae in patients receiving imatinib was neutropenia (13.6%). of the 14 deaths in the imatinib arm, 3 were due to aes unrelated to study drug, 1 was due to an ae related to study drug and 4 were due to disease progression. a total of 3 patients in the bosutinib arm and 4 patients in the imatinib arm died within 28 days of last dose; of these, 1 death in the imatinib arm was considered to be related study drug. permanent discontinuations due to adverse events the number of patients with aes leading to permanent treatment discontinuation in the bosutinib arm was higher than in the imatinib arm (25.4% vs 14.3%). the most common (1%) aes leading to discontinuation of study drug in patients receiving bosutinib were alt increased (4.9%), ast increased (2.6%) lipase increased (1.9%), diarrhea (1.5%), thrombocytopenia (1.1%), and neutropenia (1.1%) compared with thrombocytopenia (1.5%), muscle spasms (1.1%), diarrhea and myalgia (1.1%) in patients receiving imatinib. pregnancy exposure a total of 10 pregnancies were identified, 9 in the bosutinib arm and 1 in the imatinib arm."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. all 52 (100%) participants in this study had at least 1 medical problem. a total of 20 (20% or 1 out of 5) participants left the study because of medical problems. the most common medical problems  those reported by at least 20% of participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 20% of participants are listed.  the 2nd column tells how many of the 52 participants reported each medical problem that the researchers felt were due to either of the study medications. next to this number is the percentage of the 52 participants who reported the medical problem.  using these instructions, you can see that 39 out of the 52 participants taking the study medications reported feeling tired.  ","  safety results: no new safety signals were identified with axitinib in combination with pembrolizumab in patients with previously untreated arcc; the safety profile was consistent with the known safety profiles of both study drugs when used as single agents. extent of exposure patients received axitinib for a median of 21.5 cycles (range: 1 to 64 cycles) and pembrolizumab for a median of 24.5 cycles (range: 1 to 56 cycles). the median days on treatment with combination therapy (axitinib + pembrolizumab) was 440 days in 52 patients, median days on treatment with pembrolizumab after discontinuation of axitinib was 274 days in 10 patients, and median days on treatment with axitinib after discontinuation of pembrolizumab was 228 days in 11 patients. treatment-emergent adverse events all patients experienced at least 1 treatment-emergent adverse event (teae) in the entire study period. the most common teaes reported during the entire study period were diarrhea (44 [84.6%] patients), fatigue (42 [80.8%] patients), hypertension (28 [53.8%] patients), cough (25 [48.1%] patients), and dysphonia (25 [48.1%] patients). the number and percentage of patients who discontinued either of the study drugs (axitinib or pembrolizumab) due to aes were 20 (38.5%) patients: 17 (32.7%) patients discontinued axitinib and 13 (25.0%) patients discontinued pembrolizumab. the number and percentage of patients with aes leading to dose reduction of either of the study drugs were 18 (34.6%) patients: 16 (30.8%) patients had a dose reduction of axitinib and 4 (7.7%) patients had a dose reduction of pembrolizumab. the number and percentage of patients with temporary discontinuation of either of the study drugs due to aes was 44 (84.6%) patients in the entire study period. deaths a total of 14 (26.9%) patients died: 11 (21.2%) deaths were due to disease under study, 2 (3.8%) deaths were due to unknown causes, and 1 (1.9%) death due to medical procedure. of these 14 deaths, 13 (25.0%) patients died more than 90 days after last dose and 1 death occurred on treatment. the most often reported treatment-emergent saes in the entire study period were diarrhoea reported for 6 (11.5%) patients, dyspnoea reported for 4 (7.7%) patients, and alanine aminotransferase increased and colitis reported for 3 (5.8%) patients each. clinical laboratory evaluation a total of 43 (82.7%) patients had a clinical laboratory test result (including biopsies), radiologic test result, physical examination observation, and/or physiologic test result (eg, pulmonary function test) reported as an ae."
" 5 the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another drug the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. a total of 6 patients left the study due to medical problems. 105 out of 183 patients in this study had at least 1 non-serious medical problem. the most common are listed in the table on the next page. patients taking bococizumab had a similar rate of muscular medical problems (muscle pain and muscle spasms) as patients in the atorvastatin and placebo group. patients taking bococizumab had a higher amount of injection site reactions than patients did in the other groups. 14 patients (19%, or 14 out of 74 patients) taking bococizumab had a non-serious injection site reaction. 2 patients (3%, or 2 out of 73 patients) in the placebo group had a non-serious injection site reaction. no one in the atorvastatin group had an injection site reaction. 6 7 ","  safety results as the placebo group. the injection site reaction pt was recorded more frequently in subjects in the bococizumab 150 mg q2w group compared with the placebo group. musculoskeletal aes were frequently recorded in subjects in this study, with similar incidences across all treatment groups.  saes were similar across treatment groups. one subject in the bococizumab 150 mg q2w group died due to aes coded to the pts pneumonia aspiration and multi-organ failure.  the overall incidence of ada and nab in bococizumab-treated subjects was 48.6% and 25.0%, respectively."
" when new medicines are being studied, researchers keep track of all medical problems that patients have. a total of 51 out of 172 (about 30%, or 3 out of 10) patients in this study had at least 1 medical problem. one (1) patient left the study due to a medical problem. this patient was in the placebo group and had the medical problem of hyperglycemia. the most common medical problems are listed below. ","  safety results: details of the treatment-emergent sae are provided in table 10. a summary of all-causality and treatment-related non-serious aes listed by system organ class (soc) and according to meddra preferred terms is presented in table 11 and table 12, respectively. one subject in the placebo group discontinued from treatment due to an ae (hyperglycemia) that was considered unrelated to study treatment. hypoglycemic aes: one (1) subject (2.9%) in the pf-06291874 75 mg group experienced 2 haes, on days 12 and 13. these were both mild in severity and asymptomatic. three (3) other subjects, 1 each in pf-06291874 15 mg, 35 mg and 75 mg groups experienced a single hypoglycemic event prior to the start of the study. clinical laboratory evaluations: the incidence of laboratory abnormalities was comparable across the treatment groups in the study and there was no apparent dose related increase in the frequency of laboratory abnormalities (not including glucometer measurements). the most common laboratory abnormality was increased glucose defined as >1.5  upper limit of normal (uln) (uln = 100 mg/dl), which occurred in 29, 29, 20, 30, and 24 subjects in the placebo, pf-06291874 15 mg, 35 mg, 75 mg, and 150 mg treatment groups, respectively. two subjects (1 each in the placebo and pf-06291874 75 mg groups) reported aes of hyperglycemia; both observed in 12, 11, 6, 7 and 8 subjects in the placebo, pf-06291874 15 mg, 35 mg, 75 mg, and 150 mg treatment groups, respectively. on days 14 and 28, small and comparable mean increases from baseline ldl-c values were observed for the placebo group, and the 15 mg, 35 mg, and 75 mg pf-06291874 treatment groups; however the mean increase from baseline for the 150 mg pf-06291874 dose group was >10% and was statistically significant compared with placebo on days 14 and 28. on days 14 and 28, small changes from baseline values for the 15 mg, 35 mg, and 75 mg pf-06291874 groups were similar to placebo, however there was a statistically significant increase in the 150 mg treatment group. on days 14 and 28, small mean increases from baseline values were evident in each of the pf-06291874 treatment groups compared with the placebo group, however the increases were larger in the 75 mg and 150 mg treatment groups suggesting that there may be evidence of a dose dependent response. (mmrm) of percent change from baseline for ldl-c, total cholesterol, hdl-c, non hdl-c, and triglycerides on day 28 - fas day 28 ls mean - -0.84 0.57 -0.57 9.23 (mmrm) of percent change from baseline for ldl-c, total cholesterol, hdl-c, non hdl-c, and triglycerides on day 28 - fas baseline was defined as the average of days 0 and 1 predose values."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another drug the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the medical problems of an experimental drug dose might be. a total of 76 out of 736 patients who said that they took the study dose of ibuprofen at least one time during the study had at least 1 non-serious medical problem. a total of 2 patients left the study due to medical problems. the most common medical problems are listed below. ","  safety results: non-serious aes: a summary of non-serious aes is presented in table 6. a total of 76 non-serious aes were reported during the study and 26 were considered as treatment-related. the most frequently reported non-serious aes were infections and infestations (22 subjects, 3.0%), gastrointestinal (gi) disorders (18 subjects, 2.4%), and injury, poisoning and procedural complications (10 subjects, 1.4%). the number of subjects counts a subject only once within each soc. ae = adverse event; meddra = medical dictionary for regulatory activities; pt = preferred term; soc = system organ class. serious aes: a total of 6 saes were reported, of these, only 1 (coronary artery occlusion) was considered as treatment-related (table 7). the number of subjects counts a subject only once within each soc. ae = adverse event; meddra = medical dictionary for regulatory activities; pt = preferred term; sae = serious adverse event; soc = system organ class. (2) subjects were withdrawn from the study due to treatment-related aes (back pain [0.1%] and dizziness [0.1%]) (table 9). the number of subjects counts a subject only once within each soc. ae = adverse event; meddra = medical dictionary for regulatory activities; pt = preferred term; soc = system organ class. the number of subjects counts a subject only once within each soc. thus, the primary endpoint for the study met the pre-specified success criterion (lower bound of the 95% ci was >85%).  subjects were somewhat more likely to violate the 1-caplet-per-dose direction (secondary endpoint) than the 3-caplet-per-day direction (primary endpoint). within the actual use population, 84.4% (95% ci: 81.7%, 87.1%) exceeded the labeled 400 mg per dose maximum on 2 or fewer occasions (or alternatively under advice from a hcp), and thus were considered correct or acceptable for the secondary endpoint.  across all subjects, the average daily dose was the equivalent of 1.6 caplets per day.  the aes reported in this actual use trial appear consistent with those reported in previous clinical trials and in spontaneous reporting systems. most of the events were mild and unrelated to exposure to the study drug. only 1 of the saes was judged related to the investigational product. overall, results from the study support the conclusion that subjects generally used the medication according to the key directions on the dfl and other package materials. misuse was mostly limited and, with the exception of a small number of subjects taking significantly more than the labeled daily maximum, would be expected to result in minimal excess risk of events with clinical importance."
" the researchers recorded any medical problems the boys had during the study. boys could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the boy was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. during part 1, 115 out of 120 boys (96%) had at least 1 medical problem. during part 2, 103 out of 113 boys (91%) had at least 1 medical problem. during part 1, 1 boy (1%) left the study because of a medical problem. the most common medical problems during part 1 and part 2 are listed below. edical ll mmon eadache miting ver fection se, per uffy in gs nt ck ugh osebleed arrhea unny edical ll mmon fection se, per ugh eadache miting arrhea in gs fficulty unny ver ","  safety results: the majority of participants experienced at least 1 treatment-emergent adverse event (teae). the incidence of teaes was comparable between the placebo and domagrozumab groups, and among the 3 dose levels of domagrozumab. there were no clinically meaningful differences in the incidence of tier-1 and tier-2 teaes between the domagrozumab and placebo groups. the incidence of the teae of gait inability, which was due to disease progression, was comparable between the domagrozumab and placebo groups. for participants in the domagrozumab treatment group, 2 participants reported all-causality saes in period 1 and 3 participants reported all-causality saes in period 2. three participants had treatment-related saes (1 femoral neck fracture, 1 anxiety and 1 troponin increased). the ae of troponin increased was reported for 2 participants each in the placebo group and domagrozumab group in period 1. the ae of troponin increased was reported for 1 participant in the placebo treatment group and 3 participants in the domagrozumab group in period 2. all of the aes of troponin increased were mild in severity. the ae of ejection fraction decreased was reported for 1 participant in placebo group and 2 participants in the domagrozumab group in period 2. all of the aes were mild or moderate in severity and were caused by disease under study. only 1 participant in sequence 1 had both the aes of troponin increased and ejection fraction decreased. the final data did not remove this potential risk observed in sequence 1. the quantitative difference in lvef was neither statistically different nor clinically meaningful. conclusions: efficacy  the study did not achieve the primary endpoint at week 49: the difference (95% ci) in the mean change from baseline of 4sc for the domagrozumab group compared to placebo using fas was 0.2712 sec (95% ci: -7.3799, 7.9223; p-value=0.9423), which favored placebo, and was not statistically significant.  the mmrm analysis based on fas for the secondary functional endpoints including: nsaa, fvc, myometry-based muscle strength, pul and 6mwt at week 49 did not demonstrate statistically significant changes between the domagrozumab and placebo groups.  results observed on the primary endpoint and other secondary functional endpoints using the mmrm analysis methodology are difficult to interpret due to skewness in the observed data and missing data due to loss of ambulation (loa) or physical inability. sensitivity analyses have been presented to address these limitations of the mmrm method and did not contradict the findings of the primary analysis.  following the last dose of each dose level, serum domagrozumab c and c values trough 2 were similar for both process 1 (original manufacturing process) and process 2 (commercial ready process) material. overall, exposure was slightly higher for the last dose relative to first dose due to accumulation across all period 1, sequences 1 and 2 treatments.  domagrozumab demonstrated low immunogenicity potential, with only 1 participant in sequence 3 developing positive ada (titer1.88)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. all participants (100%) in part 1 had at least 1 medical problem. a total of 9 participants (10%) in part 1 stopped taking study treatment because of medical problems, and 2 of these participants stopped taking study treatment because of medical problems that were considered to be related to the study treatment (heart failure and liver injury). all participants (100%) in part 2 had at least 1 medical problem. a total of 11 participants (13%) in part 2 stopped taking study treatment because of medical problems, and 2 of these participants stopped taking study treatment because of medical problems that were considered to be related to the study treatment ( reaction to iv infusion and rash). the most common medical problems  those reported by at least 15% of participants  are described below. below are instructions on how to read tables 1 to 4. instructions for understanding tables 1 to 4.  the 1st column of table 1 lists medical problems that were commonly reported during part 1. all medical problems reported by at least 15% of participants are listed.  the 2nd column tells how many of the 87 participants taking the study medication reported each medical problem. next to this number is the percentage of the 87 participants taking the study medication who reported the medical problem.  using these instructions, you can see that 31 out of the 87 participants (36%) taking the study medication reported feeling tired. how many participants had dose-limiting toxicities? dose-limiting toxicities are certain medical problems caused by taking study treatment, which require the participant to lower the dose or stop taking the treatment (permanently or temporarily). no participants in this study had dose-limiting toxicities. the participants who stopped taking study treatment (9 participants in part 1 and 11 participants in part 2) did so for other medical problems. ","  safety results: for part a, the median duration of treatment for all patients was 73 days (range: 1 to 813 days), the median time on treatment ranged from 43.5 to 162 days across all dose levels. adverse events there were no dlts reported in part a or part b. mtd was not determined in part a or part b. for part a, all-causality aes were reported for all 87 patients, with 47 (54%) patients experiencing grade 3 or 4 aes. permanent discontinuations of pf-04518600 associated with aes were reported by 9 (10.3%) patients, with 2 patients permanently discontinuing due to treatment-related aes (1 patient in the 0.1 mg/kg cohort had grade 2 cardiac failure congestive, and 1 patient in the 250 mg cohort had grade 3 hepatocellular injury). for part a, all-causality aes that were reported in 15% of patients were fatigue, ast increased, decreased appetite, nausea, abdominal pain, pruritus, dyspnea, anemia, pyrexia, diarrhea, and vomiting (all grade 1 or 2, grade 3 aes included 7 ast increased, 1 abdominal pain, 1 anemia, 1 diarrhea, and 1 vomiting). for part b, all-causality aes that were reported in 15% of patients were fatigue, decreased appetite, anemia, nausea, constipation, and diarrhea (all grade 1 or 2, grade 3 aes included 3 fatigue, 1 decreased appetite, 6 anemia, 1 nausea and 1 diarrhea). death for part a, there were 2 deaths reported during the period from the start of treatment (c1d1) to and including 28 days after the last dose. laboratory evaluations hematology for part a, most of the hematology parameters were of grade 0, 1, or 2. grade 4 lymphopenia was reported in 4 patients (2 in the pf-04518600 10 mg/kg cohort and 2 in the pf-04518600 250 mg cohort). grade 3 lymphopenia was reported in 15 patients (3 in the pf-04518600 0.1 mg/kg cohort, 2 in the pf-04518600 1.5 mg/kg cohort, 3 in the pf-04518600 3.0 mg/kg cohort, 4 in the pf-04518600 30 mg cohort, and 3 in the pf-04518600 250 mg cohort). grade 3 anemia was reported in 4 patients (1 in the pf-04518600 3.0 mg/kg cohort and 3 in the pf-04518600 30 mg cohort). for part b, most of the hematology parameters were of grade 0, 1, or 2. grade 4 lymphopenia was reported in 1 patient in the pf-04518600 3.0 mg/kg + utomilumab 100 mg cohort. grade 3 lymphopenia was reported in 12 patients (1 in the pf-04518600 0.1 mg/kg + utomilumab 20 mg/kg cohort, 1 in the pf-04518600 0.3 mg/kg + utomilumab 20 mg cohort, 2 in the pf-04518600 0.3 mg/kg + utomilumab 100 mg cohort, 2 in the utomilumab 100 mg cohort, 5 in the pf-04518600 30 mg + utomilumab 20 mg cohort)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. all of the patients in this study had at least 1 medical problem. a total of 12 (18%) patients stopped taking the study medication because of medical problems. a total of 3 (5%) patients left the study because of medical problems. the most common medical problems are listed below. ","  safety results: dose limiting toxicity (dlts): no dlts were observed in the dose escalation cohorts and the japan lic. two patients in cohort 2a had dlts. adverse events (aes): all 65 treated patients had at least 1 all-causality treatment-emergent adverse event (teae) and 61 of them had at least 1 treatment-related teae. in the overall population, the most frequently reported all-causality aes were diarrhea and paronychia. both diarrhea and paronychia were experienced by 45 (69.2%) patients each and all of these events were considered as treatment-related aes. other frequent aes included rash (39 [60.0%] patients), stomatitis (30 [46.2%] patients), dermatitis acneiform (28 [43.1%] patients) and dry skin (27 [41.5%] patients). grade 5 aes were reported for 3 patients, none of which were related to study treatment. the frequency of treatment-related serious adverse events (saes) reported for this study was low (6 [9.2%] patients). other safety evaluations: the most frequent shifts from grade 2 at baseline to grade 3 or 4 post-baseline for hematology laboratory results were lymphopenia (8 [12.3%] patients) and anemia (5 [7.7%] patients). the most frequent shift from grade 2 at baseline to grade 3 or 4 post-baseline for chemistry results was hyponatremia (8 [12.3%] patients). no patients were observed with a post-dose corrected qt for heart rate using fridericias formula (qtcf) 500 msec or a maximum increase from baseline of qtcf 60 msec. two patients in cohort 2a had dlts.  pf-06747775 had a safety profile that was generally tolerable and manageable by dosing interruption, dose reduction, and/or standard medical therapy in patients with advanced egfrm nsclc.  pf-06747775 provided clinically benefit for the total population as evidenced by investigator-assessed orr of 41.5% (90% ci: 31.2%, 52.5%) and median dor of 11.09 (range: 2.70-34.57) months.  following single and multiple-dose administration, plasma pf-06747775 exposures based on geometric mean auc (dn) and c (dn) were generally proportional to dose tau max over the range of 25 to 600 mg qd.  in the japan lic following repeat oral administration for 11 days (japan rp2d cohort) and 15 days (japan pk cohort) in cycle 1, plasma pf-06747775 exposures (based on auc [dn] and c [dn]) were similar between the 2 cohorts. tau max  co-administration of multiple doses of pf-06747775 qd with a proton pump inhibitor (ppi) (esomeprazole), a strong cyp3a inhibitor (itraconazole), or a sensitive cyp3a substrate (sildenafil), were not associated with clinically meaningful ddis."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. of the 714 patients who received study treatment, 661 (93%) patients had at least 1 medical problem. a total of 171 (24%) patients left the study because of medical problems. the most common medical problems are listed below.   ","  safety results: all patients who were randomized and received at least 1 dose of study treatment were included in the safety population. of the 719 randomized patients, 714 received at least 1 dose of the study treatment (356 patients in the pf-06439535 group and 358 patients in the bevacizumab-eu group). the majority of all patients experienced at least 1 treatment-emergent adverse events (teae, all causalities), with 344 (96.6%) patients in the pf-06439535 group and 347 (96.9%) patients in the bevacizumab-eu group reporting a total of 2442 and 2470 teaes, respectively. approximately half of all patients experienced at least 1 bevacizumab-related teae, with 190 (53.4%) patients in the pf-06439535 group and 199 (55.6%) patients in the bevacizumab-eu group reporting a total of 625 and 574 bevacizumab-related teaes, respectively. overall, 81 (22.8%) patients in the pf-06439535 group and 80 (22.3%) patients in the bevacizumab-eu group experienced at least 1 sae (all causalities). among them, 23 (6.5%) patients in the pf-06439535 group and 17 (4.7%) patients in the bevacizumab-eu group experienced at least 1 bevacizumab-related sae. the most pf-06439535 group and 7 [2.0%] patients in the bevacizumab-eu group), and neutropenia (4 [1.1%] patients in the pf-06439535 group and 6 [1.7%] patients in the bevacizumab-eu group). the most frequently reported bevacizumab-related saes were neutropenia, which was reported by 1 (0.3%) patient in the pf-06439535 group and 3 (0.8%) patients in the bevacizumab-eu group, and pulmonary embolism, which was reported by 2 (0.6%) patients in the pf-06439535 group and 2 (0.6%) patients in the bevacizumab-eu group. the most frequently reported non-serious aes were alopecia (166 [46.6%] patients in the pf-06439535 group and 165 [46.1%] patients in the bevacizumab-eu group), and anaemia (102 [28.7%] patients in the pf-06439535 group and 106 [29.6%] patients in the bevacizumab-eu group). the most frequently reported bevacizumab-related non-serious aes were hypertension (45 [12.6%] patients in the pf-06439535 group and 40 [11.2%] patients in the bevacizumab-eu group), and anaemia (28 [7.9%] patients in the pf-06439535 group and 30 [8.4%] patients in the bevacizumab-eu group). there were 85 (23.9%) patients in the pf-06439535 group and 86 (24.0%) patients in the bevacizumab-eu group who were permanently discontinued from any treatment (ie, discontinued from bevacizumab and/or paclitaxel and/or carboplatin) due to aes. in the pf-06439535 group, out of 356 patients who received study treatment, there were 21 (5.9%) patients with grade 5 teaes within the safety reporting period. in the bevacizumab-eu group, out of 358 patients who received study treatment, there were 24 (6.7%) patients with grade 5 teaes within the safety reporting period."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. during phase 1, all patients in this study (100%) had at least 1 medical problem. a total of 6 patients (50%) left the study because of medical problems. researchers also looked at how severe the medical problems were determined to be by the study doctors. the most common medical problems during phase 1 are listed below, along with their severity. for phase 1, the researchers also looked at how many medical problems were related to study treatment. all phase 1 patients (100%) had medical problems that were considered to be related to study treatment by the study doctors. the most common related medical problems during phase 1 are listed below, along with their severity.  during phase 2, all of the patients (100%) had at least 1 medical problem. a total of 6 patients with aml (20%) and 3 patients with mds or cmml (10%) left the study because of medical problems. the most common medical problems during phase 2 are listed below. ","  safety results: lic all 12 patients in the lic had at least 1 teae. of the 230 all-causality teaes, 119 (reported in 12 [100.0%] patients) were considered to be treatment-related. the majority (8 [66.7%]) of patients had at least 1 all-causality grade 3 or 4 teae reported. nine (75.0%) patients had all-causality saes; 7 (58.3%) patients had saes considered to be treatment-related. the most frequently reported grade 3-4 aes (10% of patients) were anaemia (50.0%), neutropenia (33.3%), febrile neutropenia (33.3%) and thrombocytopenia (16.7%). all-causality grade 5 teaes were reported in 2 patients, none of which were considered to be treatment-related. the most frequently reported grade 4 hematology laboratory test abnormalities were neutrophil count decreased (8 [66.7%] patients,) and platelet count decreased (6 [50.0%] patients). electrocardiogram qt prolonged was reported in 5 (41.7%) patients, 1 of which was an sae. aml cohort: all 30 patients in the aml cohort had at least 1 teae. of the 536 all-causality teaes, 206 (reported in 29 [96.7%] patients) were considered to be treatment-related. the majority (24 [80.0%]) of patients had all-causality saes; 8 (26.7%) patients had saes considered to be treatment-related. twenty (66.7%) patients had at least 1 all-causality grade 3 or 4 teae reported. the most frequently reported treatment-related aes (20% of patients) in decreasing order of frequency were nausea (53.3%), decreased appetite (43.3%), constipation (40.0%), diarrhoea (33.3%), vomiting (33.3%) and muscle spasms (20.0%). all-causality grade 5 teaes were reported in 8 patients, none of which were considered to be treatment-related. two (6.7%) and 1 (3.3%) patients reported grade 4 hypoglycemia and hyponatremia, respectively. electrocardiogram qt prolonged was reported in 6 (20.0%) patients, 2 of which were saes. all of the events were of grade 3 except 1 grade 4 event. five (16.7%) patients had treatment-related electrocardiogram qt prolonged and both saes were considered to be treatment-related. mds cohort all 30 patients in the mds cohort had at least 1 teae. of the 533 all-causality teaes, 188 (reported in 29 [96.7%] patients) were considered to be treatment-related. the majority (24 [80.0%]) of patients had at least 1 all-causality grade 3 or 4 teae reported. eighteen (60.0%) patients had all-causality saes; 8 (26.7%) patients had saes considered to be treatment-related."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another drug the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. a total of 14 patients left the study due to medical problems. 85 out of 187 patients in this study had at least 1 non-serious medical problem. the most common are listed below. ",  safety results in this study appear in line with the historical safety data that were collected in the clinical program with the currently approved etn formulation.
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. a total of 22 out of 23 patients (96%) in this study had at least 1 medical problem (see table). a total of 4 out of the 23 patients (17%) left the study because of medical problems. the most common medical problem reported was tiredness; 19 out of the 23 patients (83%) had this medical problem. ","  safety results:  treatment-related treatment emergent adverse events (teaes) were reported for 19 (82.6%) patients and the most frequently reported teae was fatigue (17 [73.9%] patients).  one (1) death was reported: an unrelated completed suicide within 30 days after last dose of study drug.  serious teaes were reported for 9 (39.1%) patients.  teae leading to permanent discontinuation were reported for 4 (17.4%) patients.  teae leading to temporary discontinuation were reported for 8 (34.8%) patients.  teae leading to dose reduction were reported for 5 patients (21.7%). conclusions: the use of 18f-naf pet/ct imaging as a method for determining treatment response in metastatic bone lesions was evaluated. all 22 evaluable patients had responding bone lesions at the time of disease progression (psa, bone or soft tissue, or other clinically relevant progression) or at 2 years without progression. safety profile was consistent with prior studies of the study drug and no new safety signals were observed."
" the researchers recorded any medical problems the babies had during the study. babies could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another medicine the baby was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. out of 11 babies in this study, 5 babies (46%) had at least 1 non-serious medical problem (that means a medical problem that is not life-threatening, does not cause lasting problems, or does not need hospital care). of the medical problems experienced by these 5 babies, diarrhea was the only medical problem that the study doctors determined may have been related to the study treatment. diarrhea occurred in 2 babies (18%) and was considered related to the study treatment for 1 of these babies. the table below shows the medical problems that happened during the study. ","  safety results may be summarized as follows:  the majority of the aes reported were mild, non-serious, and resolved with or without treatment.  there were no aes that lead to discontinuation of study treatment or had a fatal outcome.  no deaths occurred during the study.  there were few laboratory safety analytes that were abnormal; a single laboratory abnormality was pcs.  the aes and other safety parameters such as laboratory results and vital signs were in line with that expected for the patient population and the expected safety profile of ceftaroline. overall conclusions:  overall, the aes reported in this study were consistent with the known safety profile for ceftaroline and were in line with the population under study.  all patients had a clinical outcome of either cure or indeterminate at eot and toc assessments.  this study supports the use of ceftaroline as a treatment option for neonatal late-onset sepsis."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). medical problems could have also been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. during treatment period 1, which included 596 patients, 279 patients (47%) had at least 1 non-serious medical problem (that means a medical problem that is not life-threatening, does not cause lasting problems, or does not need hospital care). viral infection of the nose, throat, and upper airways happened in 39 participants (7%) during treatment period 1. during treatment period 2, which included 551 patients, 233 patients (42%) had at least 1 non-serious medical problem (that means a medical problem that is not life-threatening, does not cause lasting problems, or does not need hospital care). viral infection of the nose, throat, and upper airways happened in 26 patients (5%) during treatment period 2. during treatment period 3, which included 505 patients, 215 patients (43%) had at least 1 non-serious medical problem (that means a medical problem that is not life-threatening, does not cause lasting problems, or does not need hospital care). common cold happened in 26 patients (5%) and worsening ra happened in 28 patients (6%) during treatment period 3. over the 3 treatment periods, a total of 31 patients (5%) left the study because of medical problems. "," methods study design: this was a multi-national, 2-armed, randomized, double blind, parallel group study designed to evaluate the safety, efficacy, population pk, and immunogenicity of pf-06410293 versus adalimumab-eu in combination with methotrexate to treat subjects with moderately to severely active ra who had an inadequate response to methotrexate therapy. upon completion of screening procedures and joint counts on study day 1, eligible subjects who met all the inclusion and exclusion criteria were randomized (1:1 ratio) into 1 of 2 study treatment arms to receive either pf-06410293 or adalimumab-eu.  treatment period 1 (tp1) began with the first dose of study drug at week 0 (day 1) and concluded with the completion of week 26 pre-dose assessments.  treatment period 3 (tp3) began with week 52 study drug dosing, with last study drug dosing scheduled on week 76 and the end of treatment (eot) visit on week 78. at the beginning of tp3, all the remaining subjects on adalimumab-eu were switched to pf-06410293 (open label). study visits for tp1 were scheduled at weeks 0, 1, 2, 4, 6, 8, 12, 18 and 26. unplanned visits may be scheduled by the investigator in order to conduct assessments required to protect the wellbeing of the subject.  subjects had to have received oral, subcutaneous (sc), or intramuscular methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to first dose of study drug. the stable dose had to be 10 to 25 mg per week, with the exception of 6 to 25 mg per week where 6 mg per week was a recommended initial dose by local guidance or standard of care.  stable dose of oral folic acid (at least 1 mg/day on 5 days per week) or oral folinic acid ( 5 mg once per week) supplementation for at least 21 days prior to the first dose of study drug. in countries which did not have approved folic acid 1 mg or folinic acid 5 mg presentations, a regimen of folic acid of at least5 mg weekly was acceptable. study treatment: initiated and maintained their study drug treatment with a uniform dose regimen at a dose of 40 mg every other week by sc injection, throughout the study treatment periods. methotrexate: subjects were required to continue their stable background regimen of oral or intramuscular methotrexate (10 to 25 mg/week, with the exception of 6 to 25 mg/week in geographic regions where 6 mg per week was a recommended initial dose by local guidance or standard of care) throughout the study. dose reductions to as low as 7.5 mg/week (or as low as 6 mg/week in geographic regions where permitted by local guidance or standard of care) were allowed for subjects who experienced intolerance to methotrexate during the study, and the dose reduction had to be documented with the investigators medical justification."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. fourteen (14) out of 15 patients (93%) in this study had at least 1 medical problem and there were 81 medical problems reported to the study doctors. no patient left the study because of medical problems. the most common medical problems are listed in the table below. no patient had severe medical problems. of the 81 medical problems, 53 were mild and 28 were considered moderate. there were 2 out of 15 patients (13%) who had medical problems that the doctors thought were related to fidanacogene elaparvovec. both of the treatment-related medical problems that were seen were moderate transaminase elevation, which refers to having high levels of certain liver enzymes, called transaminases, suggesting some inflammation or irritation of the liver. during the study, patients had blood samples taken for testing. medical problems identified in these blood tests are described below. most of the patients remained generally normal for most laboratory blood tests during the study. one (1) patient experienced 1 moderate medical problem of normocytic anemia (normal-sized red blood cells, but have a low number of them in the body) and 1 patient experienced mild medical problem of microcytic anemia (body has fewer red blood cells than normal and the red blood cells it does have are too small). both medical problems were considered not related to study drug by the study doctor. the study doctors did not note any important or study drug-related results in vital signs. there were no physical examination changes after study drug infusion that were important or related to the study drug. this does not mean that everyone in this study had these results. other studies may produce different results, as well. these are just some of the main findings of the study, and more information may be available at the websites listed at the end of this summary. ","  safety results: fourteen (14, 93.3%) out of 15 participants had at least 1 teae reported. two (2) participants reported 1 study drug-related teae each. there was no study drug discontinuation, study discontinuation, saes or deaths reported in the study. a total of 81 teaes were reported in the study. the majority of teaes (53/81) were mild in severity, and the other 28 teaes were moderate in severity. the most commonly reported teaes, regardless of causality, were in the socs of infections and infestations (8 participants, 53.3%), gastrointestinal disorders (7 participants, 46.7%) and musculoskeletal and connective disorders (6 participants, 40.0%). two (2) participants experienced a moderate drug-related teae of transaminases increased, one of whom demonstrated a suggested immune t-cell reaction as observed by positive elispot around the time of transaminases elevation. a tapering course of prednisolone (oral corticosteroid) was initiated in response to the increased transaminases and presumed immune t-cell reaction. this participant had an associated positive elispot suggesting a t-cell reaction to capsid protein during the interval from 4 to 10 weeks after spk-9001 infusion. among the remainder of 79 teaes, 77 teaes were considered not related to study drug by the investigator and 2 teaes (gastrooesophageal reflux disease and muscle injury) unlikely related to study drug. the majority of participants remained generally normal for most hematology and chemistry parameters during the study. one (1) participant experienced 1 moderate teae of normocytic anaemia and 1 mild teae of microcytic anaemia with low normal levels of erythrocytes, mean corpuscular hemoglobin (mch), hematocrit, and hemoglobin, as well as high normal levels of erythrocytes distribution width reported. both teaes were considered not related to study drug by the investigator. no clinically significant or study drug-related findings in vital signs were noted. there were isolated findings noted in the skin, gastrointestinal, musculoskeletal and other body systems for some participants, which were listed as clinically significant by the investigator. the majority of these findings were baseline hemophilic arthropathy, arthropathy and decreased joint range of motion, which were related to the participants underlying hemophilia. otherwise, there were no physical examination changes post-vector infusion that were clinically significant and/or related to the study drug. conclusions:  based on 1-year follow-up of 15 moderately severe-to-severe hemophilia b participants, spk-9001 infusion at the 5  1011 vg/kg dose level was shown to be generally well-tolerated with no notable safety findings. two (2) of these participants had positive elispots to capsid protein suggesting a t-cell mediated response to hepatocytes.  steady-state fix:c activity in all participants was above 5% of normal after infusion of spk-9001 overall and the steady-state levels were reached by approximately week 12.  the majority of participants had no on-study bleeds."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. all 55 patients in the study had at least 1 medical problem. a total of 24% (13 out of 55) of patients stopped treatment with avelumab or axitinib because of medical problems. the most common medical problems are listed below.   "," the mtd of avelumab in combination with axitinib was estimated to be equal to or greater than avelumab 10 mg/kg iv q2w + axitinib 5 mg oral bid. the rp2d of avelumab in combination with axitinib was determined to be avelumab 10 mg/kg iv q2w + axitinib 5 mg oral bid. all 55 patients (100%) who received at least 1 dose of study drug were reported with teaes. twenty-three of 55 patients (41.8%) had serious teaes and 13 of 55 patients (23.6%) had serious teaes related to study treatment as assessed by the investigator. out of the 13 patients (23.6%) who discontinued any study drug due to teaes, 11 patients (20%) discontinued due to teaes considered related to study treatment. based on the immune-related adverse event (irae) case definition and subsequent medical review, a total of 24 patients (43.6%) experienced iraes. overall, 5 patients (9.1%) were reported to have grade 3 iraes, of which, 4 patients (7.3%) were reported to have grade 3 iraes and 1 patient (1.8%) was reported to have a grade 5 irae. based on the irr case definition, a total of 18 patients (32.7%) experienced an infusion-related reaction (irr). one patient (1.8%) was reported to have a grade 3 irr with onset at the second infusion of avelumab that was reported as an sae. the laboratory results are generally consistent with the known safety profile of avelumab and axitinib. all patients had an ecog performance score of 0 (36 patients, 65.5%) or 1 (19 patients, 34.5%) at baseline. four and 3 patients (7.3% and 5.5%) worsened to an ecog of 2 and 3 during the on-treatment period, respectively. conclusions:  the mtd of avelumab in combination with axitinib was estimated to be equal to or greater than avelumab 10 mg/kg iv q2w + axitinib 5 mg oral bid. the rp2d of avelumab in combination with axitinib was determined to be avelumab 10 mg/kg iv q2w + axitinib 5 mg oral bid.  the safety profile of avelumab in combination with axitinib in treatment-nave patients with arcc was generally manageable, well tolerated, and consistent with the known safety profiles of avelumab and axitinib as single agents. the combination treatment was associated with a high orr in treatment-nave patients with arcc irrespective of pd-l1 expression on tumor-associated ics.  co-administration of multiple iv doses of avelumab with multiple oral doses of axitinib had no clinically meaningful effect on the pk of axitinib.  a higher probability of response was observed for patients whose tumors were pd-l1-positive at the 1% cutoff versus those whose tumors were pd-l1-negative, and a similar trend was also observed for patients with higher proportions of cd8+ cells within their pre-treatment tumor samples."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. a total of 31 out of 418 patients (7%) in this study had at least 1 of the most common non-serious medical problems (that means a medical problem that is not life- threatening, does not cause lasting problems, or needs hospital care). a total of 22 patients (5%) left the study because of medical problems. the most common non- serious medical problems reported by participants in this study are listed below. ","  safety results: treatment-emergent non-serious aes (>5% of subjects) are presented by system organ class and preferred term in table 7. the most frequently reported non-serious aes were nausea (epoetin hospira: 3 subjects [1.4%], standard-of-care: 13 subjects [6.3%]) and dyspnea (epoetin hospira: 7 subjects [3.3%], standard-of-care: 11 subjects [5.3%]). percentages of treatment specific events were calculated using the corresponding treatment count as denominator.an ae was considered to be treatment-emergent (teae) if the event started or worsened in severity after the start of the study drug given to 30 days after the last dose of study drug. totals for the number of subjects at a higher level are not necessarily the sum of those at the lower levels since a subject may report 2 or more different aes within the higher level category. treatment-emergent saes of the fas are summarized by system organ class and preferred term in table 8. saes were experienced by 130 subjects (31.1%): 66 subjects (31.1%) in the epoetin hospira arm and 64 subjects (31.1%) in the standard-of-care arm. the system organ classes for the most commonly reported saes across the 2 treatment groups were infections and infestations (8.6%), cardiac disorders (6.5%), respiratory, thoracic and mediastinal disorders (5.3%), general disorders and administration site conditions (5.3%), and injury, poisoning and procedural complications (5.0%). class and preferred term, full analysis set pyrexia 0 (0.0) 1 (0.5) 1 (0.2) class and preferred term, full analysis set wound dehiscence 0 (0.0) 1 (0.5) 1 (0.2) class and preferred term, full analysis set respiratory arrest 0 (0.0) 1 (0.5) 1 (0.2) class and preferred term, full analysis set a total of 22 (5.3%) subjects discontinued the study due to treatment-emergent aes. conclusions: in the primary analysis within the fas, the estimated proportion (95% ci) of time that the subjects hemoglobin levels were between 9 and 11 g/dl was 61.9% (57.5 - 66.2) for the epoetin hospira arm and 63.3% (58.7 - 67.7) for the standard-of-care arm. because the lower bound of the 95% ci for the difference in proportions (-7.6%) was greater than the pre-specified non-inferiority of -12.5%, this study demonstrated non-inferiority of epoetin hospira to the standard-of-care treatment in the maintenance of subjects hemoglobin levels using epoetin hospira cmab version 1.1 and epogen cmab version 5.1 algorithms for dosing. the overall efficacy data indicate that treatment using epoetin hospira is at least as effective as the standard-of-care treatment in the maintenance of subjects hemoglobin levels for the treatment of anemia in ckd subjects on hemodialysis using analogous dosing algorithms (fmcna algorithms epogen cmab 5 and epoetin hospira cmab 1) for each esa."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. a total of 1900 out of the 2996 patients (63%) treated in this study had at least 1 medical problem during the treatment period of the study. a total of 50 patients left the study during the treatment period because of medical problems. the most common medical problems are listed in the following table.  ","  safety results adverse events during the treatment period, adverse events were reported for a greater proportion of patients in the tanezumab 5 mg treatment group (67.1%) than in the tanezumab 2.5 mg treatment group (62.8%) (table s4). serious adverse events (saes) were reported for the greatest proportion of patients in the tanezumab 5 mg treatment group (8.0%) followed by the tanezumab 2.5 mg treatment group (5.1%) and the nsaid treatment group (4.6%). the incidence of adverse events reported during the safety follow-up period was higher in the tanezumab 5 mg treatment group (41.5%) than in the tanezumab 2.5 mg (33.5%) and nsaid (30.9%) treatment groups (table s5). saes were reported for a greater proportion of patients in the tanezumab treatment groups (tanezumab 2.5 mg, 3.8%; tanezumab 5 mg, treatment group and one patient in the nsaid treatment group discontinued the study due to an adverse event during the safety follow-up period. adverse events occurring at a greater frequency (1% difference between treatment groups) in the tanezumab treatment groups versus the nsaid treatment group included arthralgia, nasopharyngitis, osteoarthritis, joint swelling, headache, rapidly progressive osteoarthritis, and carpal tunnel syndrome (table s6). adverse events of fall were reported at a higher frequency (1% difference between treatment groups) in the tanezumab 2.5 mg treatment group than in the tanezumab 5 mg and nsaid treatment groups. upper respiratory tract infection was reported at a higher frequency (1% difference between treatment groups) in the nsaid and tanezumab 2.5 mg treatment groups than in the tanezumab 5 mg treatment group.  treatment-related adverse events: adverse events considered by the investigator to be treatment-related were reported for a higher proportion of patients in the tanezumab 5 mg treatment group (20.8%) than in the tanezumab 2.5 mg treatment group (16.5%) and the nsaid treatment group (15.9%).  severe adverse events: during the treatment period, severe adverse events were reported for more patients in the tanezumab 5 mg treatment group (6.8%) than in the tanezumab 2.5 mg treatment group (4.5%) and the nsaid treatment group (4.5%). the most commonly reported (0.5% of patients in any treatment group) severe adverse osteoarthritis that was considered severe occurred more frequently (0.5% difference between treatment groups) in the tanezumab 5 mg treatment group than in the tanezumab 2.5 mg treatment group and the nsaid treatment group. these adverse events were mild or moderate in severity, except for one adverse event of hypersensitivity in a patient in the tanezumab 5 mg treatment group that was serious and considered severe; this sae was considered related to a concomitant drug treatment and had resolved within 24 hours."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. during the treatment period, 615 out of 1008 patients who received tanezumab (61%) had at least 1 medical problem. a total of 15 patients (1%) left the study during the treatment period because of medical problems. the most common medical problems during the treatment period are listed below. "," the incidence of saes during the treatment period was lowest in the tanezumab 5 mg treatment group (2.2%) and highest in the tanezumab 10 mg treatment group (4.6%). during the 24-week safety follow-up or early termination follow-up periods, a similar proportion of patients in the placebo, tanezumab 10 mg, and tramadol pr treatment groups reported adverse events (table s6); a higher proportion of patients reported adverse events in the tanezumab 5 mg treatment group (33.5%). treatment-emergent adverse events occurring at a greater frequency (1% difference between treatment groups) in the tanezumab 5 mg treatment group versus the placebo treatment group included headache, hypoaesthesia, and pruritis (table s7). treatment-emergent adverse events occurring at a greater frequency (1% difference between treatment groups) in the tanezumab 10 mg treatment group versus the placebo treatment group included headache, upper respiratory tract infection, nasopharyngitis, paraesthesia, and hypoaesthesia. treatment-emergent adverse events occurring at a greater frequency (1% difference between treatment groups) in the tanezumab 5 mg versus the tramadol pr treatment groups included back pain, hypoaesthesia, bronchitis, fall, muscle spasms, and contusion. treatment-emergent adverse events occurring at a greater frequency (1% difference between treatment groups) in the tanezumab 10 mg treatment group versus the tramadol pr treatment group included arthralgia, upper respiratory tract infection, paraesthesia, pain in extremity, hypoaesthesia, bronchitis, bradycardia, muscle spasms, toothache. arthralgia was the most frequently reported adverse event during the 24-week safety follow-up or the early termination follow-up periods across treatment groups, and it was reported with higher frequency in the tanezumab treatment groups than in the tramadol pr and placebo treatment groups (table s9).  treatment-related adverse events: up to week 16, the overall incidence of treatment-related adverse events was similar across the placebo and tanezumab treatment groups (15.9% in the placebo treatment group, 17.9% in the tanezumab 5 mg treatment group, and 19.7% in the tanezumab 10 mg treatment group) and higher in the tramadol pr treatment group (30.2%). arthralgia was the only treatment-emergent adverse event occurring at a greater frequency (1% difference between treatment groups) in the tanezumab 5 mg treatment group versus the tramadol pr treatment group. treatment-emergent adverse events occurring at a greater frequency (1% difference between treatment groups) in the tanezumab 10 mg treatment group versus the tramadol pr treatment group included  severe adverse events: severe adverse events were infrequently reported during the treatment period (ie, up to week 56) across treatment groups. the most commonly reported all-causality severe adverse events during the treatment period were back pain (four patients [0.8%]) in the tanezumab 5 mg treatment group, rapidly progressive oa (three patients [0.6%]) in the tanezumab 10 mg treatment group, and dizziness (three patients [0.5%]) in the tramadol pr treatment group."
" the researchers recorded any medical problems the children had during the study. children could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study vaccine, or by another medicine the child was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many study groups in many studies, doctors try to understand what the side effects of an experimental vaccine might be. 365 out of 396 patients (92%) in this study had at least 1 medical problem . the most common medical problems reported by participants in this study are listed below. ","  safety results:  there were a total of 7 aes reported by 7 participants in the persistence safety analysis, none which were assessed as related to ip by the investigator. one participant who received 120 g rlp2086 reported 1 ae of scarlet fever within 48 hours after the blood draw at visit 11 (24 months after vaccination 3). one participant reported a mild continuing ae of malabsorption (ndcmc) after visit 8 (6 months after vaccination 3) and prior to booster vaccination.  local reactions were reported by 77.6% participants after the booster dose. most local reactions were mild to moderate in severity. overall, pain at injection site (70.1%) was the most commonly reported local reaction after booster vaccination. the percentage of local reactions reported after the booster dose (pain at injection site, redness, and swelling) were similar to the percentage of local reactions reported after the primary vaccination series (tenderness at injection site, redness, and swelling), respectively.  systemic events were reported by 52.4% participants after booster dose. most systemic events were mild to moderate in severity. overall, fatigue (46.3%) was the most commonly reported systemic event after booster vaccination. no systemic events lead to after the booster dose were similar to percentage reporting fever and drowsiness in the after the primary vaccination series. systemic events collected following booster vaccination differed from those collected following the primary vaccination series (vaccination 1 through 3) in order to be age appropriate.  from booster vaccination up through 1 month after booster vaccination 20 (13.6%) participants reported 26 aes. aes were most commonly reported in the system organ class (soc) of infections and infestations in 18 participants (12.2%). a total of 3 participants (2.0%) reported 6 aes related to the ip as determined by the investigator. from the booster vaccination up through 6 months after booster vaccination a total of 11 (7.5%) participants reported at least 1 mae.  two (1.4%) participants reported a total of 2 saes from booster vaccination up through 6 months after booster vaccination, neither of these saes were related to the ip as assessed by the investigator. although proportions of vaccine recipients maintaining hsba titers  lloq decline at 6, 12 and 24 months following primary vaccination, the clinical relevance remains unknown. the booster vaccine, as administered in this study, was safe and well tolerated with an acceptable safety profile in this cohort."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. one-hundred and fifty-three (153) out of 225 patients (68%) in the run-in phase had at least 1 medical problem. in the double-blind phase, 68 out of 88 patients (77%) in the study drug group and 63 out of 85 patients (74%) in the placebo group had at least 1 medical problem. a total of 26 out of 255 patients (12%) in the run-in phase left the study because of medical problems. in the double-blind phase, 16 out of 88 patients (18%) in the study drug group and 29 out of 85 patients (34%) in the placebo group left the study because of medical problems. the most common medical problems for patients in the run-in phase were upper respiratory tract infection (24 out of 225 patients [11%]), headache (16 out of 225 patients [7%]), nausea (13 out of 225 patients [6%]), and vomiting (13 out of 225 patients [6%]). the most common medical problems for patients in the study drug group of the double-blind phase were upper respiratory tract infection (13 out of 88 patients [15%]), worsening of disease (8 out of 88 patients [9%]), and common cold (nasopharyngitis) (7 out of 88 patients [8%]). the most common medical problems for patients in the placebo group of the double-blind phase were worsening of disease (13 out of 85 patients [15%]), jia (12 out of 85 patients [14%]), and upper respiratory tract infection (9 out of 85 patients [11%]). "," the most frequently reported teaes with 2% occurrence in the open-label run-in phase were upper respiratory tract infection (24 [10.7%] subjects), headache (16 [7.1%] subjects), nausea (13 [5.8%] subjects), and vomiting (13 [5.8%] subjects). overall, 26 (11.6%) subjects discontinued from the study because of an ae during the open label run-in phase. there were 16 (7.1%) subjects that discontinued from the study during the open-label run-in phase because of condition-aggravated aes (ie, worsening disease). during the open-label run-in phase, a total of 10 saes were reported by 7 subjects. double-blind phase: overall, there were 160 teaes experienced by 68 (77.3%) subjects in the tofacitinib 5 mg bid group and 166 teaes experienced by 63 (74.1%) subjects in the placebo group during the doubleblind phase. saes were reported for 1 (1.1%) and 2 (2.4%) subjects in the tofacitinib 5 mg bid and placebo groups, respectively, during the double-blind phase. there were 16 (18.2%) and 29 (34.1%) subjects discontinued from the study because of an ae in the tofacitinib 5 mg bid and placebo groups, respectively. the most frequently reported pts in the double-blind phase were:  tofacitinib 5 mg bid: upper respiratory tract infection (13 [14.8%] subjects), disease progression (8 [9.1%] subjects), and nasopharyngitis (7 [8.0%] subjects).  placebo group: disease progression (13 [15.3%] subjects), juvenile idiopathic arthritis (12 [14.1%] subjects), and upper respiratory tract infection (9 [10.6%] subjects). treatmentrelated teaes were seen in 22 (25.0%) subjects in the tofacitinib 5 mg bid group and 33 (38.8%) subjects in the placebo group during the doubleblind phase. during the double-blind phase, there were 16 (18.2%) subjects in the tofacitinib 5 mg bid group and 29 (34.1%) subjects in the placebo group that discontinued the study because of an ae. fewer subjects in the tofacitinib group discontinued from the study during the double-blind phase because of condition-aggravated (ie, worsening disease) aes than in the placebo group (14 [15.9%] vs 27 [31.8%] subjects, respectively). in the double-blind phase, 1 sae was reported by 1 subject in the tofacitinib 5 mg bid group and a total of 3 saes were reported by 2 subjects in the placebo group. conclusion(s): tofacitinib 5 mg bid treatment in subjects 2 to <18 years of age with jia resulted in significant improvements in the occurrence of disease flare at week 44 compared to subjects treated with placebo."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 129 out of 130 patients (99%) in this study had at least 1 medical problem. a total of 8 patients (6%, or 8 out of 130 patients) left the study completely because of medical problems. there were also 106 patients (82%, 106 out of 130 patients) who temporarily stopped palbociclib because of medical problems and 26 patients (20%, 26 out of 130 patients) who temporarily stopped letrozole. the most common medical problems are listed in the following table. this included low numbers of neutrophils in the blood (reported as neutropenia or neutrophil count decreased), low numbers of leukocytes in the blood, anemia where there were low numbers of red blood cells in the blood, and thrombocytopenia where there were low numbers of platelets in the blood. both neutrophils and leukocytes are a special kind of white blood cell that help the body fight an infection. red blood cells carry oxygen around the body to where it is needed. platelets are special cells in the blood that help the blood to clot after an injury. blood tests are used during chemotherapy to check the levels of the various cell types in blood as these are often reduced by treatment. in clinical studies, low numbers of white or red blood cells in the blood may be reported using different terminology that has the same meaning. for example, low numbers of neutrophils in the blood could be reported as neutropenia or as neutrophil count decreased. low numbers of white blood cells, red blood cells, and/or platelets in the blood are usually managed by reducing the dose of the chemotherapy, temporarily stopping chemotherapy, or by giving other treatment to help the body make more of these cells. a neutrophils, a type of white blood cell, could be reported as neutropenia or neutrophil count decreased ","  safety results: the median duration of palbociclib treatment was 11 treatment cycles (range: 1.0 to 31.0) with a median relative dose intensity of 90.9%. of the 130 patients who received at least 1 dose of the study drugs, 99.2% experienced all-causality teaes and 98.5% experienced palbociclib-related teaes. seven (7 [5.4%]) patients had a teae with a fatal outcome (grade 5), none of which were considered palbociclib-related or letrozole-related. the most commonly reported all-causality teaes were neutropenia (91 [70.0%] patients), leukopenia (45 [34.6%] patients) and anaemia (44 [33.8%] patients). the most common all-causality teae grade 3 was neutropenia (71 [54.6%] patients), followed by neutrophil count decreased (28 [21.5%] patients) and leukopenia (23 [17.7%] patients). the most commonly reported palbociclib-related teaes were neutropenia (91 [70.0%] patients), leukopenia (45 [34.6%] patients) and anaemia (37 [28.5%] patients). the majority of neutropenia events reported during the study were attributed to the palbociclib treatment. the most commonly reported sae was neoplasm progression (7 [5.4%] patients), most of which were non-treatment-related. sixteen (16 [12.3%]) patients had teaes that resulted in discontinuation from palbociclib, 14 (10.8%) patients had teaes that resulted in discontinuation from letrozole, and 8 (6.2%) patients had teaes that resulted in discontinuation from study. in addition to the teaes, 2 patients discontinued from study due to breast cancer and death, respectively, and both were attributed to disease under study. five (5) patients died during the study through day 28 day following the last administration of study drug (palbociclib). there were 99 (76.15%) patients who had post-dose absolute neutrophil count (anc) count <1000 cells/mm3, and the median (95% ci) time-to-first anc count <1000 cells/mm3 was 4.1 (4.0, 6.0) weeks. of the 99 patients, the majority (95 patients) had recovery of anc to 1000 cells/mm3, and the median (95% ci) time-to-recovery was 1.2 (1.1, 1.9) weeks. no apparent effect of duration of palbociclib exposure or palbociclib dose was observed on the hemoglobin a1c (hb1ac) levels. conclusions:  the study met its primary objective of providing access to palbociclib for postmenopausal women with hr-positive, her2-negative abc who were deemed appropriate for letrozole therapy in argentina, brazil, colombia, and mexico.  the combination of palbociclib with letrozole administered to patients in this study observed an orr of 24.8% (95% ci: 17.6, 33.2) with a median duration of the palbociclib treatment for 10.6 months (range: 0.1 to 29.3 months), which supported the treatment benefit."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes, the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medicine might have on a participant. while being given a study treatment, 112 out of 155 (72%) participants had at least 1 medical problem. the table below shows the most common medical problems seen in 5 or more participants. in total, 15 out of 155 (10%) participants left the study because of medical problems. "," a higher proportion of subjects in the tanezumab 20 mg treatment group reported adverse events up to the end of the study compared with the placebo treatment group. the incidence of saes or severe adverse events during this period were higher in the tanezumab 20 mg treatment group compared with the placebo treatment group (table s4). the incidence of treatment discontinuation due to an adverse event during this period was similar between the tanezumab 20 mg (4 subjects [5.6%]) and placebo (5 subjects [6.8%]) treatment groups. the incidence of adverse events reported during the treatment period was similar in the tanezumab 20 mg and placebo treatment groups. the incidence of saes or severe adverse events during the treatment period were higher in the tanezumab 20 mg treatment group compared with the placebo treatment group. the incidence of treatment discontinuation due to an adverse event during the treatment period was similar between the tanezumab 20 mg the most common adverse events occurring in the tanezumab 20 mg were anemia, arthralgia, decreased appetite, prostate cancer (verbatim term: progression of prostate cancer), peripheral edema, and pain. the proportion of subjects reporting peripheral edema was higher in the tanezumab 20 mg treatment group compared with the placebo group, as seen in previous tanezumab studies.  the majority of adverse events reported during the treatment period were moderate to severe in severity in both the tanezumab 20 mg and placebo treatment groups.  the overall incidence of treatment-related adverse events reported during this period was similar across the placebo and tanezumab 20 mg treatment groups in the placebo treatment group. up to the end of the study, the placebo treatment group had a larger proportion of subjects who discontinued from treatment and/or the study due to an adverse event (14 subjects [19.2%]) than the tanezumab 20 mg treatment group (11 subjects [15.3%]).  the incidence of discontinuations from treatment and/or the study due to adverse events in the neoplasms benign, malignant and unspecified (including cysts and polyps) soc was higher in the placebo group (9 subjects [12.3%]) compared with the tanezumab 20 mg treatment group (6 subjects [8.3%]). throughout the duration of the entire study, 2 subjects temporarily discontinued treatment due to an adverse event and both subjects were in the tanezumab 20 mg treatment group (2 subjects [2.8%]). the cause of the death for the majority of subjects across the treatment groups was neoplasm progression.  serious adverse events: the incidence of saes up to end of study was higher in the tanezumab 20 mg treatment group (39 subjects [54.2%]) compared with the placebo treatment group (28 subjects [38.4%]).  peripheral nervous system adverse events of special interest: adverse events of abnormal peripheral sensation were reported by 7 subjects (9.7%) in the tanezumab 20 mg treatment group and 4 subjects (5.5%) in the placebo treatment group."
" comparing understand ninety out of 91 (99%) participants in this study had at least 1 side effect. a total of 27 participants discontinued the study treatment because of side effects. the most common side effects  those reported by at least 20% of participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists side effects that were commonly reported during the study. all side effects reported in at least 20% of participants are listed.  the 2nd column tells how many of the 91 participants being administered the vbir and pf-06801591 reported each side effect. next to this number is the percentage of the 91 participants being administered the vbir and pf-06801591 who reported the side effect.  using these instructions, you can see that 35 out of the 91 participants (38%) being administered the vbir and pf-06801591 reported joint pain. did study participants have any dose-limiting toxicities? a dlt is a clinically significant side effect that occurs during a specific period after starting study treatment within the study (in the first 28 days after starting study treatment) and the side effects are graded based on a pre-defined grading scale. in part a of the study, 1 participant (1%) experienced a dlt in the first 28 days after treatment with the vaccine, pf-06755992. the participant experienced a serious side effect of myositis (inflammation of the muscles that are used to move the body) and myasthenia gravis (a chronic autoimmune disorder in which antibodies destroy the communication between nerves and muscle, resulting in muscle weakness). both the side effects were because of administration of the vbir and resulted in the participant permanently stopping the administration of the vbir. ","  safety results: extent of exposure the median (range) number of cycles (each cycle was 4 months long) started per patient was 2 (1, 3), 3 (1,3), 1 (1,3), and 2 (1, 3) for cohorts all mcrpc patients, 1b, 5b, and 7a and 3b combined, respectively. the median (range) duration of treatment of cohort 1b and cohort 5b were 22.06 (0.95, 47.11) months and 2.79 (0.03, 17.48) months, respectively. all-causality treatment-emergent aes (teaes), treatment-related aes (traes) and saes overview ninety (98.9%) treated patients had at least 1 all-causality teae, and 85 (93.4%) patients had at least 1 trae. in cohort 1b, 20 (100.0%) patients had teaes including 19 (95.0%) with traes. dose limiting toxicity there was 1 patient experienced dlts occurred in the first 28 days following the first adc68 vaccination:  one patient in cohort 6a experienced saes of grade 4 myositis and grade 3 myasthenia gravis. both the aes were attributable to adc68, tremelimumab, and pf-06801591, and resulted in permanent discontinuation of adc168, pdna, tremelimumab and pf-06801591 dosing. all-causality teaes in cohort 1b, the most frequently reported teaes experienced by 30% of patients were fatigue (12 patients, 60.0%), influenza like illness (12 patients, 60.0%), arthralgia (8 patients, 40.0%), haematuria, headache, and injection site pain (6 patients each, 30.0%). nine (45.0%) patients had grade 3 teaes, with the most frequently reported event being hypophosphataemia (4 patients, 20.0%). seven (46.7%) patients had grade 3 teaes, with the most frequently reported events being diarrhoea and fatigue (3 patients each, 20%). nine (16.1%) patients had grade 4 teaes, with the most frequently reported event being lipase increased and hypotension (2 patients each, 3.6%). in cohort 7a and 3b combined, the most frequently reported teaes experienced by 30% of patients were anaemia (18 patients, 56.3%), diarrhoea (13 patients, 40.6%), fatigue (12 patients, 37.5%), arthralgia (11 patients, 34.4%), constipation, nausea, and decreased appetite (10 patients each, 31.3%). five (15.6%) patients had grade 4 teaes, which were anaemia, lipase increased, hypokalaemia, muscular weakness, platelet count decreased, hypophosphataemia, hypotension, hyperglycaemia, hyperuricaemia, neutrophil count decreased, spinal cord compression, cardiac failure, cervical spinal stenosis, and hypoxia (1 patient each, 3.1%)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. all patients (100%) in this study had at least 1 non-serious medical problem (that means a medical problem that is not life-threatening, does not cause lasting problems, or does not need hospital care). the most common non-serious medical problems reported by participants in this study are listed below. ","  safety results were consistent with the known safety profile in patients treated with pegylated filgrastim [neulasta (pegfilgrastim)], with and without myelosuppressive tac chemotherapy. there were no immunogenicity concerns identified for pf-06881894 in the studied populations of breast cancer patients with and without chemotherapy. references: 1 neulasta (amgen) us prescribing information, dec 2017. available: https://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.pdf."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. of the 696 patients who received study treatment, 352 (51%) patients had at least 1 medical problem. a total of 5 (1%) patients left the study because of medical problems. the most common medical problems are listed below. "," the incidence of adverse events in the treatment period and the safety follow-up do not add up to the total incidence to end of study, as some patients had events that occurred in both time periods. the overall incidence of adverse events was similar across treatment groups both during the treatment period (49.6%, 55.4%, and 46.8% of patients in the placebo, tanezumab 2.5 mg, and tanezumab 2.5/5 mg treatment groups, respectively), and during the safety follow-up (37.3%, 40.3% and 39.5% in the placebo, tanezumab 2.5 mg, and tanezumab 2.5/5 mg treatment groups, respectively). arthralgia was the most frequently observed adverse event during the treatment period with a reported frequency of 8.2% (tanezumab 2.5 mg treatment group) to 12.5% (placebo treatment group) (table s5). back pain 7 (3.0) 10 (4.3) 6 (2.6)  treatment-related adverse events: during the treatment period, 75 patients experienced 103 adverse events considered by the investigator to be treatment-related.  severe adverse events: a total of 13 patients experienced severe adverse events during the treatment period: 5 (2.2%) in the placebo, 2 (0.9%) in the tanezumab 2.5 mg, and 6 (2.6%) in the tanezumab 2.5/5 mg treatment groups. one adverse event (oa) reported by a patient in the tanezumab 2.5 mg treatment group, led to discontinuation from treatment; this was an sae.  tier 1 adverse events: the overall incidence of tier 1 adverse events (pre-specified adverse events of potential sympathetic dysfunction [syncope, bradycardia, oh, anhidrosis, and hypohidrosis] considered clinically important) was low, 2 (0.9%) in the placebo, 5 (2.2%) in the tanezumab 2.5 mg, and 1 (0.4%) in the tanezumab 2.5/5 mg treatment groups. the incidence of tier 2 adverse events was similar across treatment groups, except for paraesthesia which occurred more frequently in the tanezumab 2.5 mg treatment group than in the placebo treatment group. the majority of events had resolved at time of last contact, with the exception of the two events that were fatal and one event of chest pain in a patient in the tanezumab 2.5/5 mg treatment group who was lost to follow-up. in all cases, the patients met criteria for consult because the adverse event was ongoing at the last study visit; one also met criteria due to having discontinued treatment and study due to the adverse event, however, the patient refused consult. consultations were performed for three of three patients in the placebo treatment group, one of three patients in the tanezumab 2.5 mg treatment group and four of six patients in the tanezumab 2.5/5 mg treatment group."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. during the treatment period, 467 out of 849 patients (55%) had at least 1 medical problem. a total of 8 (1%) patients left the study during the treatment period because of medical problems. the most common medical problems during the treatment period are listed below. "," the incidence of adverse events in the treatment period and the safety follow-up do not add up to the total incidence to end of study, as some patients had events that occurred in both time periods. subjects discontinued study drug due to ae and continued study (b) 7 (2.5) 3 (1.1) 4 (1.4)  arthralgia was the most frequently observed adverse event during the treatment period with a reported frequency of 8.1% (tanezumab 5 mg treatment group) to 12.1% (placebo treatment group) (table s6). more treatment-related adverse events were reported in the tanezumab 5 mg treatment group (84 adverse events in 48 [16.9%] patients) than in the tanezumab 2.5 mg treatment group (59 adverse events in 42 [14.8%] patients) or placebo treatment group (58 adverse events in 40 [14.2%] patients). most of the adverse events during the treatment period assessed as treatment-related were mild or moderate in severity; two patients experienced severe adverse events that were considered treatment-related during the treatment period.  severe adverse events: a total of 24 patients experienced severe adverse events during the treatment period: 4 (1.4%) in the placebo treatment group, 9 (3.2%) in the tanezumab 2.5 mg treatment group, and 11 (3.9%) in the tanezumab 5 mg treatment group.  injection site reactions: seven (7) injection site reactions were reported by six patients in total: one patient each in the placebo treatment group and the tanezumab 2.5 mg treatment group and four in the tanezumab 5 mg treatment group.  potential hypersensitivity adverse events: overall few hypersensitivity adverse events were reported during the study: 10 adverse events in 10 patients (3.5%) in the placebo treatment group, 3 adverse events in 3 patients (1.1%) in the tanezumab 2.5 mg treatment group, and 10 adverse events in 9 patients (3.2%) in the tanezumab 5 mg treatment group. two, in patients in the tanezumab 5 mg treatment group (nasopharyngitis, in an 82-year-old patient, with the cause of death reported as severe cold with probable influenza virus infection; cardio-respiratory arrest, in a 77-year-old patient), occurred during the treatment period. one death (cerebrovascular accident), in a 60-year-old patient in the tanezumab 2.5 mg treatment group, occurred in a patient who was lost to follow-up; this death was not confirmed by the family or the treating physician, but stated on a returned letter that was sent to the patient by the site. in the tanezumab 2.5 mg treatment group, one patient was diagnosed with diffuse b-cell lymphoma 202 days after last dose of study medication, and one patient was reported to have a cerebrovascular accident, which was fatal, 55 days after last dose of study medication."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. in this report, all medical problems that occurred during the study are discussed, regardless of whether or not the study doctors thought that the medical problems were related to taking the study treatment. of the 991 patients who received study treatment, 970 (98%) patients had at least 1 medical problem. a total of 125 (13%) patients stopped taking study treatment because of medical problems. the most common medical problems are listed below.   "," in general, the control arm had the lowest and the treatment arm of chemotherapy in combination with avelumab followed by avelumab maintenance had the highest proportions of patients with teaes of all causality, treatment- related teaes of grade 3, serious teaes, teaes leading to interruption or discontinuation of any study drug, and infusion-related adverse events (iraes). higher proportions of patients in the experimental arms experienced serious teaes or serious treatment-related teaes compared to patients in the control arm. deaths occurred more frequently in the experimental arms than in the control arm, and were most often due to disease progression. deaths occurred in 19 patients (5.8%) who received chemotherapy alone followed by avelumab maintenance and 21 patients (6.4%) who received chemotherapy with avelumab followed by avelumab maintenance compared with 13 patients (3.9%) who received chemotherapy alone followed by observation. these deaths were most often due to disease progression (15 patients [4.6%] who received chemotherapy alone followed by avelumab avelumab maintenance, and 11 patients [3.3%] who received chemotherapy alone followed by observation). teaes during the on-treatment period leading to death occurred in 2% of patients in all treatment arms. teaes leading to permanent discontinuation of any study drug was reported for 11.3% of patients who received chemotherapy alone followed by avelumab maintenance, 19.1% of patients who received chemotherapy with avelumab followed by avelumab maintenance, and 7.5% of patients who received chemotherapy alone followed by observation. treatment-related teaes leading to permanent discontinuation of any study drug was reported for 9.8% of patients who received chemotherapy alone followed by avelumab maintenance, 15.5% of patients who received chemotherapy with avelumab followed by avelumab maintenance, and 6.6% of patients who received chemotherapy alone followed by observation. discontinuations of any study drug due to iraes occurred in 8 patients (2.4%) who received chemotherapy alone followed by avelumab maintenance and 19 patients (5.8%) who received chemotherapy with avelumab followed by avelumab maintenance. discontinuations of any study drug due to irrs occurred in 3 patients (0.9%) who received chemotherapy alone followed by avelumab maintenance and 7 patients (2.1%) who received chemotherapy with avelumab followed by avelumab maintenance compared with 4 patients (1.2%) who received chemotherapy alone followed by observation. serious treatment-related teaes were experienced by 42 patients (12.8%) who received chemotherapy alone followed by avelumab maintenance, 63 patients (19.1%) who received chemotherapy with avelumab followed by avelumab maintenance, and 29 patients (8.7%) who received chemotherapy alone followed by observation. summary of most common serious teaes (any grade in 2% subjects or based on the irae case definition and subsequent medical review, patients who received chemotherapy with avelumab followed by avelumab maintenance most frequently experienced iraes, iraes considered grade 3, and serious iraes."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 33 out of 50 patients in this study had at least 1 medical problem. 1 patient left the study because of medical problems. the most common medical problems are listed below. ","  safety results: a total of 33 subjects reported 109 all causality treatment-emergent adverse events (teaes), of which 8 subjects experienced 18 treatment-related teaes. of the 18 treatment-related teaes, 12, 5, and 1 event was mild, moderate, and severe in severity, respectively. no deaths, malignancies, or dose reductions or temporary discontinuations due to teaes occurred in this study. one (1) and 2 subjects discontinued from study and study treatment due to teaes, respectively. three (3) of these resulted from worsening of underlying disease activity and the fourth was a case of alopecia/baldness, which was reported as related to the study drug by the investigator as a suspected unexpected serious adverse reaction (susar), but unrelated by the sponsor. immunogenicity: based on ada assay with acid pre-treatment and cell-based nab assay, the incidence of ada in this study was 82% with titer values ranging from 1.31 to 4.42 and 1 value above the assay range (>4.64). the study showed statistically significant results in the primary endpoint with an endoscopic improvement rate of 38.2% (95% ci: 23.8%, 53.7%) at week 14 in the pp population. of the 109 teaes, 18 treatment-related teaes were reported by 8 subjects: 12 teaes were mild, 5 teaes were moderate and 1 teae was severe. three (3) of these resulted from worsening of underlying disease activity and the fourth was a case of alopecia/baldness, which was reported as related to the study drug by the investigator as an susar but unrelated by the sponsor.  of the 50 subjects enrolled into the treatment/induction period, 4 subjects discontinued treatment: 1 subject was related to an sae (alopecia); 2 subjects discontinued due to non-serious aes related to worsening uc; and the other subject discontinued due to lack of efficacy.  of the 49 subjects who entered into the follow-up period of the study, 7 subjects discontinued from study. one (1) subject discontinued due to lack of efficacy, and 6 subjects withdrew from the study (2 withdrew their consent and 4 withdrew from the study as they did not want to further participate in the follow-up period of the study). there appeared to be a trend of lower stl1a target engagement starting from week 8 for ada and nab positive subjects compared to the ada and nab negative subjects. however, the small sample size, high variability, and the high ada incidence rates did not provide sufficient information to make definitive conclusion on the impact of ada/nab on the pk and efficacy. pharmacokinetics and pharmacodynamics  following multiple dose administration of 500 mg pf-06480605 intravenously q2w for a total of 7 doses in subjects with moderate to severe uc, geometric mean cmax and auc values were 263400 ng/ml and 57610000 nghr/ml, respectively, with a  geometric mean ptr of 3.0."
" the researchers recorded any medical problems the boys had during the study. boys could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the boy was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 49 out of 59 boys (83%) in this study had at least 1 medical problem. the most common medical problems are listed below. edical oblem ll eadache mmon miting osebleed ver fection se, per uffy u hroat ck omach arrhea uise ugh in unny oken g asonal researchers also found that:  no boys in this study had medical problems that caused them to temporarily stop taking domagrozumab, or that caused the dose of domagrozumab to be lowered.  most of the medical problems that happened during this study were considered to be mild in severity. 4 boys (7%) had medical problems that were considered to be severe.  6 boys (10%) had medical problems that were considered to be related to taking domagrozumab. these medical problems were considered to be mild in severity.  1 boy (2%) left this study and passed away because of a medical problem. this medical problem was not considered to be related to taking domagrozumab.  findings from lab studies, physical examination, x-rays, and other tests were used to learn more about the safety of domagrozumab. in this study, no long-term safety issues were associated with taking domagrozumab. this does not mean that everyone in this study had these results. these are just some of the main findings of the study, and more information may be available at the websites listed at the end of this summary. ","  safety results: there were 195 all causalities treatment emergent adverse events (teaes) reported by 49 (83.1%) participants. of these, 6 teaes were determined by the investigator as treatment related, and were reported by 6 (10.2%) participants. the most commonly reported teaes, regardless of causality, were in the socs of infections and infestations (28/59 participants, 47.5%), and injury, poisoning and procedural complications (23/59 participants, 39.0%). there was 1 (1.7%) participant who discontinued from study due to an sae of fat embolism syndrome that resulted in death. there were 4 (6.8%) participants who experienced severe aes, none of which were determined by the investigator as treatment related. one (1) participant from sequence 3 had a transient abnormal elevation in gldh (>2  uln) during the study; there were no other signs of hepatic injury observed. three (3) participants from sequence 1 had reported teaes of increased cardiac troponin i, one of which was determined as an sae. a mild treatment related teae of abnormal pubertal hair growth was experienced by 1 participant from sequence 2. precocious puberty was not observed. there was no apparent change observed in bone mineral density (bmd) (including z-score and height adjusted z-score) in anteroposterior (ap) spine total l1 to l4 or body without head over time. there was 1 participant from sequence 1, whose left ventricular ejection fracture (lvef) was 50% at both overall and b5161004 baseline, had an lvef of <50% at early termination visit. overall baseline for lvef was defined as the last pre-dose assessment prior to the first day of dosing in study b5161002; b5161004 baseline was defined as the last assessment prior to dosing on day 1 in study b5161004. one (1) participant from sequence 2 had suicidal ideation at week 13 but did not have any suicidal behavior. conclusions:  a 40 mg/kg dose of domagrozumab administered every 4 weeks by iv infusion over 97 weeks (b5161004) was generally safe and well tolerated in boys with dmd in this study.  there were no long-term safety issues associated with dosing dmd boys with domagrozumab in parent study b5161002 for 96 weeks following an additional 97-week treatment of domagrozumab in ole study b5161004.  in general, the mean changes from baseline for 4sc, nsaa, pfts, muscle strength, pul, 6mwt and rom appeared to be consistent with the cinrg natural history dataset.  following domagrozumab iv administration every 4 weeks at 40 mg/kg, trough values steadily increased relative to the first dose.  trough values appeared to be at steady state at approximately week 25 for all sequences.  no participants tested positive for ada in the study."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by the study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. a total of 110 out of 118 (93%) treated participants had at least 1 medical problem. nine (8%) participants stopped taking talazoparib because of medical problems. the most common medical problems  those reported by at least 10% of participants  are described below. below are instructions for understanding table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 10% of participants are listed.  the 2nd column tells how many of the 118 participants treated with talazoparib reported each medical problem. next to this number is the percentage of the 118 participants treated with talazoparib who reported the medical problem.  using these instructions, you can see that for 39 out of the 118 (33%) participants treated with talazoparib, a low number of red blood cells was reported as a medical problem.  ","  safety results: the median duration of exposure to talazoparib during this rollover study was 3.7 months (range: 0.453.7 months), with a total of 26 (22.0%) patients treated for 12 months. the median duration of exposure to talazoparib including the treatment period on the originating studies was 4.9 months (range: 1.1-106.2 months). a total of 29 (24.6%) patients were treated for 12 months from the originating studies to the end of this study. an overview of treatment-emergent adverse events (teaes) for the safety population is provided in table s4. the most frequently reported study drug-related aes (10% of patients) were anaemia (35 [29.7%] patients), nausea (17 [14.4%] patients), fatigue (16 [13.6%] patients), thrombocytopenia (15 [12.7%] patients) and neutropenia (14 [11.9%] patients). overall, 56 (47.5%) patients reported at least 1 ae of cytopenia. the most frequently reported preferred terms associated with myelosuppression were anaemia (39 [33.1%] patients), thrombocytopenia (17 [14.4%] patients) and neutropenia (14 [11.9%] patients).  overall, 1 (0.8%) patient developed a grade 4 ae of leukaemia, which was an sae and considered as possibly related to study drug in addition to other factors such as past chemotherapy (paclitaxel, cyclophosphamide, cisplatin and vinorelbine) by the investigator.  no patients had reported aes identified by the search of smq myelodysplastic syndrome for mds.  a total of 3 (2.5%) patients had an event of vte, including 2 non-serious aes of thrombophlebitis superficial and 1 non-serious ae of pulmonary embolism. one of the aes of thrombophlebitis superficial was considered possibly related to study drug, the other ae of thrombophlebitis superficial and the ae of pulmonary embolism were not considered related to study drug. one additional fatal ae, a cerebrovascular accident, was reported beyond the 30-day period from the last dose, and was considered not related to study drug. study drug-related saes were reported for 9 (7.6%) patients. a total of 51 (43.2%) patients experienced aes associated with dose interruptions, with the most frequently reported being anaemia (13 [11.0%] patients). a total of 13 (11.0%) patients experienced aes associated with dose reductions, with the most frequently reported being anaemia (6 [5.1%] patients). overall, the incidence of chemistry parameter abnormalities was low; the chemistry parameter abnormalities that increased 2 or more toxicity grades from baseline included high alkaline phosphatase (2 [1.7%] patients), high bilirubin (2 [1.7%] patients), and high creatinine (1 [0.8%] patient). conclusion: overall, the safety profile of talazoparib is consistent with the previously reported safety profile."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. one-hundred and forty-six (146) out of 317 (46%) participants in the induction of this study had at least 1 medical problem. a total of 14 participants left the study because of medical problems. the most common medical problems  those reported by more than 5% of participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 5% of participants are listed.  the 2nd column tells how many of the 150 participants taking ritlecitinib reported each medical problem. next to this number is the percentage of the 150 participants taking the ritlecitinib who reported the medical problem.  the 3rd column tells how many of the 142 participants taking brepocitinib reported each medical problem. next to this number is the percentage of the 140 participants taking the brepocitinib who reported the medical problem.  the 4th column tells how many of the 25 participants taking a placebo reported each medical problem. next to this number is the percentage of the 25 participants taking a placebo who reported the medical problem.  using these instructions, you can see that 6 out of the 150 (4%) participants taking ritlecitinib reported having a headache, and 5 out of 142 (4%) participants taking brepocitinib reported having a headache. a total of 2 out of the 25 (8%) participants taking a placebo reported having a headache. "," induction period: the 317 participants who received at least 1 dose of ritlecitinib, brepocitinib, or placebo during the induction period were analyzed in 7 treatment groups: a total of 146 (46.1%) participants reported 308 all-causality aes during the induction period, 81 of the aes were assessed by the investigator as study treatment-related. numerically more participants in the brepocitinib treatment groups (16.9%) experienced all-causality aes under the system organ class (soc) of infections and infestations when compared with the placebo (4.0%) and the ritlecitinib treatment groups (8.7%). a total of 10 (6.7%) participants in the ritlecitinib treatment groups compared to 4 (2.8%) participants in the brepocitinib treatment groups discontinued the study due to all-causality aes. three all-causality sae infections were reported in 2 participants during the induction period, both in the ritlecitinib groups (1 each in the 20 mg and 200 mg treatment groups), and none of these saes (infections) were assessed as related to the study treatment. one participant in the ritlecitinib 20 mg treatment group experienced an sae of myocardial infarction which resulted in death. during the induction period, there was 1 thromboembolic event reported as an sae of peripheral artery thrombosis (with concurrent ae of thrombocytosis) in a participant in the brepocitinib 30 mg treatment group, and the sae was considered unrelated to the study treatment. herpes simplex aes were reported in 4 participants (1 in the ritlecitinib group and 3 in the brepocitinib group and none in the pooled placebo group). herpes zoster aes were reported in 3 participants with 1 each in the brepocitinib 60 mg, ritlecitinib 70 mg and placebo group). unexplained skin rashes aes occurred in a balanced manner between ritlecitinib and brepocitinib treatment groups (5 participants in the ritlecitinib treatment groups, 4 in the brepocitinib treatment groups and 2 in the placebo group). thirty-one participants in the brepocitinib treatment groups (11.1%-30.8% across treatment groups) experienced aes under the soc of infections and infestations compared to the ritlecitinib treatment groups (20 participants, 10.3%-22.2% across treatment groups) and the pooled placebo group (8 participants, 15.4%). nineteen (6.8%) participants discontinued from the study due to all-causality aes. the majority were in the pooled placebo groups (6 participants, 16.2%), followed by brepocitinib 30 mg30 mg treatment group (4 participants, 10.3%) and ritlecitinib 20 mg50 mg treatment group (3 participants, 7.7%). two sae infections were reported in 2 participants during the chronic period, both in the brepocitinib groups (1 each in the brepocitinib 10 mg30 mg and 60 mg30 mg treatment groups), and neither of these saes (infections) were assessed as related to brepocitinib."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 149 out of 212 (70%) patients in this study had at least 1 medical problem. a total of 14 (7%) patients stopped taking study treatment because of medical problems. nine (9) of these patients (4%) had medical problems that were considered related to study treatment, including 1 patient who became pregnant and the fetus had a condition in which the lip did not develop properly. the most common medical problems are listed below. medical problem acne back bronchitis diarrhea feeling irritable feeling tired headache hot infection the throat, airways itching joint low number a white blood nausea sinus infection sore sore, cracked lips sprain the that connects the and throat pain urinary tract infection vomiting worsening psoriasis ","  safety results: subjects discontinued from study due to aes are summarized in table 1. all-causality and treatment-related treatment emergent saes are summarized in table 5 and table 6, respectively. all-causality treatment emergent non-saes occurring in >5% of subjects are summarized in table 7. one post-therapy death occurred due to gunshot wound after the subject was discontinued from the study due to noncompliance with study drug, which was considered unrelated to the study treatment by the investigator. five subjects experienced a total of 6 saes during the study; 3 of the saes were considered to be related to study drug by the investigator, of which 2 saes (pneumonia and sepsis) reported by 1 subject in the 60 mg qd to 100 mg qw group were considered not related to 2 saes of pneumonia and sepsis on day 2 before dosing and was permanently discontinued from study due to the sae of pneumonia. one subject in the 30 to 10 mg qd group was found to have a positive urine human chorionic gonadotropin test at the week 6 (day 42) visit after which confirmation with serum pregnancy test led to permanent discontinuation from study on day 53. on day 165, an obstetrical ultrasound demonstrated a right-sided cleft lip with a gap of 10 millimeters in the fetus, with no definite cleft palate. six subjects experienced aes of herpes simplex; 5 were mild in severity and 1 was a moderate ae of herpes simplex reported by 1 subject in the 60 mg qd to 100 mg qw group during the induction period. one subject in the 30 mg qd to 100 mg qw group was reported to have an ae of squamous cell carcinoma of the skin on day 2. the ae was mild and not related to the study drug as evaluated by the investigator, and resolved on day 57. serious infections (pneumonia and sepsis) were reported for 1 subject in the 60 mg qd to 100 mg qw group. the subject only had 1 dose of pf-06700841 60 mg on day 1 and the serious infections (pneumonia and sepsis) occurred on day 2 before dosing. there were no clinically meaningful observable dose dependent neutropenia, lymphopenia, thrombocytopenia, and anemia among the active treatment groups, except for 1 sae of anemia reported by 1 subject in the 60 to 10 mg qd group. during the study, the subject developed a moderate ae of acute kidney dysfunction and concomitant 30% decreases from baseline in serum creatinine (scr) based and serum cystatin-c (s cystatin-c) based estimated glomerular filtration rate (egfr), which were considered as individual clinically significant laboratory abnormalities.  statistically significantly greater decreases from baseline in pasi score at week 12 were observed in 5 active treatment groups versus placebo: 60 to 30 mg qd, 60 mg qd to 100 mg qw, 30 mg qd, 30 to 10 mg qd, and 30 mg qd to100 mg qw, with the greatest effect observed in the 30 mg qd group."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. of the 70 patients who joined the study, 25 (36%) patients had at least 1 medical problem. a total of 3 (4%) patients left the study because of medical problems. the most common medical problems are listed below. "," a total of 25 (35.7%) subjects experienced 36 treatment-emergent adverse events (teaes), among which 12 events reported by 10 (14.3%) subjects were considered treatment-related. a total of 3 (4.3%) subjects discontinued due to teaes. there was 1 mild case of herpes simplex in the pf-06651600 group that was considered to be treatment-related with no cases in the placebo group. pf-00651600 treatment group than the placebo, as was the number of subjects who discontinued due to teaes or temporarily discontinued due to teaes. number (%) of subjects by system organ class and preferred term n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) includes all data collected since the first dose of study drug. a if the same subject in a given treatment had more than 1 occurrence in the same preferred term event category, only the most severe occurrence was counted. for the tess algorithm any missing severities have been imputed as severe unless the subject experienced another occurrence of the same event in a given treatment for which severity was recorded. without regard to baseline abnormality, 70 (100%) of the 70 treated subjects experienced laboratory abnormalities (table 22). by the week 8 time point, in the pf-06651600 group, there were decreases in the median platelet counts (25% change from baseline), lymphocyte counts (21% change from baseline), neutrophil counts (24% change from baseline), and hemoglobin (3% change from baseline). categorization of vital signs (absolute values, maximum increase from baseline, and maximum decrease from baseline) are presented in table 23, table 24, and table 25, respectively. a total of 3 subjects had sitting diastolic bp values 20 mm hg increase from baseline: 3 subjects in the pf-06651600 treatment group. a total of 1 (1.4%) subject had sitting diastolic bp values 20 mm hg decrease from baseline: 1 (3.6%) subject in the placebo group.  pf-06651600 met the primary endpoint with a mean change from baseline in sdai at week 8 of -26.05 (95% ci: -29.67, -22.44) compared to placebo -16.80 (95% ci: -20.90, -12.68) with a placebo-adjusted difference of -9.25 (95% ci: -14.75, -3.79) (p <0.001).  the sensitivity models consistently estimated the adjusted treatment effect and provided evidence of statistically significant treatment effect. two (2) modifications to the primary analysis population, 1 to exclude 5 subjects who did not meet inclusion/exclusion criteria, and 1 to exclude the 4 subjects who did not complete the week 8 visit produced similar estimates of the treatment effect and its statistical significance."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 123 out of 269 patients in this study had at least 1 medical problem. a total of 12 patients (5%, 12 out of 269 patients) left the study because of medical problems. there were 20 patients (7%, 20 out of 269 patients) who stopped taking the study treatment for a short period of time or who had their dose of study treatment reduced during this study. the most common medical problems are listed below.  "," however, the mild and non-treatment-related ae of thrombocytopenia under the system organ class (soc) of blood and lymphatic system disorders from day 1 to day 30 reported by 1 subject in the pf-06650833 200 mg mr qd arm was determined as not treatment-emergent as the laboratory tests performed on day 1 were before the first dose. twelve (12) subjects permanently discontinued from study due to teaes, and 20 subjects temporarily discontinued from study or had dose reduction due to teaes. eight (8) subjects reported treatment-emergent saes, of whom 1 subject had very high elevations of liver transaminases that were reported by the investigator as an sae of liver injury based on a criterion of medical importance and that was considered treatment-related. the highest number of all-causality teaes reported by subjects were in the socs of infections and infestations (55 subjects [20.4%]) and gastrointestinal disorders (27 subjects [10.0%]). the highest number of treatment-related teaes reported by subjects were in the socs of infections and infestations (16 subjects [5.9%]) and gastrointestinal disorders (14 subjects [5.2%]). there was no clear evidence of a relationship of incidence of laboratory test abnormalities with the dose of pf-06650833. except for the placebo arm, no treatment arm had more than 1 subject meeting categorical changes in total bilirubin, ast, or alt (ie, ast/alt >3  upper limit of normal [uln], or bilirubin >2  uln). conclusions: efficacy  pf-06650833 demonstrated efficacy compared to placebo at week 12 based on the primary efficacy endpoint of change from baseline in sdai using the pre-specified bayesian analysis with an informative placebo prior (p-values 0.005 for all 4 pf-06650833 arms).  pf-06650833 also demonstrated efficacy compared to placebo at week 12 on the main sensitivity analysis of change from baseline in sdai using the pre-specified bayesian analysis with non-informative placebo prior. in this analysis, the treatment effects of the pf-06650833 200 mg and 400 mg doses remained statistically separated from placebo despite the fact that the placebo response was higher than that in the primary analysis when an informative prior was used.  pf-06650833 further demonstrated efficacy compared to placebo at week 12 at the highest 2 doses (200 mg and 400 mg qd) on various pre-specified secondary/sensitivity analyses, including mmrm analyses utilizing longitudinal data of change from baseline in sdai as well as ancova in the itt population.  the efficacy of pf-06650833 on the primary endpoint was supported by consistent trends of improvement in a number of secondary endpoints (sdai ldas, acr50 response, change from baseline in das28, das28 ldas, das28 remission, tjc [28], and hscrp).  greater efficacy was generally observed at the higher doses (200 mg and 400 mg) of pf-06650833 compared to the lower doses (20 mg and 60 mg)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease, such as their prostate cancer, or by chance). or, medical problems could also have been caused by the study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by collating medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. of the 127 participants who received study treatment, 121 (95%) participants reported at least 1 medical problem during their treatment in the study. a total of 15 (12%) participants stopped taking study treatment because of medical problems. the table below shows the most common medical problemsthose occurring in at least 20% of participantsthat happened during the study. below are instructions on how to read tables 1 and 2. instructions for understanding tables 1 and 2.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 20% of participants are listed.  the 2nd column tells how many of the 127 participants treated with talazoparib reported each medical problem. next to this number is the percentage of the 127 participants treated with talazoparib who reported the medical problem.  using these instructions, you can see that 62 out of 127 (49%) participants had low number of red blood cells. "," all-causality treatment-emergent aes and serious aes (saes): 95.3% (121/127) and 33.9% (43/127) of participants experienced teaes and treatment-emergent serious ae (te- saes), respectively.  vte were reported in 9.4% (12/127) of participants. however, all except 1 pulmonary embolism were considered unrelated to study intervention.  secondary primary malignancies (other than hematologic) were reported in 2.4% (3/127) of participants. of note, the secondary primary malignancy, lymphangiosis carcinomatosa, experienced by 1 participant was incorrectly captured as a second primary malignancy, rather it was attributed to progressive disease by the investigator.  pneumonitis was reported in 1.6% (2/127) of participants. one participant had bilateral pneumonitis (grade 2) reported by the investigator as related to the participants primary disease and resolved with concomitant medication. the second participant had asymptomatic pneumonitis (grade 1) reported as treatment-related, which was ongoing at the time the participants participation in the study ended. hematologic teaes of special interest:  all-causality hematologic teaes reported were anemia in 48.8% (62/127) of participants, thrombocytopenia was reported in 18.9% (24/127) of participants, and neutropenia was reported in 16.5% (21/127) of participants.  treatment-related hematologic teaes reported were anemia in 42.5% (54/127) of participants, thrombocytopenia in 17.3% (22/127) of participants, and neutropenia in 15.0% (19/127) of participants. deaths, other serious adverse events, and other significant adverse events:  as of the data cutoff, 54.3% (69/127) of deaths were reported. clinical laboratory results:  a total of 19.4% (24/124) and 16.1% (20/124) of participants experienced a lab shift to grade 3 or 4 postbaseline of anemia and decreased lymphocyte count, respectively.  the most common (5%) shifts to grade 3 or 4 post baseline were increased alkaline phosphatase in 7.2% (9/125) of participants and increased gamma-glutamyl transferase (ggt) in 6.0% (3/50) of participants.  the overall incidence of alanine aminotransferase (alt) or aspartate aminotransferase (ast) values 3 upper limit of normal (uln) was 1.6% (2/127), with 1 participant each experiencing alt 3 uln or ast 3 uln. vital sign results: a total of 12.0% (15/125) of participants experienced a diastolic blood pressure of 20 mmhg increase from baseline and 0.8% (1) of participants experienced a heart rate of 120 bpm and increase from baseline of >30 bpm, considered potentially clinically significant. conclusions the talapro-1 data provides evidence of substantial and durable antitumor efficacy, with a favorable benefit-risk profile in a heavily pretreated patient population, suggesting that talazoparib can provide an effective salvage therapy for patients with ddr-mutated advanced mcrpc, thus addressing the high unmet medical need for this patient population."
" the researchers recorded any medical problems the patients had during the study. patients could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the patient was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 29 out of 40 (73%) patients in this study had at least 1 medical problem. a total of 2 (5%) patients left the study because of medical problems. the most common medical problems are listed below.  ","  safety results: in total, 81 aes were reported in 29 (out of 40) subjects during the course of the study. eleven (11) of the aes were considered treatment-related, and none were serious. two (2) subjects discontinued from the study due to aes and no subjects had aes that required dose reduction or temporary discontinuation of treatment. the most frequently reported all-causality teaes by medical dictionary of regulatory activities (meddra) preferred term were nasopharyngitis (11 subjects) and headache (9 subjects), none were considered treatment-related. the most frequent treatment-related ae was application site pain which was experienced by 7 subjects. two (2) subjects discontinued from the study due to aes (treatment-emergent ad events). both were not treatment-related and reported as resolved. none of the observed laboratory abnormalities were clinically significant. any clinically significant physical examination findings were to be reported as aes. conclusions:  the primary efficacy endpoint was achieved in subjects with mild to moderate ad. the crisaborole treated lesions showed a statistically significant reduction in tss at day 15 compared with the vehicle treated lesions (-4.5 versus -2.1). intra-subject difference of tss change from baseline was -2.4 with a p-value <0.0001.  in subjects with mild to moderate ad, crisaborole 2% was superior to vehicle for the changes from baseline in lesion tss at day 8 and lesion isga at day 8 and day 15.   a significant improvement with crisaborole 2% treatment for pruritus nrs was maintained from 1 day following the first application through day 15 compared with vehicle.   the primary biomarker endpoint was reached as crisaborole 2% reduced the key skin biomarkers measured at day 15, and the reduction was significant for the key biomarkers of ccl17 (tlda), ccl18 (tlda), ccl22 (tlda), il-13 (qpcr, but not tlda), keratin 16 (tlda), pi3 (tlda) and s100a12 (tlda).  crisaborole 2% reduced key skin biomarkers measured at day 8, and the reduction was significant for ccl17 (tlda), ccl22 (tlda), keratin 16 (tlda), pi3 (tlda) and s100a12 (tlda) but not significant for ccl18 (tlda), il-13 (tlda) and il-13 (qpcr).  at day 15, flg normalization rate, histological response rate and keratin 16 improvement rate were higher in the crisaborole 2% treated area compared with the vehicle treated area.   crisaborole ointment 2% was well-tolerated and had an acceptable safety profile in subjects with mild to moderate ad."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. approximately two-thirds of the 305 participants who were treated in this study had at least 1 medical problem. a total of 22 participants left the study because of medical problems. there were 13 participants who had their dose of pf-05221304 reduced or stopped treatment temporarily because of medical problems. the most common medical problems are listed in the following table.  a the 244 participants treated included 63 with 2 mg, 62 with 10 mg, 58 with 25 mg, and 61 with 50 mg pf-05221304. b in clinical studies, increased amounts of triglycerides (a certain type of fat or lipid) in the blood may be reported using different terminology that has the same meaning such as hypertriglyceridemia or blood triglycerides increased. ","  safety results: a total of 16 participants experienced 22 saes during the study. of these, 13 saes including 1 fatal event in 10 participants occurred prior to randomization and 9 saes in 6 participants occurred during post randomization. none of the saes reported post randomization was considered treatment-related by the investigator and none resulted in permanent discontinuation from the study. approximately two-thirds of the 305 participants reporting teaes of severe intensity. a total of 23 (7.5%) of the 305 randomized participants were permanently discontinued due to aes while 13 (4.3%) participants had a temporary discontinuation of study drug due to aes. total reflects participants who were randomized and had received at least 1 dose of double-blinded treatment.meddra version 22.0 coding dictionary applied. at week 16, significant, dose-responsive reductions in hdl-c, apolipoprotein a1, and low non-hdl, apolipoprotein b, triglycerides, apolipoprotein c3, very low density lipoprotein (vldl), and apolipoprotein e were observed with the top 3 doses of pf-05221304 (10 mg, 25 mg and 50 mg) relative to placebo. the increases in fasting serum triglycerides, non- hdl along with decreases in hdl-c and direct ldl-c were evident as early as week 2 and appeared to plateau at the latest by week 8, with a return to baseline observed once study drug was stopped (ie, at follow-up visit). across the fasted apolipoproteins assessed, increases in apolipoprotein b, c3, and e (along with reduction in apolipoprotein a1) were evident by week 4 with no further change despite continued dosing until week 16. compared to placebo, pf-05221304 had no clinical meaningful effect on vital signs or cardiac conduction intervals as assessed by 12-lead ecgs. conclusions:  over the dosing duration of 16 weeks, pf-05221304 was found to decrease hepatic steatosis in a dose-dependent manner with effect clearly separating from placebo at the top 3 doses evaluated (10 mg to 50 mg) in this study in adults with nafld.  pf-05221304, in the sub-set of adults with alt >uln - ie, (presumed) nash, decreased non-specific/non-selective markers of overall liver health (alt), in a dose-dependent manner, with this effect clearly separating from placebo at the top 3 doses evaluated (10 mg to 50 mg), in this study.  the 25-fold dose range of pf-05221304 was found to be generally well tolerated in this study.  however, the observed changes in serum triglycerides and accompanying effect on other lipid parameters at the top 2 doses of pf-05221304 are undesirable due to their potential implications for long term cardiometabolic health."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. a total of 17 out of 20 (85%) participants in this study had at least 1 medical problem. the most common medical problems  those reported by more than 1 participant  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 1 participant are listed.  the 2nd column tells how many of the 10 participants taking pf-06687234 plus infliximab reported each medical problem. next to this number is the percentage of the 10 participants taking pf-06687234 plus infliximab who reported the medical problem.  the 3rd column tells how many of the 10 participants taking a placebo plus infliximab reported each medical problem. next to this number is the percentage of the 10 participants taking a placebo plus infliximab who reported the medical problem.  using these instructions, you can see that none of the 10 participants taking pf-06687234 plus infliximab reported worsening uc. a total of 3 out of the 10 (30%) participants taking a placebo reported worsening uc. there were 3 participants (15%, or 3 out of 20 participants) who left the study because of medical problems; 1 in the pf-06687234 plus infliximab group and 2 in the placebo plus infliximab group. ","  safety results: in the placebo group, 8 (80.0%) participants had 16 treatment-emergent adverse events (teaes) reported, of which, 2 were considered to be treatment-related and reported in 1 (10.0%) participant. two (20.0%) participants discontinued study drug due to aes and continued in the study. two (20.0%) participants had severe teaes (1 participant had a severe sae of colitis ulcerative and 1 participant had severe nsaes of colitis ulcerative and acne). one (10.0%) participant temporarily discontinued due to aes. none of the teaes were reported by more than 1 participant except for colitis ulcerative (3 [30.0%] participants) and headache (2 [20.0%] participants). in the pf-06687234 group, 9 (90.0%) participants had 29 teaes reported, of which, 8 were considered to be treatment-related and reported in 7 (70.0%) participants. one (10.0%) participant discontinued study drug due to aes and continued in the study. one (10.0%) participant temporarily discontinued due to aes. the most frequently reported teae was injection site reaction (3 [30.0%] participants) which were all considered to be treatment-related. most of the teaes were reported by single participants. the incidence of teaes was comparable between 2 groups. the majority of teaes were mild in severity. one participant in the placebo group had a serious adverse event (sae) of colitis ulcerative. eighteen (90.0%) participants (9 in each group) had laboratory test abnormalities. the most frequently reported abnormalities were leukocyte esterase 1 (7 [35.0%] participants). the most frequently reported finding was sitting diastolic blood pressure (dbp) change  20 mmhg decrease (5 [25.0%] participants). none of the findings were considered to be clinically significant. one participant in the pf-06687234 group had corrected qt interval using fridericias formula (qtcf) change  30-<60 msec. conclusions: efficacy: generally, no significant difference was observed in participants achieving efficacy improvement (modified clinical remission, endoscopic improvement, decreases in histology scores, clinical response and decreases in mayo scores) between the pf-06687234-treated group and placebo-treated group. pk: only 2 participants were included in the pk subgroup. immunogenicity: generally, there were no differences in anti-pf-06687234 response between pf-06687234- and placebo-treated groups. there were no new safety findings in participants treated with combination of pf-06687234 and infliximab. there were no deaths, generally no difference in saes, severe aes, or aes leading to discontinuation between the 2 treatment groups. the most frequently reported ae in the pf-06687234 group was injection site reaction."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. below are instructions for understanding table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 15% of participants are listed.  the 2nd column tells how many of the 37 participants taking binimetinib + nivolumab reported each medical problem. next to this number is the percentage of the 37 participants taking binimetinib + nivolumab who reported the medical problem.  the 3rd column tells how many of the 38 participants taking binimetinib + nivolumab+ ipilimumab reported each medical problem. next to this number is the percentage of the 38 participants taking binimetinib + nivolumab+ ipilimumab who reported the medical problem.  using these instructions, you can see that 20 out of the 37 participants (54%) taking binimetinib + nivolumab reported diarrhea. a total of 19 out of the 38 participants (50%) taking binimetinib + nivolumab+ ipilimumab reported diarrhea. all 75 participants (100%) treated in this study had at least 1 medical problem. a total of 16 (21%) participants stopped taking study treatment because of medical problems. the most common medical problems  those reported by at least 15% of participants in any group  are described below.   ","  safety results: adverse events: the following sections presents treatment-emergent adverse events (teaes) unless all 75 treated participants were reported with aes, and 74 (98.7%) participants were reported with treatment-related aes. a total of 34 (45.3%) participants were reported with serious adverse events (saes), and a total of 17 (22.7%) participants were reported with treatment-related saes. a total of 16 (21.3%) participants were reported with aes leading to discontinuation of any study drug. of the 9 participants evaluable for dlts in arm 1a, 1 (11.1%) participant was reported to have a dlt. of the 11 participants evaluable for dlts in arm 1b, 2 (18.2%) participants were reported to have a dlt. a total of 37 (100%) participants in doublet arm and 38 (100%) participants in triplet arm were reported with at least an ae. deaths were reported for 57 (76.0%) participants in total, with on-treatment deaths (ie, deaths occurring during treatment or within 30 days of the last study medication) reported for 7 (9.3%) participants (1 [10.0%] in arm 1a, 2 [7.4%] in arm 2a, 2 [18.2%] in arm 1b, and 2 [7.4%] in arm 2b). the most frequently reported all-causality saes were pyrexia and pericardial effusion (each reported in 2 [5.4%] participants) in doublet arm, and pneumonia, pleural effusion and pneumonitis (each reported in 2 [5.3%] participants) in triplet arm. all treatment-related saes were reported in 1 participant each except for pneumonitis, which was reported in 2 participants in triplet all-causality aes leading to binimetinib discontinuation were reported for 3 (8.1%) participants in doublet arm, and 13 (34.2%) participants in triplet arm. other safety evaluations: for 37 participants in doublet arm and 38 participants in triplet arm, shift for corrected qt interval using bazetts correction formula (qtcb) from 450 msec at baseline to >450 msec post-baseline was reported for 8 participants in doublet arm and 4 participants in triplet arm. conclusion(s): efficacy:  in phase 2, the confirmed orr was 0% for the doublet regimen and 7.4% (90% ci: 1.3, 21.5) for the triplet regimen, which was not considered clinically meaningful. the protocol did not meet a priori expected response rate, which was defined as clinically meaningful response rate of 20% (doublet) and 30% (triplet), whereas the null hypothesis was that the response rate was at most 5% (doublet) and at most 10% (triplet). safety:  one (11.1%) and 2 (18.2%) participants were reported to have a dlt in arm 1a and arm 1b, respectively."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by the study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. all 95 participants (100%) in this study had a medical problem, and 89 participants (94%) had a medical problem that was considered to be related to the study treatment. a total of 39 (41%) participants stopped taking study treatment because of medical problems. the table below shows the most common medical problemsthose occurring in at least 30% of participantsthat happened during the study, some of which resulted in participants having to stop treatment. below are instructions on how to read tables 1 and 2. instructions for understanding tables 1 and 2.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 30% of participants are listed.  the 2nd column tells how many of the 95 participants treated with pf-06804103 reported each medical problem. next to this number is the percentage of the 95 participants treated with pf-06804103 who reported the medical problem.  using these instructions, you can see that 43 (45%) participants reported hair loss. did study participants have any dose-limiting toxicities (dlts)? during part 1a, 4 out of 47 (9%) participants had dlts:  1 participant in the pf-06804103 3 mg/kg cohort had joint pain and nerve pain  1 participant in the pf-06804103 3 mg/kg cohort had musculoskeletal (muscles, bones, and joints) pain  1 participant in the pf-06804103 4 mg/kg cohort had decreased ability of the heart to pump blood  1 participant in the pf-06804103 4 mg/kg cohort had muscle pain, joint pain, and tiredness based on these results, the researchers selected 4 mg/kg as the recommended dose to study further, with flexibility to reduce to a lower dose (such as 3 mg/kg), if needed. ","  safety results: of the 1121 all-causality treatment-emergent adverse events (teaes) reported in 95 (100%) participants, 731 were considered to be treatment-related. all participants had at least 1 teae, whereas 89 (93.7%) participants had treatment-related aes. the most frequently reported all-causality teaes were alopecia (45.3%), fatigue (41.1%), peripheral sensory neuropathy (32.6%), myalgia (31.6%), constipation (30.5%) and rash (30.5%). the most frequently reported treatment-related aes were alopecia (45.3%), fatigue (33.7%), peripheral sensory neuropathy (31.6%), myalgia (30.5%), rash (27.4%), arthralgia (23.2%), decreased appetite (23.2%), neuropathy peripheral (22.1%), weight decreased (21.1%) and stomatitis (20.0%). a total of 39 (41.1%) participants had teaes associated with drug withdrawal. generally, higher percentage of participants had maximum grade 3-4 teaes, treatment-related aes and drug withdrawal due to aes reported in pf-06804103 >2.0 mg/kg groups. in part 1a, a total of 4 participants had dlts reported. two participants in the pf-06804103 3.0 mg/kg group had dlts. one participant had grade 3 non-serious adverse events (nsae) of arthralgia and grade 3 sae of neuralgia, which were both considered to be treatment-related. one participant had grade 3 musculoskeletal pain, which was considered to be treatment-related and associated with drug withdrawal. two participants in the pf-06804103 4.0 mg/kg group had dlts. one participant had grade 2 ejection fraction decreased, which was considered to be treatment-related. one participant had grade 3 aes of arthralgia, myalgia, and fatigue, which were all considered to be treatment-related. one participant with hr+ her2-low bc in part 2a receiving pf-06804103 3.0 mg/kg died due to non-treatment-related neoplasm progression. the participant only received 1 dose of pf-06804103. of them, 29 (30.5%) participants had grade 3-5 saes and 19 (20.0%) participants had treatment-related saes. twenty-eight (29.5%) participants had 30 mmhg increase from baseline in systolic blood pressure (sbp); 18 (18.9%) participants had 30 mmhg decrease from baseline in sbp. the 3 mg/kg dose was better tolerated but appeared less efficacious and vice versa for 4 mg/kg seen in both her2+ bc and hr+ her2-low bc. in participants with her2+ bc, only 1 confirmed responder was observed receiving pf-06804103 3 mg/kg and this participant had the longest dr of 18.9 months; 5 confirmed responders receiving pf-06804103 4 mg/kg had the median dr of 7.0 months (range: 2.4, 18.7). the exposure of all 3 analytes increased in a dose dependent manner following single and multiple dosing, and dose accumulation was minimal following repeated dosing."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 272 out of 387 patients in this study had at least 1 medical problem. a total of 25 patients left the study because of medical problems. the most common medical problems are listed below. ","  safety results:  a higher incidence of subjects with all-causality treatment-emergent aes (teaes) occurred in the pf-04965842 treatment groups compared with the placebo group (table 8).  the majority of teaes were mild or moderate; the incidence of severe teaes was lower in the pf-04965842 treatment groups compared with the placebo group.  a similar proportion of subjects had serious teaes across all treatment groups (3.2% to 3.9%) and no deaths were reported in the study.  the incidence of subjects who permanently discontinued from the study due to teaes was lower in the pf-04965842 treatment groups compared with the placebo group. subjects evaluable for adverse events 77 156 154 conclusions: efficacy  both pf-04965842 dose groups (200 mg qd and 100 mg qd) met the co-primary endpoints of iga response of clear (0) or almost clear (1) and 2-points improvement from baseline at week 12 and easi response 75% improvement from baseline at week 12.  both pf-04965842 dose groups (200 mg qd and 100 mg qd) had statistically significantly greater changes from baseline in psaad total scores than the placebo group at week 12, with early separation of efficacy at week 1 for both pf-04965842 groups compared with the placebo group.  both pf-04965842 treatment groups demonstrated statistically significantly greater differences from the placebo group in easi-50 and easi-90; easi-50 responses occurred at all time points and easi-90 responses started at week 4 in the pf-04965842 200 mg qd group and week 8 in the pf-04965842 100 mg qd group.  both pf-04965842 dose groups had statistically significant differences from the placebo group for iga responses beginning at week 2 in the pf-04965842 200 mg qd group and week 8 in the pf-04965842 100 mg qd group, and for easi-75 responses beginning at week 2 for the pf-04965842 200 mg qd group and at week 4 for the pf-04965842 100 mg qd group.  both pf-04965842 treatment groups demonstrated statistically significant differences of scorad50 from the placebo group as early as week 2 that were maintained up to week 12. beginning at week 2 for the pf-04965842 200 mg qd group and only at week 8 for the pf-04965842 100 mg qd group, statistically significant differences of scorad75 from the placebo group were observed. patient-reported outcomes  favorable differences across all pro measures were observed for both pf-04965842 treatment groups compared with the placebo group at week 12. for all measures assessed (dlqi/cdlqi, hads, poem, ptga, and eq-5d-5l), treatment differences emerged as early as week 2 and were maintained at subsequent time points up to week 12.  an improvement in the frequency of symptoms associated with atopic dermatitis in the poem assessment was seen in both pf-04965842 treatment groups compared with the placebo group.  an improvement in patient impression of severity of disease within the ptga was seen in both pf-04965842 treatment groups compared with the placebo group. pharmacokinetics  pf-04965842 plasma concentrations in moderate-to-severe ad subjects increased in a proportion similar to the 2-fold increase in the dose between the pf-04965842 200 mg qd group and pf-04965842 100 mg qd group."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. fourteen (14) out of 20 participants in this study had at least 1 medical problem. no participants left the study because of medical problems. the most common medical problems are listed below. "," there was 1 (10.0%) participant who experienced saes which were not determined by the investigator to be treatment-related. there was 1 (10.0%) participant who experienced grade 3 or 4 aes which were not determined by the investigator to be treatment-related. of these, 1 teae was determined by the investigator as treatment-related, and was reported by 1 (10.0%) participant. there was 1 (10.0%) participant who experienced grade 3 or 4 aes which were not determined by the investigator to be treatment-related. among the overall 300 mg dose cohorts, the most commonly reported teaes, regardless of causality, were in the system organ classes (socs) of general disorders and administration site conditions (3 participants, 30.0%) and injury, poisoning and procedural complications (3 participants, 30.0%). the majority of all-causality teaes were of grade 1 (5 participants, 50.0%). one participant from the 300 mg - 300 mg non-inhibitor dose cohort had a grade 3 non-serious non-treatment-related teae of skull fracture and a grade 3 serious non-treatment-related teae of cerebral haemorrhage. among the overall 300 mg loading + 150 mg dose cohorts, the most commonly reported teaes, regardless of causality, were in the socs of musculoskeletal and connective tissue disorders (3 participants, 30.0%) and vascular disorders (3 participants, 30.0%). the majority of all-causality teaes were of grade 1 (4 participants, 40.0%) and grade 2 (2 participants, 20.0%). among the overall 300 mg dose cohorts, 2 treatment-related grade 1 teaes (injection site haematoma and injection site reaction) were reported in 1 participant each (10.0%). among the overall 300 mg loading + 150 mg dose cohorts, 1 treatment-related grade 2 teae of injection site reaction was reported in 1 participant (10.0%). one participant from the 300 mg - 300 mg non-inhibitor dose cohort experienced 2 saes: cerebral haemorrhage (grade 3) and generalised tonic-clonic seizure (grade 2), which were both not considered to be treatment-related by the investigator. there were no clinically significant abnormalities observed for prothrombin, fibrinogen and troponin i. in the 450 mg  300 mg loading + 150 mg non-inhibitor dose cohort, 1 participant had supine sbp increase from baseline 30 mm hg and supine dbp increase from baseline 20 mm hg; this participant had a grade 1 non-treatment-related ae of hypertension. in the 300 mg  300 mg inhibitor dose cohort, 1 participant had supine dbp increase from baseline 20 mm hg; this participant had a grade 1 non-treatment-related ae of hypertension. one participant from the 300 mg  300 mg non-inhibitor dose cohort had mild aes of injection site reaction on day 112 and day 316. one participant from the de novo 300 mg loading + 150 mg inhibitors dose cohort had a severe ae of injection site reaction."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. in the intensive treatment group, 394 out of 399 (99%) participants in this study had at least 1 medical problem. a total of 41 (10%) participants left the study because of medical problems. in the non-intensive treatment group, 319 out of 322 (99%) participants in this study had at least 1 medical problem. a total of 108 (34%) participants left the study because of medical problems. the most common medical problems  those reported by at least 30% of participants  are described below. below are instructions on how to read table 1 and 2. these instructions can also be used for table 3 and 4, which lists serious medical problems. instructions for understanding table 1 and 2.  the 1st column of table 1 and 2 lists medical problems that were commonly reported during the study. all medical problems reported by at least 30% of participants are listed.  the 2nd column tells how many of the participants taking the glasdegib plus intensive or standard chemotherapy reported each medical problem. next to this number is the percentage of the participants taking glasdegib plus intensive or standard chemotherapy who reported the medical problem.  the 3rd column tells how many of the participants taking placebo plus intensive or standard chemotherapy reported each medical problem. next to this number is the percentage of the participants taking placebo plus intensive or standard chemotherapy who reported the medical problem.  using these instructions, you can see that: o in the intensive treatment group, 110 out of the 198 (56%) participants taking glasdegib plus intensive chemotherapy reported nausea. a total of 108 out of the 201 (54%) participants taking a placebo plus intensive chemotherapy reported nausea. o in the non-intensive treatment group, 75 out of the 162 (46%) participants taking glasdegib plus standard chemotherapy reported low numbers of red blood cells in the blood. a total of 73 out of the 160 (46%) participants taking placebo plus standard chemotherapy reported low numbers of red blood cells in the blood  "," all-causality teaes occurring in 10% participants were reported in 161 (99.4%) participants in the glasdegib arm and 158 (98.8%) participants in the placebo arm. treatment-related teaes occurring in 10% participants were reported in 121 (74.7%) participants in the glasdegib arm and 107 (66.9%) participants in the placebo arm.  the most frequently reported all-causality teaes (in the glasdegib arm and placebo arm) were anaemia (75 [46.3%] and 73 [45.6%] participants), constipation (59 [36.4%] and 52 [32.5%] participants), nausea (58 [35.8%] and 44 [27.5%] participants), pneumonia (43 [26.5%] and 48 [30.0%] participants), and pyrexia (48 [29.6%] and 42 [26.3%] participants).  the most frequently reported treatment-related teaes (in the glasdegib arm and placebo arm) were anaemia (45 [27.8%] and 48 [30.0%] participants) and nausea (44 [27.2%] and 37 [23.1%] participants). consistently, there were more participants with treatment-related teaes of dysgeusia (34 [21.0%] participants vs 7 [4.4%] participants) and muscle spasms (30 [18.5%] participants vs 2 [1.3%] participants) in the glasdegib arm vs placebo arm.  the most frequently reported teaes leading to death were disease progression (14 [8.6%] participants in the glasdegib arm and 22 [13.8%] participants in the placebo arm) and pneumonia (11 [6.8%] participants in the glasdegib arm and 7 [4.4%] participants in the placebo arm). a total of 108 (33.2%) participants died within 28 days after last dose of study treatment, with the most common reasons of disease progression (50 [15.4%] participants) and aes not related to study treatment (47 [14.5%] participants). serious teaes the incidence of serious teaes was comparable between the 2 treatment arms (117 [72.2%] participants in the glasdegib arm and 124 [77.5%] participants in the placebo arm).  most aeosi in the glasdegib and placebo arms were at ctcae grades 3-4 (74 [45.7%] participants and 81 [50.6%] participants, respectively) or grades 3-5 (101 [62.3%] participants and 103 [64.4%] participants, respectively). a total of 4 (2.5%) participants in the glasdegib arm and 7 (4.4%) participants in the placebo arm experienced treatment-emergent covid-19-related aeosi, and the maximum ctcae grades of these events were at grades 3-5. clinical laboratory and other safety evaluations there were no clinically meaningful findings in the laboratory safety assessments."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. 60 out of 61 (98%) participants in this study had at least 1 medical problem. a total of 3 out of 61 (5%) participants discontinued talazoparib because of a medical problem. medical problems were managed by holding talazoparib doses (33%), providing blood transfusions (33%), and reducing talazoparib doses (39%). the most common medical problems  those reported by at least 10% of participants  are described below. below are instructions on how to read table 1 and table 2. instructions for understanding table 1 and table 2.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 10% of participants are listed.  the 2nd column tells how many of the 61 participants taking talazoparib reported each medical problem. next to this number is the percentage of the 61 participants taking talazoparib who reported the medical problem.  using these instructions, you can see that 48 out of the 61 (79%) participants taking talazoparib reported feeling tired.  ","  safety results: a total of 98.4% and 95.1% of patients experienced all-causality and treatment-related aes, respectively. the most frequent treatment-related aes were fatigue (77.0% patients), nausea (63.9% patients) and alopecia (57.4% patients), which were experienced by more than half of patients. other common treatment-related aes were anemia (47.5% patients), headache (31.1% patients), dizziness (19.7% patients) and constipation (18.0% patients). most aes specified above (except for anemia) were grade 1 or 2 in severity. anemia was the most common grade 3 treatment-related ae (39.3% patients). three patients permanently discontinued from study treatment due to grade 3 treatment-related anemia (2) and grade 3 treatment-related vertigo (1). anemia was also the primary reason leading to dose reductions (32.8% patients) and temporary discontinuations (26.2% patients). treatment-related saes were reported in 14.8% patients with anemia (14.8% patients) being the most frequent. anemia is a known ae with talazoparib. eight (13.1%) patients had shifts from grade 2 at baseline to grade 3 or 4 post baseline for anemia laboratory results. few patients had abnormalities in blood chemistry results and there were few shifts from grade 2 at baseline to grade 3 or 4 post-baseline on chemistry laboratory parameters. conclusions:  talazoparib exhibited clinical benefit in the neoadjuvant setting for gbrca1/2 mutation positive, early tnbc as evidenced by pcr rate (breast and axilla) of 45.8% (80% ci: 36.42%, 55.22%) by icr in the evaluable analysis set. the study did not meet the pre-defined success criterion as the posterior probability that the true pcr rate by icr was 45% was 0.55.  talazoparib 1 mg qd was generally well tolerated in patients with early gbrca 1/2 mutation positive, early tnbc. the safety profile was generally consistent with the known safety profile for talazoparib.  there was generally a deterioration in ghs/qol and functionings and an increase in severity in symptoms with the talazoparib treatment. a low proportion of pre-menopausal patients had missed an expected menstrual period suggesting potential preservation of ovarian function with talazoparib treatment.  trough plasma talazoparib concentrations were similar for cycles 2, 3, and 4; the geometric mean of within-patient average plasma trough concentration at steady state was 5001 pg/ml.  tumor brca mutations were evident in 98% of evaluable patients, with brca loh evident in all but 1 brca-mutated tumor evaluable for zygosity. low patient numbers and/or subgroup numerical imbalances precluded meaningful assessment of correlations of tp53 mutational status, or of gloh high/low status, with pcr.  these biomarker results support the central role of brca mutations in tumor pathobiology in this indication."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. the researchers looked at medical problems that happened during the first 48 weeks of the study. 196 out of 269 patients (73%) in this study had at least 1 medical problem, including 103 out of 133 patients (77%) who received tofacitinib and 93 out of 136 patients (68%) who received placebo for 16 weeks and switched to open-label tofacitinib. a total of 1 patient (less than 1%) left the study because of medical problems. the most common medical problems are listed in the table below. ","  safety results: safety was assessed in all subjects who received at least 1 dose of the investigational product.  the proportion of patients who experienced all-causality treatment-emergent adverse events (teaes) was slightly higher in the tofacitinib 5 mg bid group compared to placebo up to weeks 16 and placebo advanced to tofacitinib 5 mg bid up to week 48 (table s6).  the majority of reported all-causality teaes were mild to moderate in both treatment groups up to weeks 16 and 48; with a low number of severe teaes occurring in the tofacitinib 5 mg bid group.  all serious adverse events (saes) up to weeks 16 and 48 were in subjects who received tofacitinib 5 mg bid (6 subjects in the tofacitinib 5 mg bid group and 1 subject after advancing from placebo to tofacitinib 5 mg bid group).  no subjects discontinued the study due to aes up to weeks 16 and 48 (per protocol design).  up to weeks 16 and 48, a higher proportion of subjects in the tofacitinib 5 mg group discontinued study drug or had a temporary discontinuation due to aes (there were no dose reductions; tofacitinib 5 mg bid was the only dose regimen per protocol).  no subjects experienced herpes zoster up to week 16. up to week 48, 5 non-serious herpes zoster cases including 1 herpes ophthalmic were reported (4 subjects in the tofacitinib 5 mg bid group and 1 subject in tofacitinib 5 mg bid after advancing from placebo group). the herpes ophthalmic case was adjudicated as not meeting the oi  the laboratory changes for tofacitinib 5 mg bid dose in subjects with as were consistent with the safety profile of tofacitinib across other tofacitinib programs.  tofacitinib 5 mg bid is efficacious in controlling the signs and symptoms of as:  the study met the primary objective demonstrating that tofacitinib 5 mg bid was superior to placebo in asas20 response at week 16. the study met the key secondary objective demonstrating that tofacitinib 5 mg bid was superior to placebo in asas40 response at week 16. sponsor: pfizer, inc. investigational product: tofacitinib clinical study report synopsis: protocol a3921120 protocol title: a phase 3, randomized, double-blind, placebo-controlled, study of the efficacy and safety of tofacitinib in subjects with active ankylosing spondylitis (as). study center(s): a total of 57 sites randomized subjects from the following countries: australia (3), bulgaria (2), canada (2), china (5), czech republic (3), france (1), hungary (2), republic of korea (3), poland (9), russian federation (6), turkey (4), ukraine (5), united states (12)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. in the sentinel cohort, 16 out of 168 participants in this study had at least 1 medical problem within 1 month after vaccination 1. in the expanded cohort, 164 out of 1065 participants had at least 1 medical problem within 1 month after vaccination 1. a total of 3 participants left the study because of safety reasons due to medical problems. these were a bone infection in 1 participant and lung cancer in 2 participants. the researchers at the study center did not think these medical problems were related to the rsvpref vaccine. medical problems were reported by 3 or fewer participants (25%) in any one group in the sentinel cohort and by 11 or fewer participants (26%) in the expanded cohort within 1 month after vaccination 1 in the non-placebo groups. medical problems were reported by a 1 participant (8%) in the placebo group in the sentinel cohort and by 5 or fewer participants (12%) in the placebo group in the expanded cohort within 1 month after vaccination 1. these medical problems were generally similar between the different vaccine groups in each cohort. in the sentinel cohort and expanded cohort in participants 18 through 49 years of age, the most common medical problems were symptoms of a common cold or stomach upsets. in the sentinel cohort in participants 50 through 85 years of age and in the expanded cohort in participants 65 through 85 years of age, the most common medical problems were symptoms of a common cold, stomach upsets, or falls. medical problem that the researcher at the study center considered to be related to study vaccines were reported by no participants in the sentinel cohort and by 3 or fewer participants (8%) in the expanded cohort within 1 month after vaccination 1 in the non-placebo groups. medical problems were reported by 13 or fewer participants (33%) in the expanded cohort within 1 month after vaccination 2 in the non-placebo group and by 7 or fewer participants (17%) in the placebo group at this time point. "," few participants reported a fever within 14 days after vaccination 1 (5 participants [12.2%] in the rsvpref 120 g + siiv group in the 18 through 49 year age group in the expanded cohort; 2 (4.9%) participants or fewer in any other vaccine group in both cohorts and across age all groups).  the proportion of participants reporting any unsolicited ae within 1 month after vaccination 1 was generally similar (5.0% to 26.2%) across vaccine groups for both age groups in both cohorts.  maes were reported by 16.7% or fewer participants in any vaccine group or the placebo group across the two age groups for both cohorts.  throughout the 12 month period after vaccination 1, 3 saes were reported in the 50 through 85 year age group (1 in the rsvpref 240 g group [8.3%] and 2 in the rsvpref 240 g + al(oh) group [16.7%]) in the sentinel cohort. in the expanded cohort, saes were reported by 0.0% to 7.3% of participants in the 18 through 49 year age group, and by 5.0% to 10.0% of participants in the 65 through 85 year age group. the incidence rate was 2.4% and 7.3% among participants in the placebo group in the 18 through 49 and 65 through 85 year age groups, respectively.  throughout the 12 month period after vaccination 1, among the sentinel cohort in the 18 through 49 year age group, maes were reported in 0.0% to 33.3% of participants across all vaccine groups versus 16.7% of participants in the placebo group. among the sentinel cohort in the 50 through 85 year age group, maes were reported in all vaccine groups (range: 16.7% to 50.0%) and in 16.7% of participants in the placebo group.  throughout the 12 month period after vaccination 1, among the expanded cohort in the 18 through 49 year age group, maes were reported in all vaccine groups (range: 9.8% to 24.4%) and in 22% of participants in the placebo group. among the expanded cohort in the 65 through 85 year age group, maes were reported in all vaccine groups (range: 15.0% to 47.5%) and in 14.6% of participants in the placebo group. date of current version: 10 february 2022 date(s) of previous report(s): not applicable   key exclusion criteria were as follows: 1. sentinel cohort participants only: any screening hematology and/or blood chemistry laboratory value that met the definition of a grade 1 abnormality. note: with the exception of bilirubin, participants with any stable grade 1 abnormalities (according to the toxicity grading scale) may have been considered eligible at the discretion of the investigator."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by the study vaccine, or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many vaccine groups in many studies, doctors try to understand what the side effects of an experimental drug or vaccine might be. 33 out of 206 participants (16%) in this study had at least 1 medical problem within 1 month of being given the 13vpnc vaccine. this included 6 participants who had a medical problem that the doctor thought was related to the 13vpnc vaccine (3%, or 6 out of 206 participants, with 3 participants in each age group). in the group of participants aged 6 to under 18 years, these related medical problems were 1 report each of vaccination site pain, vaccination site swelling, and reduced appetite. in the group of participants aged 18 to under 65 years, these related medical problems were 2 reports of vaccination site pain and 1 report of waking from sleep during the middle of the night. most of the medical problems were mild or moderate in severity. there were 2 severe medical problems (1 case of severe asthma in a participant aged 6 to under 18 years and 1 case of severe back pain in a participant aged 18 to under 65 years). the study doctors did not think these severe medical problems were related to the 13vpnc vaccine. none of the participants left the study because of medical problems. the most common medical problems reported by 2 or more participants are listed below. this does not mean that everyone in this study had these results. other studies may produce different results, as well. these are just some of the main findings of the study, and more information may be available at the websites listed at the end of this summary. ","  safety results:  the majority of subjects reported any local reactions within 7 days after vaccination in the 6- to <18-year age group (82.7%) and 14 days after vaccination in the 18- to <65-year age group (67.1%). in both age groups, pain at the injection site was the most frequently reported local reaction. the majority of local reactions were mild or moderate in severity, except for 1 case of severe swelling in the 6- to <18-year age group and 2 cases of severe pain at the injection site in the 18- to <65-year age group. the proportions of subjects who reported local reactions were generally higher in the 6- to <18-year age group than in the 18- to <65-year age group.  the majority of subjects reported any systemic events within 7 days after vaccination in the 6- to <18-year age group (60.8%) and 14 days after vaccination in the 18- to <65-year age group (58.6%). in both age groups, the 3 most frequently reported systemic events were fatigue, muscle pain, and headache. the majority of systemic events were mild or moderate in severity, except for 1 case each of severe fatigue and severe headache in the 6- to <18-year age group, and 1 case each of severe diarrhea, severe muscle pain, and severe joint pain in the 18- to <65-year age group. the proportions of subjects who reported systemic events were broadly similar in the 6- to <18-year and 18- to <65-year age groups.  overall, few aes were reported (16.0% of subjects overall). there were no saes, life-threatening aes, or immediate aes reported during the study. there were no deaths, and no subjects were withdrawn for safety-related reasons during the study.  aes that were assessed by the investigator to be related to ip were reported by 6 (2.9%) subjects. these were mild events associated with ip injection site reaction, except for 1 event each of decreased appetite and middle insomnia.  two (2) subjects reported severe aes, including 1 ae of severe back pain and 1 ae of severe asthma, neither of which was assessed as vaccine related.  overall, 13vpnc was well tolerated with an acceptable safety profile in japanese subjects aged 6 to <65 years who were considered at increased risk of pd and nave to pneumococcal vaccines. conclusions: in japanese individuals aged 6 to <65 years who were considered to be at increased risk of pd and who were nave to pneumococcal vaccines, 13vpnc was immunogenic for each of the 13 serotypes and was well-tolerated with an acceptable safety profile. the results support the extension of the indication of 13vpnc for the prevention of pd in japan."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. all of the participants in this study had at least 1 medical problem. a total of 3 participants stopped all the study treatment because of medical problems. the most common medical problems  those reported by more than 30% of participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 30% of participants are listed.  the 2nd column tells how many of the 22 participants taking binimetinib and avelumab reported each medical problem. next to this number is the percentage of the 22 participants taking the study medication who reported the medical problem.  the 3rd column tells how many of the 13 participants taking binimetinib and talazoparib reported each medical problem. next to this number is the percentage of the 13 participants taking binimetinib and talazoparib who reported the medical problem.  using these instructions, you can see that 12 out of the 22 (55%) participants taking binimetinib and avelumab reported rash. a total of 3 out of the 13 (23%) participants taking binimetinib and talazoparib reported rash. ","  safety results: dose limiting toxicities the number of participants with dlt and the posterior probability of dlt rate being in the 3 toxicity intervals of underdosing (<0.16), target toxicity (0.16 and <0.33) and overdosing (0.33) are summarized by treatment group in table s6. the avelumab + binimetinib 45 mg and binimetinib 45 mg + talazoparib 0.75 mg treatment groups had a posterior probability of overdose (prod) of 0.535 and 0.359, respectively, exceeding the ewoc criterion that the risk for excessive toxicity should be less than 0.25. dlts reported in each treatment group are summarized by system organ class (soc) and preferred term (pt) in table s7. dlt incidence were 30.0%, 45.5%, 33.3%, and 40.0% for treatments with avelumab + binimetinib 30 mg, avelumab + binimetinib 45 mg, binimetinib 30 mg + talazoparib 0.75 mg, binimetinib 45 mg + talazoparib 0.75 mg, respectively. of the 22 participants in pooled avelumab + binimetinib treatment group, grade 3 all-causality and treatment-related teaes were reported in 19 (86.4%) and 12 (54.5%) participants, respectively. of the 13 participants in pooled binimetinib + talazoparib treatment group, grade 3 all-causality and treatment-related teaes were reported in 9 (69.2%) and 3 (23.1%) participants, respectively. grade 3 treatment-related teaes were dermatitis acneiform and diarrhoea reported in 1 (7.7%) participant each. all teaes leading to discontinuation of any study drug by soc or pt were single occurrences, except blood cpk increased reported in 3 (13.6%) participants in the pooled avelumab + binimetinib treatment group. the most frequent teaes leading to interruption of binimetinib were alt increased and blood cpk increased (3 [13.6%], each) in the pooled avelumab + binimetinib treatment group and platelet count decreased and nausea (2 [15.4%]) in the pooled binimetinib + talazoparib treatment group. the most common teae leading to talazoparib interruption was nausea in 3 (23.1%) participants, followed by vomiting, anaemia, and platelet count decreased (2 [15.4%], each). during the on-treatment period, 3 participants died due to teaes in each of the pooled combination treatment group. disease progression led to death of 3 (with avelumab + binimetinib 45 mg treatment) and 2 participants (1 participant each with treatments of binimetinib 30 mg + talazoparib 0.75 mg and binimetinib 45 mg + talazoparib 0.75 mg). death in 1 participant treated with binimetinib 30 mg + talazoparib 0.75 mg. none of these teaes leading to death were assessed as treatment-related by the investigator. treatment-related serious teaes were reported in 3 (13.6%) participants including 1 (4.5%) participant each with mucosal inflammation and pneumonitis, and 1 (4.5%) participant with alt increased and ast increased."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. below are instructions for understanding table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 10% of participants in any group are listed.  the 2nd column tells how many of the 65 participants taking ritlecitinib 200/50 mg reported each medical problem. next to this number is the percentage of the 65 participants taking ritlecitinib 200/50 mg who reported the medical problem.  the 3rd column tells how many of the 67 participants taking ritlecitinib 100/50 mg reported each medical problem. next to this number is the percentage of the 67 participants taking ritlecitinib 100/50 mg who reported the medical problem.  the 4th column tells how many of the 67 participants taking ritlecitinib 50 mg reported each medical problem. next to this number is the percentage of the 67 participants taking ritlecitinib 50 mg who reported the medical problem.  the 5th column tells how many of the 50 participants taking ritlecitinib 30 mg reported each medical problem. next to this number is the percentage of the 50 participants taking ritlecitinib 30 mg who reported the medical problem. instructions for understanding table 1.  the 6th column tells how many of the 49 participants taking ritlecitinib 10 mg reported each medical problem. next to this number is the percentage of the 49 participants taking ritlecitinib 10 mg who reported the medical problem.  the 7th column tells how many of the 66 participants taking placebo reported each medical problem. next to this number is the percentage of the 66 participants taking placebo who reported the medical problem.  using these instructions, you can see that 8 out of the 65 participants (12%) taking ritlecitinib 200/50 mg reported common cold. a total of 10 out of the 67 participants (15%) taking ritlecitinib 100/50 mg reported common cold. 277 out of 364 (76%) participants treated in part 1 had at least 1 medical problem. a total of 19 (5%) participants left the study because of medical problems. the most common medical problems (both related and unrelated to study treatment)  those reported by more than 10% of participants in any group  are described below. below are instructions for understanding table 2. instructions for understanding table 2.  the 1st column of table 2 lists medical problems that were commonly reported during the study. all medical problems reported by more than 10% of participants in any group and at least 2 participants overall are listed.  the 2nd column tells how many of the 55 participants taking brepocitinib 60/30 mg reported each medical problem. next to this number is the percentage of the 55 participants taking brepocitinib 60/30 mg who reported the medical problem.  the 3rd column tells how many of the 43 participants taking ritlecitinib 200/50 mg + uv reported each medical problem. next to this number is the percentage of the 43 participants taking ritlecitinib 200/50 mg + uv who reported the medical problem.  the 4th column tells how many of the 187 participants taking ritlecitinib 200/50 mg reported each medical problem. next to this number is the percentage of the 187 participants taking ritlecitinib 200/50 mg who reported the medical problem.  the 5th column tells how many of the 6 participants taking ritlecitinib 50 mg reported each medical problem. next to this number is the percentage of the 6 participants taking ritlecitinib 50 mg who reported the medical problem.  the 6th column tells how many of the 2 participants taking ritlecitinib 30 mg reported each medical problem. next to this number is the percentage of the 2 participants taking ritlecitinib 30 mg who reported the medical problem.  using these instructions, you can see that 1 out of the 55 participants (2%) taking brepocitinib 60/30 mg reported urinary tract infection. a total of 3 out of 43 participants (7%) taking ritlecitinib 200/50 mg + uv reported urinary tract infection. 194 out of 293 (66%) participants treated in part 2 had at least 1 medical problem. a total of 10 (3%) participants left the study because of medical problems. the most common medical problems (both related and unrelated to study treatment)  those reported by more than 10% of participants in any group and at least 2 participants overall  are described below.  ","  in total, there were 277 (76.1%) participants with 756 all-causality teaes, and 126 (34.6%) participants with 195 treatment-related aes.  the majority of all teaes (both all-causality and treatment-related) across treatment groups were mild or moderate in severity.  there were 19 (5.2%) and 12 (3.3%) participants who were discontinued from the study due to all-causality and treatment-related aes, respectively.  the 3 most frequently reported preferred term teaes were: nasopharyngitis, upper respiratory tract infection (urti), and headache (all-causality); nasopharyngitis, diarrhea, and headache (treatment-related).  in total, there were 194 (66.2%) participants with 454 all-causality teaes, and 68 (23.2%) participants with 99 treatment-related teaes.  there were 2 (0.7%) participants with saes, and in 1 participant the sae (from brepocitinib group) was treatment-related.  the majority of all teaes (both all-causality and treatment-related) across treatment groups were mild or moderate in severity. there were 8 (2.7%) participants with severe aes (2 from brepocitinib group and 6 from extgp3), and in 1 participant (from brepocitinib group) the severe ae was treatment-related.  there were 10 (3.4%) and 8 (2.7%) participants who were discontinued from the study due to all-causality and treatment-related aes, respectively.  the 3 most frequently reported all-causality preferred term teaes were urinary tract infection, urti, and headache. the 2 treatment-related teaes that occurred in >1.0% of participants across treatment groups were decreased neutrophil count and headache. extgp3 (dr and ext)  teaes and saes  overall, there were 162 (86.6%) participants with 647 all-causality teaes, and 82 (43.9%) participants with 152 treatment-related teaes.  the majority of all teaes (both all-causality and treatment-related) during the entire study were mild or moderate in severity.  six (3.2%) participants in extgp3 were discontinued from the study due to teaes (all treatment-related; 5 were discontinued due to aes reported during the ext period).  the 3 most frequently reported preferred teaes (both all-causality and treatment-related) were nasopharyngitis, urti, and headache.  chemistry o there were no clinically meaningful changes in lipid profile across treatment groups in the dr or ext period. o no trends in creatine kinase (ck) were noted with ritlecitinib in the dr or ext period had ck 3  upper limit of normal (uln); 7 participants in the study had ck >10  uln.  hematology: the mean absolute values of hematology parameters (platelets, lymphocytes, neutrophils, hemoglobin, hematocrit, erythrocytes, and reticulocytes/erythrocytes) for all participants stayed within the normal ranges in the dr and ext periods."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. four-hundred fifty-two (452) out of 837 patients in this study had at least 1 medical problem. a total of 29 patients left the study because of medical problems. the most common medical problems are listed below.  ","  safety results:  the proportion of subjects with all-causality teaes was higher for the abrocitinib 200 mg group compared to the abrocitinib 100 mg, dupilumab and placebo groups (table s9).  discontinuations from the study due to teaes were low and similar across the treatment groups (table s9). conclusion(s): efficacy co-primary endpoints:  the study met both co-primary endpoints of iga and easi-75 responses at week 12, demonstrating that both abrocitinib 200 mg and 100 mg treatment groups were superior to the placebo group. key secondary endpoints:  both abrocitinib groups had statistically significant improvement compared with placebo in all 3 key secondary endpoints (p0.0002): proportion of subjects with pp-nrs4 at week 2, iga response at week 16, and easi-75 at week 16.  at week 2, abrocitinib 200 mg group compared with the dupilumab group, had statistically significantly higher proportion of subjects with pp-nrs4, indicating earlier onset of action (p<0.0001).  at week 16, abrocitinib 200 mg group compared with the dupilumab group, showed higher proportion of iga responders, based on 95% ci of the treatment difference between the groups.  at week 16, proportion of easi-75 responders was numerically greater in abrocitinib 200 mg group than in dupilumab group and was numerically lesser in abrocitinib 100 mg group than in dupilumab group; 95% ci for the differences did not support true difference in treatment responses. iga responses (clear (0) or almost clear (1) and 2 point reduction from baseline)  both abrocitinib treatment groups had statistically significantly greater proportion of iga responders compared with placebo at all time points.  both abrocitinib groups had greater proportions of iga responders than the dupilumab group at week 2, and the 200 mg group had more responders than dupilumab group at weeks 4, 8, 12, and 16; these were true treatment differences per 95% cis. easi  both abrocitinib treatment groups had statistically significantly greater proportions of easi-50, easi-75 and easi-90 responders compared with the placebo group at all time points.  both abrocitinib treatment groups compared with the placebo group demonstrated statistically significant improvement from baseline in the total easi score at each timepoint up to week 16.  both abrocitinib group had earlier onset of action than dupilumab group based on observations in change from baseline in the total easi score and responders for easi-50, easi-75, easi 90, and easi 100; the greater than dupilumab responses were maintained for longer duration in the abrocitinib 200 mg group.  the median time to achieve first pp-nrs4 was faster in both abrocitinib treatment groups compared with the placebo group.  both abrocitinib groups had earlier onset of action than the dupilumab group; median time to pp-nrs4 was 31 days in the dupilumab group."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 163 out of 285 patients in this study had at least 1 medical problem. a total of 5 patients left the study because of medical problems. the most common medical problems are listed below.  "," the proportion of participants with all-causality teaes was higher for the abrocitinib 200 mg group (62.8%) compared to the abrocitinib 100 mg (56.8%) and placebo (52.1%) groups (table s7). three participants reported saes (2 from the placebo group and 1 from the abrocitinib 200 mg group; table s7), and no saes were treatment-related. note: there were 2 teaes (hand fracture in the abrocitinib 100 mg group, pustule in the placebo group) missing in table s7, both teaes were not treatment-related and had no substantive impact on efficacy and/or safety interpretation as well as on the statistical conclusions for this study. the proportion of participants experiencing severe aes and aes leading to study discontinuations or temporary discontinuations were low and similar across all treatment groups. the most frequently reported system organ class (soc) was infections and infestations, with slightly higher proportion of participants reported in the abrocitinib 200 mg (36.2%) and 100 mg (35.8%) groups compared with the placebo group (31.3%). only 1 participant in the abrocitinib 100 mg group experienced a tier-1 event of herpes zoster and the event was mild in severity. there were no clinically significant hematologic parameters except for platelet which has a dose-dependent decrease in abrocitinib groups with nadir at week 4; majority of participants remained within the normal range. there were no clinically meaningful changes in the ldl/high-density lipoprotein (hdl) ratio in any treatment groups at week 4 or week 12. compared with the placebo group, there were dose-dependent increases of creatine kinase in abrocitinib treatment groups. conclusions: efficacy co-primary endpoints:  the study met both co-primary endpoints of iga and easi-75 responses at week 12, demonstrating that both abrocitinib 100 mg and 200 mg treatment groups were superior to the placebo group. pp-nrs:  the proportions of pp-nrs4 responders from day 2 to day 15 and at week 8 were all numerically greater in the abrocitinib 200 mg and 100 mg groups than in the placebo group.  time to first pp-nrs4 showed the time to response was statistically significantly faster in the abrocitinib 100 mg (p=0.0159) and 200 mg (p=0.0003) groups compared with the placebo group.  abrocitinib 200 mg group had a greater proportion of iga responders than the abrocitinib 100 mg group at weeks 4 and 8. easi:  statistically significantly greater easi-50, easi-75, and easi-90 responses for both abrocitinib treatment groups compared with the placebo group were observed at all scheduled timepoints (weeks 2, 4, 8, and 12) except easi-75 at week 12.  the lsm of percent change from baseline in the total easi score demonstrated statistically significant decreases in both abrocitinib treatment groups compared with the placebo group at weeks 2, 4, 8, and 12."
" the researchers recorded any medical problems the children had during the study. children could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment, or by another medicine the child was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. 58 out of 87 children (67%) in this study had at least 1 medical problem. 1 child (1%) left the study because of medical problems. the medical problems reported in at least 5% of children during either treatment are listed in the table below. the table shows the number and percent of children who experienced these medical problems during each treatment. ","  safety results: the proportion of participants with all-causality treatment-emergent adverse events (teaes) was higher during the once weekly somatrogon injection schedule than during the once daily genotropin injection schedule (table s4).  no participants reported any saes and 1 participant discontinued the study due to an ae (injection site pain of moderate severity during the once weekly somatrogon injection schedule that was considered by the investigator to be related to study intervention).  three participants had a temporary discontinuation due to an ae (during the once daily genotropin injection schedule). the most frequently reported all-causality teae by system organ class (soc) was infections and infestations (18 [20.7%] participants during the once weekly somatrogon injection schedule; 19 [22.1%] during the once daily genotropin injection schedule). the number of participants who experienced at least 1 injection site reaction ae (general disorders and administration site conditions system organ class [soc]) was higher during the once weekly somatrogon injection schedule (19 [21.8%]]) than during the once daily genotropin injection schedule (14 [16.3%]).  except for 1 participant, none of these injection site reactions resulted in study discontinuation. no clinically meaningful differences between treatment groups were observed for chemistry, hematology, liver function test, igf-1 and igf-1 sds, glucose metabolism, and urinalysis no participant in either treatment sequence met the criteria for hys law or temples corollary. four participants in the somatrogon then genotropin sequence tested positive for anti-drug antibodies (ada) during the first 12 weeks of treatment period 1, but none of these participants tested positive for neutralizing antibodies (nab) during the study. conclusion(s):  in this study, the treatment burden, as assessed by the difference in the mean overall life interference total scores, was lower for children with ghd and their caregivers during the once weekly somatrogon injection schedule than during the once daily genotropin injection schedule.  improvements in most variables for treatment experience, as assessed by estimated differences in mean score within the dcoa 1 questionnaire, were also observed during the once weekly somatrogon injection schedule compared with the once daily genotropin injection schedule. o the point estimate of the mean satisfaction with the overall treatment experience improved for participants and their caregivers in the once weekly somatrogon injection schedule compared with those in the once daily genotropin injection schedule, but the estimated mean difference was not statistically significant.  the once weekly somatrogon injection schedule had less impact on the daily activities than the once daily genotropin injection schedule based on the lower in this study, once weekly somatrogon administration was generally well tolerated in children with ghd. all but 2 events were mild and only 1 participant discontinued from the study due to an ae of injection site pain that occurred while receiving somatrogon."
" the researchers recorded any significant medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by study vaccine or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by looking at significant medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug (in this case experimental vaccine) might be. what percentage of participants had significant medical problems within 1 month after being vaccinated? 69 out of 873 participants in this study (8%) had at least 1 significant medical problem within 1 month after being vaccinated. among participants who were vaccinated with 20vpnc, 19 out of 253 participants in category 1 (received ppsv23 prior to the study) (8%), 12 out of 246 participants in category 2 (received 13vpnc prior to the study) (5%), and 13 out of 125 participants in category 3 (received 13vpnc and ppsv23 prior to the study) (10%) had significant medical problems within 1 month after being vaccinated. no single significant medical problem occurred in 4 or more participants during this time. no participants left the study due to medical problems. what percentage of participants had redness, swelling, or pain at the injection site within 10 days after being vaccinated? the percentage of participants with redness, swelling, or pain at the injection site within 10 days after being vaccinated was generally similar regardless of vaccine received prior to the study, and was similar among participants who received 20vpnc or the control vaccine within each category, 13vpnc or ppsv23. the tables below show the percentage of participants with these reactions.  what percentage of participants had fever, headache, tiredness, muscle pain, or joint pain within 7 days after being vaccinated? the percentage of participants with fever, headache, tiredness, muscle pain, or joint pain within 7 days after being vaccinated was similar regardless of vaccine received prior to the study, and was similar among participants who received 20vpnc or the control vaccines 13vpnc or ppsv23. in category 2 participants (previously received 13vpnc only prior to the study), a higher percentage of participants who received ppsv23 (46%) had muscle pain than participants who received 20vpnc (34%). a fever is a body temperature that is 38.0 degrees celsius or higher (100.4 degrees fahrenheit or higher). the tables below show the percentage of participants with these reactions.  "," results subject disposition and demography: there were 375 participants enrolled into cohort a, 375 participants enrolled into cohort b, and 125 participants enrolled into cohort c. all participants in cohorts a and c received study vaccination; 2 participants in the 20vpnc group in cohort b were randomized but did not receive study vaccine. all participants in cohort c and nearly all participants (97.5%) in each vaccine group in cohorts a and b completed the study. cohort b enrolled the highest percentages of participants 80 years of age and older (9.8% and 9.4% in the 20vpnc and control group, respectively), while cohort a had the lowest percentages (2.0% and 1.6% in the 20vpnc and control group, respectively). immunogenicity results:  immune responses to all 20 vaccine serotypes were observed 1 month after 20vpnc in adults 65 years of age as assessed by opa gmts, gmfrs, proportions of participants with a 4-fold-rise in opa titers, and proportions of participants with opa titers  lloq in the 3 cohorts, regardless of prior pneumococcal vaccination.  opa gmts to the 20 vaccine serotypes at 1 month after 20vpnc tended to be numerically highest in participants who had previously received 13vpnc only, followed by those who had previously received 13vpnc and ppsv23, and were lowest among those who had previously received ppsv23 only.  for the 13vpnc serotypes, a trend of somewhat higher opa gmfrs and higher proportions of participants with 4-fold rise in opa titers were noted in the group who had previously received 13vpnc only prior to receiving 20vpnc compared to those who had previously received ppsv23 only or 13vpnc and ppsv23.  for the additional 7 serotypes, gmfrs were larger and proportions of participants with a 4-fold rise in opa titers were higher in the group who had previously received 13vpnc only prior to receiving 20vpnc (ie, nave to vaccination with those serotypes) compared to those who had previously received ppsv23 only or 13vpnc and ppsv23. safety results:  the proportions of participants who reported prompted local reactions and systemic events after 20vpnc were generally similar regardless of prior pneumococcal vaccination and were generally similar to the corresponding control vaccines (13vpnc or ppsv23).  rates of aes within 1 month after vaccination were low after 20vpnc. aes after 20vpnc were generally similar across cohorts, regardless of prior pneumococcal vaccination, and similar to the corresponding control groups (13vpnc or ppsv23). conclusion(s): the safety and tolerability profile of 20vpnc was generally similar in participants with different prior pneumococcal vaccine history and was generally similar to 13vpnc and ppsv23 control groups. this study shows that 20vpnc elicits immune responses to all 20 vaccine serotypes in adults 65 years of age and above in individuals who have previously received pneumococcal vaccine, with the strongest responses noted in persons who have previously received 13vpnc only."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug might be. none of the 16 participants in this study had any medical problems and none left the study because of medical problems. ","  safety results: no treatment-emergent aes were reported for the study, ie, no aes were reported to have occurred following start of treatment or increased in severity after treatment. the most frequently reported laboratory test abnormalities without regard to baseline abnormality were platelets, prothrombin time, total bilirubin, and urobilinogen with 5 (62.5%) participants each for the severe hepatic impairment group. the most frequently reported laboratory test abnormality without regard to baseline abnormality was partial thromboplastin time (ptt) with 3 (37.5%) participants for the normal hepatic function group. none of the laboratory test abnormalities were considered clinically significant by the investigator and therefore, none of these laboratory test abnormalities were reported as aes. one (12.5%) participant in the severe hepatic impairment group had a 30 mm hg increase in supine systolic bp from baseline on day 7 meeting the categorical criterion of 30 mm hg increase from baseline. one (12.5%) participant in the normal hepatic function group had a 28 mm hg increase in supine diastolic bp from baseline on day 7 meeting the categorical criterion of 20 mm hg increase from baseline. none of the categorical vital sign values were considered clinically significant by the investigator and therefore none were reported as no participants in either hepatic function group had a qt interval calculated using fridericias correction factor (qtcf) value 500 msec or a 60 msec increase from baseline in qtcf. no participants in either hepatic function group met categorical summarization criteria in other ecg results, ie, pr interval, qrs complex or qt interval. conclusion(s):  following administration of a single dose of dacomitinib 30 mg, participants with severe hepatic impairment had similar auc values and an approximately 31% increase in c inf max when compared to participants with normal hepatic function.  a single oral dose of dacomitinib 30 mg was well tolerated in participants with severe hepatic impairment and normal hepatic function; no new safety issues were identified."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. a total of 109 out of 178 (61%) participants during the investigational treatment period had at least 1 medical problem. a total of 9 participants (5%) left the study during the investigational treatment period because of medical problems. the most common medical problems  those reported by more than 3 participants  are described in the table below: below are instructions on how to read table 1 and table 2. instructions for understanding table 1 and table 2.  the 1st column of table 1 lists medical problems that were commonly reported during the study during the investigational treatment period. all commonly reported medical problems that happened in 3 or more participants are listed.  the 2nd column of table 1 tells how many of the 133 participants taking the study medication, pf-06826647, at all of the doses (50 mg, 100 mg, 200 mg, and 400 mg combined) reported each medical problem. next to this number is the percentage (%) of the 133 participants taking pf-06826647 at all doses who reported the medical problem.  the 3rd column of table 1 tells how many of the 45 participants taking the placebo reported each medical problem. next to this number is the percentage (%) of the 45 participants taking the placebo who reported the medical problem.  using these instructions for table 1, in the 2nd column you can see that 23 out of the 133 (17%) participants taking the pf-06826647 at all doses reported inflammation of the nose and throat. in the 3rd column, you can see that 6 out of the 45 (13%) participants taking the placebo reported inflammation of the nose and throat. 96 participants out of the 152 (63%) participants in the extension treatment period had at least 1 medical problem. a total of 9 participants out of 152 (6%) participants left the study during the extension treatment period because of medical problems. the most common medical problems  those reported by more than 3 participants  are described in the table below. "," the proportion of participants with aes up to week 16 was comparable across all the treatment groups, but numerically higher in the active treatment groups (59.1% to 69.6%) than that in the placebo group (51.1%). laboratory values: for participants with confirmed (through re-testing within 48 hours) laboratory abnormalities meeting the pre-specified criteria, the study drug was permanently discontinued:  there was a confirmed case of 2 sequential hemoglobin <10.0 g/dl for 1 participant in the 200 to 200 mg qd group, which led to the discontinuation of study drug.  there was a confirmed case of 2 sequential alanine aminotransferase (alt) >3upper limit of normal (uln) for 1 participant in the placebo qd group, which led to the discontinuation of study drug. hemoglobin: abnormally low levels of hemoglobin (<0.8lower limit of normal [lln]) were reported for participants receiving either pf-06826647 400 mg qd or 200 mg qd (5 participants up to week 16 and 2 participants from week 16 to week 40). there appeared to be a dose-dependent decline in reticulocytes in the active treatment groups within the first 2 weeks of treatment followed by a return towards baseline after week 2. the mean decrease from baseline in reticulocyte count was similar across the treatment groups from week 16 to week 40 and was maintained over time for all the treatment groups. platelet: abnormally low platelet counts (<0.5lln) were reported for participants receiving pf-06826647 400 mg qd (1 participant up to week 16 and 1 participant from week 16 to week 40). a numerically greater mean increase from baseline in platelet counts was observed for all the active treatment groups compared with the placebo qd group up to week 16, with the greatest difference from the placebo qd group in the 400 mg qd group or 200 mg qd group. the most frequently reported laboratory abnormality aes (treatment-related) during the investigational treatment period by medical dictionary for regulatory activities (meddra) soc were: investigations in 14 (7.9%) participants and blood and lymphatic system disorders in 6 (3.4%) participants. the most frequently reported laboratory abnormality aes (treatment-related) during the extension treatment period by meddra soc were: investigations in 13 (8.6%) participants and blood and lymphatic system disorders in 14 (9.2%) participants. conclusions:  pf-06826647 400 mg qd and 200 mg qd were both statistically superior to placebo for the proportion of participants achieving pasi 90 at week 16. for both pf-06826647 400 mg qd and 200 mg qd groups, there were significant differences from placebo in the proportion of participants achieving pasi 90 responses from week 4 to week 16.  pf-06826647 400 mg qd and 200 mg qd both showed significant efficacy over placebo based on proportion of participants achieving pasi 75 and pga response of clear or almost clear; there was significant improvement compared with placebo based on the proportion of participants achieving the responses from week 4 to week 16."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. all 13 participants (100%) in this study had at least 1 medical problem. this included all 10 participants in part 1 and all 3 participants in part 2. one (1) participant (8%) left the study because of medical problems (decreased appetite, dehydration, and feeling very tired); this happened during part 1. the most common medical problems  those reported by at least 10% of participants in either part 1 or part 2 of the study  are described in the table on the next page. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 10% of participants in either part 1 or part 2 are listed.  the 2nd column tells how many of the 10 participants taking the high dose encorafenib + binimetinib combination treatment during part 1 reported each medical problem. next to this number is the percentage of the 10 participants taking the high dose combination treatment who reported the medical problem.  the 3rd column tells how many of the 3 participants taking the standard dose encorafenib + binimetinib combination treatment during part 2 reported each medical problem. next to this number is the percentage of the 3 participants taking the standard dose combination treatment who reported the medical problem.  using these instructions, you can see that 6 out of the 10 participants (60%) taking the high dose combination treatment in part 1 reported feeling very tired. one (1) out of the 3 participants (33%) taking the standard dose combination treatment in part 2 reported feeling very tired. "," six (46.2%) and 8 (61.5%) participants had at least 1 dose reduction of encorafenib and binimetinib, respectively. ten (76.9%) and 10 (76.9%) participants had at least 1 dose interruption of encorafenib and binimetinib, respectively. dose limiting toxicity: a total of 9 out of 10 participants in the sli who completed one 28-day cycle of treatment and received at least 75% of the planned cumulative dose of both study drugs or experienced a dlt were included in the dose-determining set. all 13 participants were reported with at least 1 ae. a total of 12 (92.3%) participants were reported with at least 1 treatment-related ae. a total of 7 (53.8%) participants were reported with ctcae grade 3 teae (6 in the sli and 1 in phase 2). aes requiring dose reduction of encorafenib, binimetinib, and both were reported in 5 (38.5%) participants each (4 in the sli and 1 in phase 2). all-causality saes were reported for 5 (38.5%) participants (4 in the sli and 1 in phase 2). treatment-related saes were reported for 2 (15.4%) participants in the sli; 1 grade 2 pyrexia and 1 grade 3 dehydration were reported in 1 participant each. deaths were reported for 10 (76.9%) participants in total (7 in the sli and 3 in phase 2), with on-treatment deaths ( 30 days after last dose of study treatment) due to disease progression reported for 2 participants (both in phase 2). laboratory values: hematology and coagulation: three participants in the sli had shifts for hematology and coagulation abnormalities of lymphocyte count decreased from grade 2 at baseline to grade 3 post-baseline. chemistry: for chemistry abnormalities, shifts from grade 2 at baseline to grade 3 post-baseline are listed below:  alt increased was reported for 1 participant in the sli.  ast increased was reported for 1 participant in phase 2. alt increased and ck increased, shifts from grade 2 at baseline to grade 4 post-baseline, were reported for 1 participant in phase 2 and 1 in the sli, respectively. hepatic laboratory values: in total, 5 participants (3 in the sli and 2 in phase 2) and 4 participants (3 in the sli and 1 in phase 2) had a notable post-baseline alt 3  uln and ast 3  uln, respectively. electrocardiogram: an increase from baseline in qtcf of >30 msec was observed in 6 (46.2%) participants (5 in the sli and 1 in phase 2). an increase from baseline in heart rate of >25% and to a value >100 beats per minute was observed in 1 (7.7%) participant in the sli."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). alternatively, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. one hundred and nineteen out of 218 (55%) participants in this study had at least 1 medical problem in the first 16 weeks of the study. one hundred and sixty out of 218 (73%) participants in this study had at least 1 medical problem by week 52. a total of 3 participants left the study by week 52 because of medical problems. the most common medical problems, those reported by more than 5% of participants, are described in table 1 below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 5% of participants are listed.  the 2nd to 7th column tells us the number of participants in the groups below who reported each medical problem. next to this number is the percentage of the participants taking the study medication who reported the medical problem. o pf-06700841 60 mg group o pf-06700841 30 mg group o pf-06700841 10 mg to pf-06700841 60 mg group o pf-06700841 10 mg to pf-06700841 30 mg group o placebo to pf-06700841 30 mg group o placebo to pf-06700841 60 mg group  using these instructions, you can see that 2 out of the 60 participants in the pf-06700841 60 mg group taking the study medication reported low red blood cell count. (0%) (0%) (0%) (0%) (3%) (0%) (3%) (0%) (0%) (3%) (6%) (0%) (0%) (0%) (0%) (9%) (0%) (6%) (3%) (0%) (0%) (3%) (6%) (0%) (0%) (3%) (6%) (0%) (3%) (9%) (0%) (0%) (0%) (0%) (6%) (6%) (3%) "," up to week 16: a total of 119 participants reported 257 aes during the placebo-controlled period, 65 of the aes were characterized by the investigator as treatment-related. the percentages of participants with all- causality (treatment-related) aes were 47.8% (13.4%) in the placebo group, 45.2% (19.4%) in the pf-06700841 10 mg treatment group, 55.0% (20.0%) in the pf-06700841 30 mg treatment group and 66.7% (25.0%) in the pf-06700841 60 mg treatment group. the top 4 socs containing the highest percentage of participants experiencing all-causality aes were: infections and infestations (30.7%), followed by investigations (14.2%) and gastrointestinal disorders (11.0%) and nervous system disorders (8.3%). during the whole study (inclusive of the 16-week placebo-controlled period): a total of 469 aes were reported during the study, of which 108 were characterized by the investigator as treatment-related. the percentages of participants with all-causality aes were similar across all 6 treatment groups (ranged from 62.5% to 76.7%), and between combinedpf-06700841 30 mg treatment group (74.1%) and combinedpf-06700841 60 mg treatment group (72.7%). herpes zoster (one varicella event [sae] included) was reported in 4 participants and herpes simplex was reported in 1 participant. both events were considered not related to the study drug a total of 15 all-causality sae cases were reported in 12 participants (5.5%) during the study, of which 3 sae cases were considered treatment-related. between week 16 and week 52, there were 4 participants who developed serious infections including pneumonia viral, pneumonia, varicella (which resulted in permanent withdrawal from the study treatment) and covid-19 pneumonia (which resulted in permanent withdrawal from the study treatment). laboratory values: up to week 16, there were 47 (70.1%) participants in the placebo group who reported laboratory abnormalities, compared with 25 (80.6%), 47 (79.7%) and 50 (83.3%) participants in the pf-06700841 10 mg, 30 mg and 60 mg treatment groups, respectively. the decrease in hemoglobin level was most pronounced at the highest dose of pf-06700841 but was not associated with the incidence of hemoglobin related aes (i.e., anaemia) reported during the study. at week 16, pf-06700841 30 mg and 60 mg treatment groups showed significant improvement in acr20/50/70, pasi75/90 and mda when compared with the placebo group. the dose dependent trend in efficacy endpoints was apparent during the placebo controlled period (up to week 16), most notably in the skin endpoints, but was not apparent up to week 52 where the numerically higher responses for multiple efficacy endpoints were observed in the combinedpf-06700841 30 mg treatment group."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. 7 out of 164 (4%; 4 out of 100) participants in this study had at least 1 treatment-related medical problem. treatment-related medical problems were reported in:  4 (7%) participants in the pf-06835919 150 mg group  2 (4%) participants in the placebo group  1 (2%) participant in the pf-06835919 300 mg group a total of 2 participants stopped pf-06835919 because of medical problems: 1 participant in the pf-06835919 300 mg group and 1 participant in the pf-06835919 group stopped treatment because of medical problems. two participants left the study because of medical problems. the most common medical problems  those reported by 2 or more participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 2 or more participants are listed.  the 2nd column tells how many of the 55 participants taking pf-06835919 300 mg reported each medical problem. next to this number is the percentage of participants taking pf-06835919 300 mg who reported the medical problem.  the 3rd column tells how many of the 55 participants taking pf- 06835919 150 mg reported each medical problem. next to this number is the percentage of participants taking pf-06835919 150 mg who reported the medical problem.  the 4th column tells how many of the 54 participants taking a placebo reported each medical problem. next to this number is the percentage of participants taking a placebo who reported the medical problem.  using these instructions, you can see that 4 out of the 55 participants (7%) taking pf-06835919 150 mg reported high blood sugar. a total of 0 out of the 54 (0%) participants taking a placebo reported high blood sugar.  ","  in this study, there were 22 (40.7%), 25 (45.5%) and 18 (32.7%) participants that experienced at least 1 all-causality teae in the placebo, pf-06835919 150 mg and pf-06835919 300 mg groups, respectively. of these participants, 2 (3.6%) participants in the pf-06835919 150 mg group and 1 (1.8%) participant in the pf-06835919 300 mg group experienced teaes in severe intensity; none of these severe teaes were considered as treatment-related.  in this study, 1 sae was reported in 1 participant in the pf-06835919 150 mg group, which was reported as not treatment-related. the incidence of all-causality teaes was similar between the placebo and pf-06835919 treatment groups, with 25 (45.5%) participants in the pf-06835919 150 mg group and 18 (32.7%) participants in the pf-06835919 300 mg group, compared with 22 (40.7%) participants in the placebo group. overall, the proportion of participants experiencing treatment-related teaes was low across the treatment groups with 4 (7.3%) participants in the pf-06835919 150 mg group and 1 (1.8%) participant in the pf-06835919 300 mg group reporting treatment-related teaes, compared with 2 (3.7%) participants in the placebo group. two treatment-related teaes experienced by 2 (3.6%) participants in the pf-06835919 150 mg group and 1 treatment-related teae experienced by 1 (1.8%) participant in the pf-06835919 300 mg group were of moderate severity. one participant in the pf-06835919 300 mg group discontinued the study drug due to a mild teae of anaemia but continued in the study, and this event was considered not related to treatment.  another participant in the pf-06835919 300 mg group discontinued from the study permanently due to a mild teae of pyrexia, which was considered not related to treatment.  another participant in the pf-06835919 300 mg group temporarily discontinued the study drug due to a mild teae of dizziness, and this event was deemed not related to treatment. hypoglycemia aes  in the placebo group, 3 (5.6%) participants experienced teaes of hypoglycaemia, among whom 1 (1.9%) participant had treatment-related hypoglycaemia.  in the pf-06835919 150 mg group, 1 (1.8%) participant experienced teae of hypoglycaemia, which was considered as treatment-related by the investigator.  one (1.9%) participant in the placebo group, 1 (1.8%) participant in the pf-06835919 150 mg group and no participants in the pf-06835919 300 mg group experienced asymptomatic hypoglycemia. clinical laboratory evaluation without regard to baseline abnormality, the proportion of participants who had laboratory test abnormalities was similar across the 3 treatment groups (52 [98.1%], 52 [96.3%] and 51 [92.7%] participants in the placebo, pf-06835919 150 mg and pf-06835919 300 mg groups, respectively)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. a total of 224 out of 411 participants (55%) in this study had at least 1 medical problem. a total of 45 participants (11%) stopped study treatment and 12 participants (3%) left the study because of medical problems. the most common medical problems reported by 5% or more of total participants are shown in table 1. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 5% or more of total participants are listed.  the 2nd  7th columns tell how many of the participants in each treatment group (treated with danuglipron or placebo) reported each medical problem. next to this number is the percentage of the participants taking danuglipron or placebo who reported the medical problem.  using these instructions, you can see that 5 out of the 68 participants (7%) taking danuglipron 2.5 mg twice daily reported nausea. a total of 2 of 66 participants (3%) taking a placebo reported nausea.  "," in this study, out of the 411 treated participants, 224 (54.5%) participants experienced a total of 538 all-causality teaes. the number of all-causality teaes generally increased with higher doses of danuglipron (74, 75, 93, 122, and 129 all-causality teaes in the danuglipron 2.5 mg, 10 mg, 40 mg, 80 mg, and 120 mg bid groups, respectively) and was higher in all danuglipron dose groups compared with the placebo group (45 all-causality teaes). there were 13 (3.2%) participants who experienced saes, and 1 of these saes, which occurred in the danuglipron 80 mg bid group, was reported as treatment-related by the investigator. twelve (2.9%) participants discontinued from the study due to all-causality teaes, while 45 (10.9%) participants discontinued the study drug due to all-causality teaes but continued in the study. clinical study report synopsis clinical study report synopsis clinical study report synopsis the most frequently reported all-causality teaes (5% of participants) were nausea (68 [16.5%] participants), diarrhoea (36 [8.8%] participants), vomiting (35 [8.5%] participants) and headache (23 [5.6%] participants). in general, a greater number of moderate and severe aes, combined, were reported across the 2 highest doses of danuglipron (80 mg and 120 mg bid), when compared with lower doses of danuglipron and placebo. a similar number of moderate and severe aes, combined, were reported across the lower doses of danuglipron (2.5 mg, 10 mg and 40 mg bid), which were greater than that reported for placebo. the most frequently reported treatment-related teaes (5% of participants) were nausea (66 [16.1%] participants), vomiting (33 [8.0%] participants), and diarrhoea (26 [6.3%] participants). in general, a greater number of moderate and severe aes were reported for the 2 highest doses of danuglipron (80 mg and 120 mg bid), when compared with lower doses of danuglipron and placebo. one sae in the danuglipron 80 mg bid group of cholecystitis acute was reported as related to danuglipron by the investigator; of note, this sae occurred on study day 45, which was 42 days after the last dose of study medication on study day 3 and was assessed as not related to study medication by the sponsor. hypoglycemic aes aes of hypoglycaemia were reported in 15 (3.6%) participants in this study, with higher incidence at doses of danuglipron 40 mg bid and above, compared with lower doses of danuglipron; no participants experienced ae of hypoglycaemia in the placebo group. covid-19-related aes a total of 20 (4.9%) participants had corona virus disease 2019 (covid-19)-related teaes coronavirus 2 (sarscov2) test positive, 4 participants had a teae of suspected covid-19 and 2 participants had a teae of covid-19 pneumonia."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. the number and percentage of women participants with medical problems after vaccination was similar between participants given the rsvpref and placebo (see figure below). there were 144 out of 579 (25%) participants in this study who had at least 1 medical problem. the most common medical problems  those reported by more than 3% of women participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 3% of participants are listed.  the 2nd column tells how many of the 115 participants given rsvpref 120 g without aluminum hydroxide reported each medical problem. next to this number is the percentage of the 115 participants given rsvpref 120 g without aluminum hydroxide who reported the medical problem.  the 3rd column tells how many of the 117 participants given rsvpref 120 g with aluminum hydroxide reported each medical problem. next to this number is the percentage of the 117 participants given rsvpref 120 g with aluminum hydroxide who reported the medical problem.  the 4th column tells how many of the 116 participants given rsvpref 240 g without aluminum hydroxide reported each medical problem. next to this number is the percentage of the 116 participants given rsvpref 240 g without aluminum hydroxide who reported the medical problem.  the 5th column tells how many of the 114 participants given rsvpref 240 g with aluminum hydroxide reported each medical problem. next to this number is the percentage of the 114 participants given rsvpref 240 g with aluminum hydroxide who reported the medical problem.  the 6th column tells how many of the 117 participants given placebo reported each medical problem. next to this number is the percentage of the 117 participants given placebo who reported the medical problem.  using these instructions, you can see that 4 out of the 116 participants given rsvpref 240 g without aluminum hydroxide reported stomach pain. there were no other participants in the other rsvpref groups (115, 117, and 114 participants) or the placebo group (117 participants) who reported stomach pain. the medical problems seen in infants were events that are commonly seen from birth through 12 months and were similar between groups. none of the participants left the study because of medical problems within 1 month after vaccination. there was a single infant who left the study because of severe heart and lung problems. this infants mother had received the placebo vaccine. there was only a single medical problem of dizziness that was considered related to the vaccination in the women participants (1 out of a total of 144 medical problems reported, or less than 1%). none of the medical problems reported by infant participants were considered related to the vaccination. ","  safety results: local reactions were reported more frequently by maternal participants who received rsvpref compared with the placebo group. the most common local reaction in maternal participants across all rsvpref vaccine groups and placebo was pain at the injection site. severe local reactions (pain at the injection site) were reported by 2 participants who received 120 g rsvpref + al(oh) and 1 participant who received 3 240 g rsvpref. one participant who received 120 g rsvpref + al(oh)3 reported a grade 4 fever. adverse events (aes) in maternal participants within 1 month after vaccination were reported in a similar frequency across all vaccine groups with no clear association with dose level or formulation (table s4). within 1 month after vaccination, serious aes (saes), severe aes, and medically attended aes (maes) were reported in a similar frequency across all groups. one participant who received rsvpref 120 g reported a related ae of dizziness that began on day 1 with a severity of mild that resolved the same day. tier 2 aes reported within 1 month after vaccination in maternal participants were abdominal pain, nausea, and premature delivery. aes in infant participants within 1 month of age were reported in a similar frequency across all vaccine groups with no clear association with dose level or formulation (table s5). saes, severe aes, and maes in infant participants within 1 month of age were reported in a similar frequency across all vaccine groups with no clear association with dose level or formulation. one infant participant who received placebo was withdrawn due to aes. the most frequently reported aes across all vaccine groups for tier 2 aes reported in infant participants were hyperbilirubinaemia (range of 2 to 11 participants) and jaundice (range of 5 to 12 participants). no tier 2 ae in any vaccine group had a 95% confidence interval for the difference compared to placebo which was entirely above zero. one stillbirth occurred in a maternal participant who received placebo. maternal-to-infant placental transfer ratios were >1 for all vaccine groups; while there were higher rsv neutralizing gmts in maternal participants after vaccination with rsvpref formulated with al(oh) than without al(oh) , this difference did not 3 3 translate into higher rsv neutralizing gmts in infants. in general, rsvpref was safe and well-tolerated regardless of formulation (with or without al[oh] ) or dose (120 or 240 g). the most frequently reported local reaction was pain at 3 the injection site (reported more frequently in participants who received rsvpref formulated with al[oh] ) and the most frequently reported systemic event was fatigue. for maternal participants, these events were most often related to complications of pregnancy, labor, delivery, and the immediate postpartum period; for infants, aes and saes were generally common events that occur during the neonatal period and throughout the first year of life."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by study vaccine or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by looking at medical problems across many treatment groups in many studies, doctors try to understand what the side effects of an experimental drug (in this case experimental vaccine) might be. what percentage of participants had local reactions within 7 days after vaccination? redness, swelling, or pain at the injection site are known as local reactions. the table on the following page shows the percentage of participants with local reactions within 7 days after vaccination. what percentage of participants had systemic events within 7 days after vaccination? fever, headache, tiredness, muscle pain, joint pain, nausea, vomiting, and diarrhea are known as systemic events. the table on the following page shows the number of participants with systemic events within 7 days after vaccination. what percentage of participants had medical problems within 1 month after vaccination? 55 out of 709 vaccinated participants (8%) had at least 1 new or worsening medical problem within 1 month after vaccination, including:  low dose rsvpref and placebo: 8 out of 141 participants (6%)  low dose rsvpref and tdap: 11 out of 141 participants (8%)  high dose rsvpref + aluminum hydroxide and placebo: 8 out of 142 participants (6%)  high dose rsvpref + aluminum hydroxide and tdap: 15 out of 144 participants (10%)  placebo and tdap: 13 out of 141 participants (9%) a total of 6 participants (1%) had a medical problem that the study doctor considered to be related to study vaccines. most of the related medical problems were mild to moderate in severity, with short duration. the table below shows the most common medical problems that happened within 1 month after study vaccination. ","  safety results:  most reported local reactions (pain at the injection site, redness, or swelling) or systemic events (fever, fatigue/tiredness, headache, nausea, muscle pain, joint pain, vomiting, or diarrhea) were mild or moderate in intensity. severe pain at the injection site was reported by 2 participants (1 participant each in the rsvpref 120 g/tdap and rsvpref 240 g + al(oh) /placebo groups, respectively). there was a lower observed incidence 3 of any systemic events of severe intensity in the placebo/tdap group (0.7%) than in the + al(oh) /tdap (4.2%), and rsvpref 240 g + al(oh) /placebo (2.8%) groups. no 3 3 participant withdrawals due to severe local reactions or systemic events occurred. the observed incidence and median durations of local reactions and systemic events were similar across vaccine groups.  the frequency of reported aes was higher in the rsvpref 240 g + al(oh)3/tdap (10.4%) and placebo/tdap (9.2%) groups than in the rsvpref 120 g/tdap (7.8%), rsvpref 120 g/placebo (5.7%) or rsvpref 240 g + al(oh) /placebo (5.6%) groups. 3 the incidence of each ae by pt was 5% of participants per vaccine group. there were no saes, immediate aes, or life-threatening aes reported within 1 month of vaccination and no aes that led to withdrawal.  tier 2 aes of upper respiratory tract infection were reported in the placebo/tdap (4 [2.8%]) group, the rsvpref 240 g + al(oh) /placebo (2 [1.4%]) group and 3 rsvpref 240 g + al(oh) /tdap (2 [1.4%]) group. there were no reports of upper 3 respiratory tract infection in the rsvpref 120 g/placebo or rsvpref 120 g/tdap groups. there were no other tier 2 aes reported within 1 month of vaccination. all medically- attended aes were reported by single participants except for the aes of ear infection and tonsillitis, which were reported by the same participant.  one (1) sae of spontaneous abortion was reported by a participant in the rsvpref 240 g + al(oh) /placebo group after visit 2 (day 42). this event was not considered 3 to be related to study treatment. conclusion(s): this study evaluated the noninferiority of immune responses to rsvpref and tdap after concomitant administration of rsvpref with tdap to rsvpref alone or tdap alone. the results of this study confirm that the 2 rsvpref formulations when administered with and without the al(oh) adjuvant were 3 safe and well tolerated when administered alone or concomitantly with tdap in healthy non-pregnant women 18 through 49 years of age."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. a total of 27 out of 65 participants (42%) in this study had at least 1 medical problem. there were 7 out of the 65 participants (11%) who stopped taking the treatment because of medical problems but decided to continue in the study. no participants left the study because of medical problems. the most common medical problems reported by more than 5% of participants in either group are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 5% of participants in either group are listed.  the 2nd column tells how many of the 33 participants taking the crisaborole ointment reported each medical problem. next to this number is the percentage of the 33 participants taking the crisaborole ointment who reported the medical problem.  the 3rd column tells how many of the 32 participants taking the vehicle ointment reported each medical problem. next to this number  ","  in the crisaborole 2% bid group: 13 (39.4%) participants experienced 28 teaes, among whom, 3 (9.1%) participants experienced 14 mild teaes, 9 (27.3%) participants experienced 13 moderate teaes and 1 (3.0%) participant experienced 1 severe teae. a total of 3 (9.1%) participants in the crisaborole 2% bid group had 7 treatment-related teaes, and all these treatment-related teaes were of mild or moderate severity.  overall, the most frequently reported system organ class (soc) with all-causality teaes was skin and subcutaneous tissue disorders, which was reported in 3 (9.4%) participants in the vehicle group and 4 (12.1%) participants in the crisaborole 2% bid group.  erythema and pruritus in the skin and subcutaneous tissue disorders soc were the only treatment-related teaes occurring in 5% participants of either treatment group. teaes in treatment area the incidence of teaes in the treatment area was slightly higher in the vehicle group compared to the crisaborole 2% bid group.  in the vehicle group: 6 (18.8%) participants experienced 12 all-causality teaes in the treatment area, among whom, 5 (15.6%) participants experienced 11 mild teaes and 1 (3.1%) participant experienced 1 severe teae.  in the crisaborole 2% bid group: 4 (12.1%) participants experienced 9 all-causality teaes in the treatment area, among whom, 3 (9.1%) participants experienced 2 mild and 6 moderate teaes, and 1 (3.0%) participant experienced 1 severe teae. a total of 3 (9.1%) participants had 7 treatment-related teaes in the treatment area, and all these treatment-related teaes were of mild or moderate severity. three participants in the vehicle group discontinued treatment due to teaes and continued in the study. one participant discontinued treatment due to the ae of ulcer haemorrhage, but this event was not teae. four participants in the crisaborole 2% bid group discontinued treatment due to teaes and continued in the study. one participant in the vehicle group had dose reduction due to the ae of limb injury, but this event was not teae.  one (3.33%) participant in the crisaborole 2% bid group while no participants in the vehicle group achieved isga success at week 6/eot based on hvp in-person assessment.  the proportion of participants achieving isga success in the crisaborole 2% bid group was greater than that in the vehicle group at weeks 1, 5 and 6 based on digital images assessment by central readers.  the proportion of participants achieving isga clear/almost clear in the crisaborole 2% bid group was greater than that in the vehicle group at all time points from week 1 to week 6 based on digital images assessment by central readers and at week 6/eot based on hvp in-person assessment."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. 108 out of 194 (56%) participants in this study had at least 1 medical problem. most of these problems were not related to the treatment based on doctors assessment. only 45 participants (23%) had treatment-related medical problems. a total of 8 participants left the study because of medical problems. the most common medical problems  those reported by more than or equal to 5% of participants  are described below.  below are instructions on how to read table 1.  instructions for understanding table 1  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than or equal to 5% of participants are listed.  the 2nd column tells how many of the 48 participants taking a placebo reported each medical problem. next to this number is the percentage of the 48 participants taking the study medication who reported the medical problem.  the 3rd column tells how many of the 47 participants taking zimlovisertib reported each medical problem. next to this number is the percentage of the 47 participants taking zimlovisertib who reported the medical problem.  the 4th column tells how many of the 52 participants taking brepocitinib reported each medical problem. next to this number is the percentage of the 52 participants taking brepocitinib who reported the medical problem.  the 5th column tells how many of the 47 participants taking pf- 06826647 reported each medical problem. next to this number is the percentage of the 47 participants taking pf-06826647 who reported the medical problem using these instructions, you can see that 4 out of the 47 (9%) participants taking zimlovisertib, 5 out of 52 (10%)participants taking brepocitinib and 4 out of the 47 (9%) taking pf-0682664 reported acne. a total of 1 out of the 48 (2%) participants taking a placebo reported acne. ","  safety results: secondary safety endpoints (aes, clinical laboratory abnormalities, vital signs, ecg, physical examination) teaes among 194 randomized participants, 108 participants (55.7%) had 231 all-causality teaes, 45 participants (23.2%) had 71 treatment-related teaes. four participants reported 4 saes, including 2 in the pf-06650833 group (1 treatment-related sae of leading to discontinuation from the study; 1 sae of cellulitis not related to study treatment) and 2 in the pf-06826647 group (1 treatment-related sae of hidradenitis; 1 sae of covid-19, not related to study treatment, and leading to discontinuation from the study). the number and percentage of participants with severe teaes were higher in the pf-06826647 group (4 [8.5%]) compared the other groups (placebo: 1 [2.1%]; pf-06650833: 2 [4.3%]; pf-06700841 group: 1 [1.9%]). the pf-06826647 group had higher number and proportion of participants who permanently discontinued from study (6 [12.8%]) or temporarily discontinued from study (5 [10.6%]) due to all-causality teaes compared to the other groups (placebo group: 0, 2 [4.2%]; trends were observed in discontinuations from study due to treatment-related teaes. two participants discontinued from the study due to saes, 1 in the pf-06650833 group (suicidal ideation) and 1 in the pf-06826647 group (covid-19). four participants had edp events occurred in this study; 2 in the placebo group (one participant discontinued) and 2 in the pf-06650833 group (one participant discontinued, one participant had a during follow-up, which after database release was updated to be a treatment-related sae of no participant had herpes infections.  pf-06700841 group versus placebo group: infections and infestations (12 participants, 23.1% vs 5 participants, 10.4%), skin and subcutaneous tissue disorders (10, 19.2% vs 7, 14.6%), investigations (7, 13.5% vs 2, 4.2%), nervous system disorders (6, 11.5% vs 3, 6.3%), general disorders and administration site conditions (5, 9.6% vs 3, 6.3%) and psychiatric disorders (4, 7.7% vs 1, 2.1%).  pf-06826647 group versus placebo group: skin and subcutaneous tissue disorders (13 participants, 27.7% vs 5 participants, 10.4%), investigations (11, 23.4% vs 2, 4.2%), gastrointestinal disorders (6, 12.8% vs 4, 8.3%), blood and lymphatic disorders (4, 8.5% vs 1, 2.1%). a total of 6 participants met the discontinuation criteria of absolute neutrophil value <1  103/mm3, and 3 of these participants discontinued from the study due to this abnormality."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. in treatment period 1, 107 out of 445 (24%) participants in this study had at least 1 medical problem and there were 12 (3%) participants who left the study because of medical problems. the medical problems seen were as expected for participants treated with humira. in treatment period 2 to the end of the study, 82 out of the 213 (38%) participants in the switching arm and 62 out of the 214 (29%) participants in the non-switching arm had at least 1 medical problem. the most common medical problems  those reported by more than 1% of participants  are described in table 1 for treatment period 2 to the end of the study. a total of 8 (4%) participants in the switching arm and 9 (4%) participants in the non-switching arm left the study because of medical problems. below are instructions on how to read table 1. these instructions can also be used to understand table 2. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported from treatment period 2 to the end of the study. all medical problems reported by more than 1% of participants are listed.  the 2nd column tells how many of the 213 participants in the switching arm reported each medical problem. next to this number is the percentage of the 213 participants in the switching arm who reported the medical problem.  the 3rd column tells how many of the 214 participants in the non-switching arm reported each medical problem. next to this number is the percentage of the 214 participants in the non-switching arm who reported the medical problem.  using these instructions, you can see that 46 out of the 213 (22%) participants in the switching arm had medical problems compared with 38 out of the 214 (18%) participants in the non-switching arm during treatment period 2 to the end of the study. alt:alanine aminotransferase (one of the liver enzymes tested in liver function tests); ast: aspartate aminotransferase (one of the liver enzymes tested in liver function tests); covid-19: coronavirus disease 2019. ","  safety results: the median doses administered to the 445 study participants in tp1 were 5, over a median duration of treatment of 57.0 days. median study drug duration post randomization (tp2 and beyond) and the median total number of doses administered were balanced across both treatment arms. there were no deaths at any time during the study in any treatment period. in tp1, 107 out of 445 participants had 198 all-causality adverse events, of these 13 out of 445 (2.9 %) participants reported treatment-emergent serious aes. participants in non-switching arm had 152 and 123 had all-causality aes, respectively. in tp2 and beyond, 3 (1.4%) participants in switching arm and 8 (3.7%) participants in non-switching arm had serious teaes (table s6). conclusions: the results of this clinical study support that the risk of switching between treatment with humira and pf-06410293 in terms of safety or diminished efficacy (using pk as surrogate) is not greater than the risk of using humira without the switch. pharmacokinetics  the primary analysis demonstrated that gmr 90% cis for auc and c were within tau max the prespecified (80.00% - 125.00%) margin, therefore pk equivalence was established between the switching treatment with humira and pf-06410293 compared with treatment with humira without the switch.  there were no clinically meaningful differences in exposures comparing the mean steady-state pk concentrations in the switching arm and the non-switching arm.  number and percentage of ada and nab positive participants, and titers were balanced between the 2 treatment arms at every visit during the study.  the impact of ada on the mean steady-state pk was similar in the switching and the non-switching arm. the lower pk concentrations (g/ml) between week 30 and week 32 in ada positive participants was similar across both treatment arms.  the impact of nab on the mean steady-state pk was similar in the switching and the non-switching arms. the lower pk concentrations (g/ml) between week 30 and week 32 in nab positive samples at week 30 was similar across both treatment arms. immunogenicity  the review of events identified as potentially immunogenic reactions to the drug, including injection site reactions did not identify any clinically meaningful imbalance.  there was no medically evaluated case meeting sampson criteria for anaphylaxis in any treatment arm.  number and percent of participants with potentially immunogenic reactions to the drug by ada status over time was small, with no clinically significant differences between the 2 treatment arms safety based on the assessment of saes and aesi, including immunogenic aes to the drug, there were no clinically meaningful differences between the switching and non-switching arm.  occurrence of grade 3 or higher aesis, including immunogenic aes to the drug, was balanced between the two treatment arms.  permanent discontinuations due to aes were balanced between the two treatment arms."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. there were 113 out of 122 (93%) participants in this study who had at least 1 medical problem. most of these medical problems were mild. a total of 3 participants stopped treatment because of medical problems. the most common medical problems  those reported by 5% or more participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 5% or more participants are listed.  the 2nd column tells how many of the 42 participants given low dose dex reported each medical problem. next to this number is the percentage of the 42 participants given low dose dex who reported the medical problem.  the 3rd column tells how many of the 42 participants given middle dose dex reported each medical problem. next to this number is the percentage of the 42 participants given the middle dose of dex who reported the medical problem.  the 4th column tells how many of the 38 participants given high dose dex reported each medical problem. next to this number is the percentage of the 38 participants given high dose dex who reported the medical problem.  using these instructions, you can see that 24 out of the 42 (57%) participants given low dose dex and 24 out of the 42 (57%) given the middle dose of dex had a heartbeat that was slower than normal compared to 27 out of the 38 (71%) participants given high dose dex who had a heartbeat that was slower than normal.  "," in addition, 1 participant experienced severe saes of acute respiratory failure and sepsis on day 30 following planned surgery on day 24, and 1 participant (who underwent an mri for assessment of an underlying ) experienced 2 mild saes of seizure on days 2 and 21 that were reported as non-serious by the investigator but upgraded to serious by the sponsor.  three participants, 1 in each dose group, discontinued study treatment due to teaes (bradycardia, bradypnea, and hypertension)  no participant discontinued the study due to an ae.  incidence of teaes: the most commonly reported all-causality teaes by pt (5% participants in any dose group) were bradypnea, bradycardia, hypertension, hypotension, hypoxia, diastolic hypertension, systolic hypertension, tachycardia. the majority of all-causality teaes were mild, except for 4 participants who reported moderate all-causality teaes: 2 participants in the dex low dose group (1 participant each with hypoxia and hypotension) and 2 participants in the dex high dose group (1 participant with bradycardia, and 1 participant with bradycardia, tachycardia, and hypertension). a decrease in the proportion of participants with bradypnea was observed with increasing dex dose: dex low dose level (33 participants [78.6%]), dex middle dose level (27 participants [64.3%]), and dex high dose level (22 participants [57.9%]). a similar decrease in hypoxia was observed with increasing dex dose: dex low dose level (6 participants [14.3%]), dex middle dose level (3 participants [7.1%]), and dex high dose level (1 participant [2.6%]). a higher proportion of participants at the dex high dose level (27 participants [71.1%]) reported bradycardia compared with the low and middle dose levels (24 participants [57.1%] each).  protocol-specified teaes requiring intervention: overall, in the combined age cohorts, 5 participants (4.1%) experienced protocol-specified teaes requiring intervention: 2 participants (4.8%) in the low dose group, 1 participant (2.4%) in the middle dose group, and 2 participants (5.3%) in the high dose group.  withdrawal-related adverse events: overall, 3 participants experienced withdrawal-related aes (1 event of agitation and 2 events of anesthetic complication neurological [investigator entry: emergence delirium]) after discontinuation of the dex infusion.  hemodynamic stability: overall (total dex), in both the combined and individual age cohorts, the ratio for the time outside of the hemodynamically stable range was 0.5 or lower, indicating that on average, the time outside of the hemodynamically stable range was less than or equal to half of the time period of evaluation."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. 44 out of 51 (86%) participants with t2dm and 14 out of 15 (93%) participants with obesity had at least 1 medical problem. a total of 3 participants left the study because of medical problems. the most common medical problems  those reported by more than 5% of the total number of participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 5% of participants are listed in decreasing order.  the 2nd - 7th column tells how many of the 66 participants taking the pf-07081532 or placebo reported each medical problem. next to this number is the percentage of the participants taking the pf-07081532 or placebo who reported the medical problem.  for example, using these instructions, you can see that a total of 26 out of the 52 (50%) participants taking pf-07081532 and a total of 4 out of the 14 (29%) participants taking a placebo reported nausea. using these instructions, you can see that nausea was reported by 19 out of the 40 (48%) participants with t2dm taking pf 07081532 and 3 out of the 11 (27%) participants with t2dm taking placebo.    "," in participants with t2dm, a total of 174 teaes were reported in 44 (86.3%) participants. in pf-07081532 treatment groups, the 10 mg group had the lowest number of all-causality aes with 5 events, and the 180 mg group had the highest number of all-causality aes with 47 events. one participant in the 30 mg group had an sae of obstructive pancreatitis (considered treatment-related by the investigator but considered unrelated by the sponsor). this participant also experienced severe aes of hypotension (not related to study treatment but related to pancreatitis) and increased transaminases (treatment-related) on the same day of the sae onset. in participants with t2dm, 2 participants discontinued from the blinded treatment phase due to aes: 1 in pf-07081532 60 mg group (day 13, 40 mg dose) due to moderate nausea, and 1 in pf-07081532 120 mg group (day 5, 40 mg dose) due to mild hypoglycemia. one participant in pf-07081532 120 mg group had a dose reduction to 100 mg due to moderate nausea and moderate dyspepsia, both considered treatment-related. in participants with obesity, a total of 66 aes were reported in 14 (93.3%) participants. in pf-07081532 180 mg group, 1 participant discontinued study drug due to moderate treatment-related upper abdominal pain and continued study; 1 participant had a dose reduction to 150 mg due to mild nausea (treatment-related). in this study, all-causality teaes in the system organ class (soc) of gastrointestinal disorders were most frequently reported (56.1% of events in participants with t2dm, 56.4% of events in participants with obesity). the most frequently reported all-causality teae by preferred term (pt) was nausea in participants with t2dm, and nausea and constipation in participants with obesity. a total of 12 participants (6 participants with t2dm and 6 participants with obesity) experienced hypoglycemic aes (all treatment-related). all of these aes were considered mild in severity, with the exception of 1 moderate documented symptomatic hypoglycemia reported in part a pf-07081532 120 mg group. in participants with t2dm, on day 1, time-matched double differences in pulse rate for most pf-07081532 doses were similar to placebo. across the dosing interval, the maximum mean time-matched double difference for pulse rate was 6.8 bpm in placebo, ranged from 3.9 to 8.3 bpm in part a pf-07081532 groups, and 10.1 bpm in part c 180 mg group. in participants with obesity, on day 1, time-matched double differences in pulse rate for 180 mg dose group were similar to placebo. across the dosing interval to day 42, increases in the 180 mg group were observed compared with day 1. the maximum mean time-matched double difference in pulse rate in the 180 mg group was 13.9 bpm on day 42 compared to 6.7 bpm in placebo."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. a total of 178 out of 391 (46%) participants in this study had at least 1 medical problem. there was 20 out of the 391 participants, or 5%, who stopped using the study medication permanently or left the study because of medical problems. the most common medical problems  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 8 or more participants are listed.  the 2nd column tells how many of the 260 participants using crisaborole ointment reported each medical problem. next to this number is the percentage of the 260 participants using crisaborole ointment who reported the medical problem.  the 3rd column tells how many of the 131 participants using the vehicle ointment reported each medical problem. next to this number is the percentage of the 131 participants using the vehicle ointment who reported the medical problem.  using these instructions, you can see that 34 out of the 260 (13%) participants using crisaborole ointment reported pain where the ointment was applied. a total of 5 out of the 131 (4%) participants using the vehicle ointment reported pain where the ointment was applied.  "," all-causality saes were observed in 1 participant each in the vehicle and crisaborole 2% bid groups (0.8% and 0.4%, respectively); neither of the saes were treatment-related.  the most frequently reported treatment-related aes in the vehicle and crisaborole 2% bid groups were application site pain (3.8% and 13.1%, respectively), dermatitis atopic (4.6% and 2.3%, respectively), folliculitis (3.8% and 2.3%, respectively) and application site discolouration (0.8% and 3.1%, respectively).  eight (6.1%) and 11 (4.2%) participants discontinued from study treatment due to aes and continued study in the vehicle and crisaborole 2% bid groups, respectively. six (4.6%) and 8 (3.1%) participants discontinued from study treatment due to treatment-related aes and continued study in the vehicle and crisaborole 2% bid groups, respectively.  the proportion of participants with aes associated with dose reduction was low (2 [0.8%] participants in the crisaborole 2% bid group and 1 [0.8%] in the vehicle group).  the proportion of participants with aes of application site reaction in the crisaborole 2% bid group was higher than that in the vehicle group (all-causality: 20.4% versus 7.6%; treatment-related: 19.2% versus 6.9%). the most frequently reported ae in both treatment groups was application site pain (13.1% in the crisaborole 2% bid group and 3.8% in the vehicle group), all of which were considered treatment-related.  all-causality saes were reported in 1 participant each in the vehicle and crisaborole 2% bid groups. in the crisaborole 2% bid group, 1 participant at china site experienced an ae of carpal tunnel syndrome on study day 17. no action was taken in response to this ae. in the vehicle group, 1 participant at china site experienced sae of myocardial necrosis marker increased on study day 32. concomitant medications including fructose diphosphate sodium, fructose diphosphate sodium and ascorbic acid were given in response to this event. efficacy crisaborole is shown to be statistically superior to vehicle with respect to the primary efficacy endpoint, percent change from baseline in easi total score at day 29, and key secondary efficacy endpoints - achievement of improvement in isga at day 29, achievement of success in isga at day 29 and the change from baseline in pp-nrs at week 4 for participants 12 years.  the study met its primary objective: statistically significant reduction in percent change from baseline in easi total score was observed for participants in the crisaborole 2% bid group at day 29 compared to vehicle, with lsm difference of -17.13% and p-value of 0.0002.  the study met its key secondary objectives:  improvement in isga at day 29 was achieved in 41.4% of the participants in the crisaborole 2% bid group, which was statistically significantly higher, compared with 28.5% of the participants in the vehicle group (p=0.0124)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. a total of 5 out of 11 participants (45%) in this study had at least 1 medical problem. no participants left the study because of a medical problem. the table below shows the medical problems that happened during the study.  ","  safety results: an overview of all-causality and treatment related treatment-emergent adverse events (teaes) is provided in table s10. no serious aes (saes), severe aes, permanent discontinuation from study due to aes, permanent discontinuation from study treatment due to aes, dose reduction, or temporary discontinuation due to aes were reported in this study. five participants experienced all-causality teaes, of which 2 were in the normal renal function group and 3 were in the severe renal impairment group (diarrhoea, decreased appetite, and headache, all were mild in severity and resolved). in the normal renal function group, no participant experienced any treatment-related teae. in the severe renal impairment group, 3 participants experienced treatment-related teaes. participants evaluable for adverse 6 5 11 there were no individual clinically significant laboratory abnormalities in this study. there was 1 participant who had vital sign change meeting the pre-defined categorical criteria in the severe renal impairment group, which was supine systolic bp change 30 mm hg increase. no participant had vital sign change meeting the pre-defined categorization criteria in the normal renal function group. no vital sign finding was clinically significant nor reported by the investigator as an ae. the values of qtc interval 450 milliseconds but 480 milliseconds and qtcf 450 milliseconds but 480 milliseconds were reported in 2 participants each in severe renal impairment group. there were no participants with ecg data that met the pre-specified categorical criteria in the normal renal function group. no vital ecg finding was clinically significant nor reported by the investigator as an ae. conclusions:  following multiple infusions of the proposed adjusted atm-avi dose regimen (675 mg/225 mg iv q8h) in participants with severe renal impairment, the atm total daily exposure (auc ) was ~21% lower and the avi total daily exposure was ~24% 24,ss higher compared to participants with normal renal function receiving standard dose (1500 mg/500 mg iv q6h). peak exposure (c ) of atm was ~24% lower in max participants with severe renal impairment receiving the adjusted dose while avi peak exposure was comparable to that in participants with normal renal function receiving standard dose.  atm-avi was generally safe and well tolerated in participants with severe renal impairment and participants with normal renal function (healthy adults)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. among 71 participants who entered part 1:  29 out of 36 participants (81%) in the ritlecitinib group had at least 1 medical problem.  22 out of 35 participants (63%) in the placebo group had at least 1 medical problem. no medical problem led to participants leaving the study during part 1. table 1 shows the most common medical problems (those reported by 3 or more participants in any group). below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during part 1. it lists all medical problems reported by 3 or more participants in any group.  the 2nd column tells how many of the 36 participants taking ritlecitinib reported each medical problem. next to this number is the percentage of the 36 participants taking ritlecitinib who reported the medical problem.  the 3rd column tells how many of the 35 participants taking placebo reported each medical problem. next to this number is the percentage of the 35 participants taking placebo who reported the medical problem.  using these instructions, you can see that 3 out of the 36 participants (8%) taking ritlecitinib reported diarrhea. no participants taking placebo reported diarrhea. ","  safety results primary endpoint cfb in i-v interwave latency on baep at a stimulus intensity of 80 db at month 9 bl mean (sd) value (ms) of i-v interwave latency on baep at 80 db was 4.085 (0.1614) in 200/50 mg and 3.989 (0.1946) in placebo on the right side, and 4.103 (0.1531) in 200/50 mg and 3.988 (0.2235) in placebo on the left side. there was 1 participant in placebo with lengthened i-v interwave latency beyond 2 sds of the published mean (mean [sd]: 4.0 [0.21] ms) at month 9. the baep results for this participant did not suggest any neuro safety concerns. secondary endpoints cfb in i-v interwave latency on baep at a stimulus intensity of 80 db at month 6 at month 6:  there were no notable changes from bl in 200/50 mg or placebo on either side. cfb in ienfd in skin punch biopsies at month 9 bl values of ienfd (/mm) in skin punch biopsies were comparable in 200/50 mg (mean [sd]: 10.2 [3.81], median [quartile 1 {q1}, quartile 3 {q3}]: 9.8 [7.4, 13.3]) and placebo (mean [sd]: 11.0 [3.95], median [q1, q3]: 10.7 [7.7, 13.6]). both at bl and end of placebo-controlled phase (eop) (month 9 [or month 6 for the 2 participants who entered the active therapy extension phase at month 6]), the ienfd mean (sd) and median (q1, q3) values for 200/50 mg and placebo were consistent with published normal ranges (mean [sd]: 9.8 [3.6]/mm to 13.8 [6.7]/mm, median: 6.6 [5.3, 9.0]/mm). no changes were apparent in consistent there was 1 participant in 200/50 mg with a history of who had symptoms of hypoesthesia in the lower extremities that started intermittently and became chronic. three other participants who had similar or greater decreases in ienfd from or cfb in percentage of ienf with axonal swellings in skin punch biopsies at month 9 intra-epidermal axonal swellings are known to occur with low, but variable frequency in healthy individuals at the distal leg. two participants had saes: 1 in placebo had humerus fracture (severe, not related, recovering); 1 in ext 50 mg had takayasus arteritis (not related, not recovered) and was discontinued from study due to the ae. severe aes occurred in 2 (2.8%) participants, both in placebo: 1 had a humerus fracture (also an sae) during intense exercises and 1 had a limb injury when . a total of 7 participants had study drug interruptions due to aes (6 in 200/50 mg and 1 in placebo), of which 3 participants in 200/50 mg had study drug interruptions due to treatment-related aes (diarrhea, vomiting; post procedural hemorrhage [bleeding from the biopsy site]; urticaria)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study vaccine or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many vaccine groups in many studies, doctors try to understand what effects a study vaccine might have on a participant. how many participants had redness, swelling, or pain at the injection site within 10 days after vaccination with 20vpnc? 444 out of 876 (51%) participants in group 1 (20vpnc and siiv given together) had redness, swelling, or pain at the injection site within 10 days after vaccination with 20vpnc. 453 out of 855 (53%) participants in group 2 (20vpnc and siiv given separately) had redness, swelling, or pain at the injection site within 10 days after vaccination with 20vpnc. pain at the injection site was the most frequent of these reactions. how many participants had fever, headache, tiredness, muscle pain, or joint pain within 7 days after vaccination with 20vpnc? 418 out of 877 (48%) participants in group 1 (20vpnc and siiv given together) had fever, headache, tiredness, muscle pain, or joint pain within 7 days after vaccination with 20vpnc. 300 out of 855 (35%) participants in group 2 (20vpnc and siiv given separately) had fever, headache, tiredness, muscle pain, or joint pain within 7 days after vaccination with 20vpnc. tiredness was the most frequent of these symptoms. how many participants had medical problems within 1 month after each vaccination? 81 out of 895 (9%) participants in group 1 had at least 1 medical problem within 1 month after vaccination. out of those who received 20vpnc and siiv separately, 72 out of 896 (8%) participants had at least 1 medical problem within 1 month after vaccination with siiv and 76 out of 878 (9%) participants had at least 1 medical problem within 1 month after vaccination with 20vpnc. a total of 3 (less than 1%) participants left the study because of medical problems, including 2 participants in group 1 and 1 participant in group 2. the most common medical problems  those reported by at least 1% of participants in any group  are described below. below are instructions for understanding tables 1 and 2. instructions for understanding tables 1 and 2.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 1% of participants in any group are listed.  the 2nd column tells how many of the 895 participants receiving 20vpnc and siiv together reported each medical problem. next to this number is the percentage of the 895 participants receiving 20vpnc and siiv together who reported the medical problem.  the 3rd column tells how many of the 878 participants receiving 20vpnc and 896 participants receiving siiv separately reported each medical problem. next to this number is the percentage of the 878 participants receiving 20vpnc separately and 896 participants receiving siiv separately who reported the medical problem.  using these instructions, you can see that 9 out of the 895 (1%) participants receiving 20vpnc and siiv together reported a positive covid-19 test. a total of 14 out of the 878 (2%) participants receiving 20vpnc separately reported a positive covid-19 test. a total of 6 out of the 896 (1%) participants receiving siiv separately reported a positive covid-19 test. ","  safety results:  local reactions at the 20vpnc injection site were similar when 20vpnc was coadministered with siiv or given separately 1 month after siiv. there was a trend for somewhat higher proportions of participants reporting mild or moderate fatigue in the group receiving 20vpnc coadministered with siiv over either vaccine given alone, but the difference between the groups was not clinically significant. the rate of any fever was low (1.5%) in all groups.  rates of reported aes within 1 month after vaccination were low and similar after 20vpnc was coadministered with siiv, 20vpnc was administered separately, or siiv administered separately).  less than or equal to 1.7% of participants in either group reported any sae within 1 separate administration of 20vpnc. the proportions of participants who reported saes within 6 months after vaccination in either the coadministration or separate administration group were low (3.7% in both groups) and consistent with medical events that may occur in this population.  the proportions of participants who reported ndcmcs within 6 months after vaccination in either the coadministration or separate administration group were low (3.8%), similar in the 2 groups, and consistent with medical events that may occur in this population. conclusions: the responses after coadministration of 20vpnc and siiv met noninferiority for all 20 vaccine serotypes when compared to 20vpnc given separately, and for all 4 influenza strains compared to siiv given separately. 20vpnc was observed to have a similar safety profile when coadministered with or administered 1 month after siiv. the results from this study support the safety and immunogenicity of 20vpnc coadministered with siiv."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study vaccine or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many vaccine groups in many studies, doctors try to understand what effects a study vaccine might have on a participant. how many participants had pain, redness, or swelling at the injection site within 7 days after vaccination? 109 out of 119 (92%) participants who received bnt162b2 had redness, swelling, or pain at the injection site (or the skin area where the needle was injected) within 7 days of the first or second study vaccination. 1 (2%) participant who received placebo had pain at the injection site, and no participants who received placebo had redness or swelling at the injection site. the charts below in figure 2 show that pain at the injection site was the most common reaction after both vaccination 1 and vaccination 2 in participants who received bnt162b2. figure 2. how many participants had redness, swelling, or pain at the injection site within 7 days of each study vaccination? how many participants had fever, tiredness, headache, chills, vomiting, diarrhea, muscle pain, or joint pain within 7 days after vaccination? 93 out of 119 (78%) participants who received bnt162b2 and 9 out of 41 (22%) participants who received placebo had fever, tiredness, headache, chills, vomiting, diarrhea, muscle pain, or joint pain within 7 days of study vaccination. the charts in figure 3 below show that headache and fatigue were the most common symptoms. figure 3. how many participants had fever, tiredness, headache, chills, vomiting, diarrhea, muscle pain, or joint pain within 7 days of each study vaccination? how many participants from a clinical laboratory subset had abnormal blood test results 1 and 7 days after their first vaccination and 7 days after their second vaccination? abnormal blood test results were uncommon, and almost all were considered to be mild in severity. how many participants had any medical problems within 1 month after their second vaccination? 13 out of 119 (11%) participants in the bnt162b2 group and 3 out of 41 (7%) participants in the placebo group had a medical problem from dose 1 to one month after dose 2. 1 participant in the bnt162b2 group left the study because of medical problems that were considered to be related to the study vaccine (chills, tiredness, headache, joint pain, and injection site pain). the table below describes the most common medical problems  those reported by at least 2 participants in either group. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists the most common medical problems reported during the study. it lists all medical problems reported by at least 2 participants in either group.  the 2nd and 3rd columns tell how many of the participants in each group had a medical problem. next to this number is the percentage of participants in either group who had the medical problem.  using these instructions, you can see that 3 out of 119 participants (3%) who received bnt162b2 had common cold. 1 out of 41 (2%) participants who received placebo had common cold. ","  safety results: local reactions  pain at the injection site was the most common local reaction after both dose 1 and dose 2 in the bnt162b2 group, regardless of age group. severe pain at the injection site was reported by 2 (1.7%) participants after dose 1 and by 2 (1.7%) participants after dose 2. no grade 4 local reactions were reported during the study.  the frequency and severity of local reactions after dose 2 were similar to those after dose 1. the frequency and severity of local reactions were similar for each age group. severe pain at the injection site was reported by participants in the younger age group (20 to 64 years) after dose 1 (2 [2.1%] participants) and dose 2 (2 [2.1%] participants).  one (2.4%) participant in the placebo group reported mild pain at the injection site after dose 1. no other local reactions were reported by the participants in the placebo group. systemic events  fatigue was the most common systemic event after both dose 1 and dose 2 in the bnt162b2 group, regardless of age group. after dose 2, participants in the bnt162b2 group reported severe fatigue (4 [3.4%] participants), headache and chills (each 2 [1.7%] participants), and new or worsening joint pain (1 [0.9%] participant).  very few participants in the placebo group reported systemic events (7 [17.1%] participants after dose 1 and 5 [12.2%] participants after dose 2).  in the placebo group, 1 (12.5%) participant in the older age group reported a mild headache after dose 1. all other systemic events in the placebo group were reported by participants in the younger age group.  the use of antipyretic or pain medication after dose 1 was reported by 19.3% of participants in the bnt162b2 group (22.7% in the younger age group and 4.5% in the older age group and 4.9% of participants in the placebo group). adverse events  the percentage of participants who reported aes other than local or systemic reactogenicity events from dose 1 to 1 month after dose 2 was low, with 10.9% of the participants in the bnt162b2 group and 7.3% of participants in the placebo group. there were no immediate aes (reported within 30 minutes of vaccination) after either dose 1 or dose 2. there were no deaths, related saes, or life-threatening events reported from dose 1 to 12 months after dose 2.  in the bnt162b2 group, infections and infestations was the most common system organ class and the most frequently reported aes were nasopharyngitis (3 [2.5%] participants) and headache (2 [1.7%] participants)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. four (4) out of 24 (17%) participants in this study had at least 1 medical problem. none of the participants left the study because of medical problems. medical problems reported by 1 or more participants are described below. below are instructions on how to read table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 1 or more participants are listed.  the 2nd to 4th column tells how many of the 24 participants in group 1 to 4 reported each medical problem. next to this number is the percentage of the 24 participants taking the study medication who reported the medical problem.  using these instructions, you can see that 3 out of the 24 participants taking the danuglipron reported nausea. ","  safety results:  no deaths, serious adverse events (saes), severe aes, or discontinuations from the study due to aes were reported in the study.  a total of 5 treatment-emergent adverse events (teaes) were reported in the study. a total of 1, 2, and 2 teaes were reported in 1, 2, and 1 participant(s) in the mild, moderate, and severe hepatic impairment groups, respectively.  all 5 teaes reported in 4 participants were in the gastrointestinal disorders system organ class (soc). nausea was reported in 3 participants, 2 in the moderate hepatic impairment group, and 1 in the severe hepatic impairment group. diarrhea was reported in 1 participant in the mild hepatic impairment group. vomiting was reported in 1 participant in the severe hepatic impairment group. as expected, a higher proportion of laboratory abnormalities in liver tests were observed in participants with severe hepatic impairment compared to participants in the other 3 groups.  increases in blood pressure from baseline (20 mm hg in sitting diastolic blood pressure [dbp] or 30 mm hg in sitting systolic blood pressure [sbp]) were observed in the normal hepatic function group and moderate and severe hepatic impairment groups, and low blood pressure (sitting dbp <50 mm hg or sitting sbp <90 mmhg) was observed in the severe hepatic impairment group.  qtcf value >450 milliseconds and 480 milliseconds was observed in 5 participants across the three hepatic impairment groups, and pr interval baseline >200 milliseconds and 25% increase from baseline or baseline 200 milliseconds and 50% increase was observed in 1 participant in the severe hepatic impairment group. relative to the normal last max hepatic function group, the adjusted geometric mean ratios (90% cis) for auc were inf 122.70% (61.33%, 245.49%), 282.73% (141.32%, 565.66%), and 640.78% (320.27%, 1282.00%) in mild, moderate, and severe hepatic impairment groups, respectively. relative to the normal hepatic function group, the adjusted geometric mean ratios (90% cis) for auc were 104.59% (48.76%, inf,u 224.31%), 272.28% (126.95%, 583.96%), and 866.17% (403.86%, 1857.71%) in mild, moderate and severe hepatic impairment groups, respectively. the ratios (90% cis) for c were 113.43% (64.71%, last,u max,u 198.84%), 211.96% (120.91%, 371.57%) and 451.66% (257.65%, 791.75%) in mild, moderate, and severe hepatic impairment groups, respectively, relative to the normal hepatic function group."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. twenty-seven (27) out of 104 (26%) participants in this study had at least 1 medical problem. there were no participants who stopped using pf-07038124 ointment because of medical problems. there were 5 (10%) participants who stopped using the plain ointment because of medical problems. the most common medical problems  those reported by 2 or more participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 2 or more participants are listed.  the 2nd column tells how many of the 53 participants in the pf-07038124 ointment group with atopic dermatitis or plaque psoriasis reported each medical problem. next to this number is the percentage of the 53 participants in the pf-07038124 ointment with atopic dermatitis or plaque psoriasis who reported the medical problem.  the 3rd column tells how many of the 51 participants in the plain ointment group with atopic dermatitis or plaque psoriasis reported each medical problem. next to this number is the percentage of the 51 participants in the plain ointment group with atopic dermatitis or plaque psoriasis who reported the medical problem.  using these instructions, you can see that none of the 53 participants in the pf-07038124 group with atopic dermatitis or plaque psoriasis reported itching where the ointment was applied. a total of 2 out of the 51 (4%) participants in the plain ointment with atopic dermatitis or plaque psoriasis reported itching where the ointment was applied. covid-19: coronavirus disease 2019. "," the number of teaes (all-causality) and participants reporting teaes were higher in the vehicle group (15 [29.4%] participants with 26 events) compared to the pf-07038124 group (12 [22.6%] participants with 16 events). there were 3 (5.9%) participants in the vehicle group with 3 teaes related to coronavirus disease-19 (covid-19), and 1 (2.0%) participant had a temporary discontinuation due to covid-19. the most common all-causality teaes by system organ class (soc) in the pf-07038124 (0.01% ointment qd) group was infections and infestations (11.3%), and in vehicle group was skin and subcutaneous tissue disorders (13.7%). most cases of skin tolerability issues were mild (grade = 1), with the numbers about twice as likely to be reported in the vehicle group vs. the pf-07038124 (0.01% ointment qd) group (16 vs. 10 occurrences of mild skin tolerability issues, and 11 vs. 4 occurrences of moderate skin tolerability issues [grade = 2]). all severe skin tolerability issues (grade = 3) to study treatment application resulting in discontinuation from study treatment (in 2 participants) occurred in the vehicle group. ad:  pf-07038124 (0.01% ointment qd) met the primary efficacy endpoint in the c3941002 study for ad: pf-07038124 (0.01% ointment qd) was statistically significantly different from vehicle in percentage change from baseline in easi score at week 6.  there was statistically significant difference in key secondary endpoint: response rate for iga (clear - 0 or almost clear - 1 and a reduction from baseline of 2 points) at week 6 between pf-07038124 (0.01% ointment qd) group and vehicle group, which supported the findings of primary endpoint analysis. plaque psoriasis:  pf-07038124 (0.01% ointment qd) met the primary efficacy endpoint in the c3941002 study for plaque psoriasis: pf-07038124 (0.01% ointment qd) was statistically significantly different from vehicle in change from baseline in pasi score at week 6.  there was no statistically significant difference in key secondary endpoint: response rate for pga (clear - 0 or almost clear - 1 and a reduction from baseline of 2 points) at week 6 between pf-07038124 (0.01% ointment qd) group and vehicle group, although observed response rate was higher in pf-07038124 (0.01% ointment qd) group than vehicle group. severe aes (in 4 participants) and severe skin tolerability to study treatment application (in 2 participants) all occurred in the vehicle group.  the number of teaes (all-causality) and participants reporting teaes were higher in the vehicle group compared to the pf-07038124 group.  the most common soc for aes in pf-07038124 (0.01% ointment qd) group was infections and infestations."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by solid cancers or underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. medical problems regardless of the cause were reported for participants who took hard capsules or soft-gel capsules. during the treatment phase:  42 out of 65 (65%) participants who took talazoparib hard capsules on an empty stomach reported at least 1 medical problem  36 out of 60 (60%) participants who took talazoparib soft-gel capsule on an empty stomach reported at least 1 medical problem  15 out of 30 (50%) participants who took talazoparib soft-gel capsule with a meal reported at least 1 medical problem during the maintenance phase:  31 out of 41 (76%) participants who took talazoparib hard capsules reported at least 1 medical problem a total of 11 participants left the study because of medical problems. the most common medical problems  those reported by more than 10% of participants  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 10% of participants in any group are listed.  the 2nd column tells how many of the 65 participants taking the talazoparib hard capsule on an empty stomach reported each medical problem. next to this number is the percentage of the 65 participants taking the talazoparib hard capsule on an empty stomach who reported the medical problem.  the 3rd column tells how many of the 60 participants taking the talazoparib soft-gel capsule on an empty stomach reported each medical problem. next to this number is the percentage of the 60 participants taking the talazoparib soft-gel capsule on an empty stomach who reported the medical problem.  the 4th column tells how many of the 30 participants taking the talazoparib soft-gel capsule with a meal reported each medical problem. next to this number is the percentage of the 30 participants taking the talazoparib soft-gel capsule with a meal who reported the medical problem.  the 5th column tells how many of the 41 participants in the maintenance phase taking the talazoparib hard capsule reported each medical problem. next to this number is the percentage of the 41 participants taking the talazoparib hard capsule on an empty stomach who reported the medical problem.  using these instructions, you can see that 8 out of the 65 (12%) participants taking talazoparib hard capsules on an empty stomach reported low red blood cell count. a total of 8 out of the 60 (13%) participants taking talazoparib soft-gel capsule on an empty stomach reported low red blood cell count. a total of 5 out of the 30 (17%) participants taking talazoparib soft-gel capsule with a meal reported low red blood cell count. a total of 11 out of the 41 (27%) participants taking talazoparib hard capsules during the maintenance phase reported low red blood cell count. ","  safety results: all-causality treatment emergent adverse events (teaes) during the treatment of commercial capsule (administered under fasted conditions):  42 (42/65, 64.6%) participants had at least 1 teae (all-causality).  the most frequent (reported in 10% participants) teaes were anemia (8/65, 12.3%) and nausea (7/65, 10.8%). during the treatment of the soft gel capsule (administered under fasted conditions):  35 (35/60, 58.3%) participants had at least 1 teae (all-causality).  the most frequent (reported in 10% participants) teaes were fatigue (11/60, 18.3%) and anemia (8/60, 13.3%). during the food-effect phase:  15 (15/30, 50.0%) participants had at least 1 teae (all-causality).  no participant had maximum grade 5 teae, and 1 (1/30, 3.3%) participant discontinued study intervention due to teae. during the maintenance phase:  29 (29/41, 70.7%) participants had at least 1 teae (all-causality).  the most frequent (reported in 10% participants) teaes were anemia (9/41, 22.0%), fatigue (6/41, 14.6%), and alopecia (5/41, 12.2%). treatment-related teaes during the treatment of commercial capsule (administered under fasted conditions):  22 (22/65, 33.8%) participants had at least 1 treatment-related teae. during the treatment of the soft gel capsule (administered under fasted conditions):  26 (26/60, 43.3%) participants had at least 1 treatment-related teae.  8 (8/60, 13.3%) participants had maximum grade 3 or 4 treatment-related teaes, and 1 (1/60, 1.7%) participant discontinued study intervention due to treatment-related teae. during the food-effect phase:  11 (11/30, 36.7%) participants had at least 1 treatment-related teae. during the maintenance phase:  15 (15/41, 36.6%) participants had at least 1 treatment-related teae. during the treatment of commercial capsule (administered under fasted conditions), 4 (4/65, 6.2%) participants died, among which, 3 (3/65, 4.6%) participants died due to cause of disease under study and 1 (1/65, 1.5%) participant died due to cause of other. during the treatment of the soft gel capsule (administered under fasted conditions), 5 (5/60, 8.3%) participants died, among which, 2 (2/60, 3.3%) participants died due to cause of disease under study, 2 (2/60, 3.3%) participants died due to cause of other, and 1 (1/60, 1.7%) participant died due to cause of unknown."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study vaccine or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many vaccine groups in many studies, doctors try to understand what effects a study vaccine might have on a participant. how many participants had redness, swelling, or pain at 2 the injection site within 7 days of receiving each vaccination? the point on the arm where the vaccine was injected is called injection site. known medical problems seen within 7 days of bnt162b2 vaccination are: redness, swelling, or pain at the injection site. these are also called injection site reactions. in part 1, the percentage of participants who had any injection site reactions within 7 days of receiving either dose of bnt162b2 was slightly lower in the freeze-dried bnt162b2 group than in the frozen-liquid bnt162b2 group. 240 out of 279 participants (86%) 262 out of 280 participants (94%) who got freeze-dried bnt162b2. who got frozen-liquid bnt162b2. most of the injection site reactions were mild to moderate in intensity and went away after about 1 to 2 days. pain was the most common injection site reaction after each dose of freeze-dried or frozen-liquid bnt162b2. in part 2, the percentage of participants who had any injection site reactions within 7 days of receiving either dose of bnt162b2 was slightly higher in the frozen-liquid bnt162b2 group than in the rtu bnt162b2 group. 31 out of 35 participants (89%) 28 out of 35 participants (80%) who got frozen-liquid bnt162b2. who got rtu bnt162b2. most of the injection site reactions were mild to moderate in intensity and went away after about 1 to 2 days. pain was the most common injection site reaction after each dose of frozen-liquid or rtu bnt162b2. none of the participants who received frozen-liquid bnt162b2 had redness or swelling at the injection site. how many participants had fever, tiredness, headache, 3 chills, vomiting, diarrhea, or muscle or joint pain within 7 days of receiving each vaccination? known medical problems seen within 7 days of bnt162b2 vaccination are: fever, tiredness, headache, chills, vomiting, diarrhea, or muscle or joint pain. in part 1, the percentage of participants who had any fever, tiredness, headache, chills, vomiting, diarrhea, or muscle or joint pain within 7 days of receiving either dose of bnt162b2 was slightly lower in the freeze-dried bnt162b2 group than in the frozen-liquid bnt162b2 group. 236 out of 279 participants (85%) 263 out of 280 participants (94%) who got freeze-dried bnt162b2. who got frozen-liquid bnt162b2. most of these medical problems were mild to moderate in intensity and went away after about 1 to 2 days. tiredness and headache were the most common of these medical problems after each dose of freeze-dried or frozen-liquid bnt162b2. in part 2, the percentages of participants who had any fever, tiredness, headache, chills, vomiting, diarrhea, or muscle or joint pain within 7 days of receiving either dose of bnt162b2 were similar between the frozen-liquid and rtu bnt162b2 groups. 28 out of 35 participants (80%) 27 out of 35 participants (77%) who got frozen-liquid bnt162b2. who got rtu bnt162b2. most of these medical problems were mild to moderate in intensity and went away after about 1 to 3 days. tiredness and headache were the most common of these medical problems after each dose of frozen-liquid or rtu bnt162b2. how many participants had a medical problem during the 4 study? researchers checked how many participants had a medical problem within 1 month after the 2nd dose of bnt162b2. in part 1, the percentages of participants who had at least 1 medical problem were similar between the freeze-dried and frozen-liquid bnt162b2 groups. 16 out of 279 participants (6%) 21 out of 280 participants (8%) who got freeze-dried bnt162b2. who got frozen-liquid bnt162b2. the most common medical problems happened in 2 participants in either group: headache and back pain. the study doctors did not think these medical problems were related to bnt162b2. all other medical problems happened in 1 participant each in either group. overall, 2 participants left part 1 because of a medical problem they had during the study.  one (1) participant who received freeze-dried bnt162b2 left because of tiredness, which the study doctors thought was related to bnt162b2.  one (1) participant who received frozen-liquid bnt162b2 left because of diarrhea, which the study doctors did not think was related to bnt162b2. in part 2, the percentages of participants who had at least 1 medical problem were similar between the frozen-liquid and rtu bnt162b2 groups. 4 out of 35 participants (11%) 4 out of 35 participants (11%) who got frozen-liquid bnt162b2. who got rtu bnt162b2. all medical problems happened in 1 participant each in either group. none of the participants left part 2 because of a medical problem they had during the study. ","  safety results:  pain at the injection site was the most frequently reported local reaction in both groups after each dose and was slightly higher in the frozen-liquid mdv group compared with the lyophilized sdv group. after dose 2, 1 participant in the lyophilized sdv group and 5 participants in the frozen-liquid mdv group reported fever >38.9c to 40.0c.  the frequency of participants with any ae from dose 1 to 1 month after dose 2 was similar in the lyophilized sdv and frozen-liquid mdv groups. summary of results  part 2  frozen-liquid bnt162b2 with lnp size at the upper end of specification (lnp size) (pbs) and rtu bnt162b2 (tris/sucrose): demographic and other baseline characteristics: demographic characteristics in part 2 were similar in the frozen-liquid (lnp size) and rtu groups. exposure: in part 2, all 35 (100%) participants in each of the frozen-liquid (lnp size) and rtu groups received doses 1 and 2. immunogenicity results:  frozen-liquid bnt162b2 with lnp size at the upper end of specification and rtu bnt162b2 formulations elicited robust immune response as assessed by sars-cov-2 full-length s-binding igg levels. gmcs and gmfrs in the frozen-liquid (lnp size) group were slightly higher than those in the rtu group, although the sample size was small in this part of the study. safety results:  pain at the injection site was the most frequently reported local reaction in both groups after each dose and was slightly higher in the frozen-liquid (lnp size) group compared with the rtu group. redness and swelling were not reported in the frozen-liquid bnt162b2 (lnp size) group and infrequently reported in the rtu group (no redness reported after dose 2).  the frequency of participants with any ae from dose 1 to 1 month after dose 2 was similar in the frozen-liquid (lnp size) and rtu groups. summary of results  participants who received dose 3 of bnt162b2 (frozen-liquid mdv): demographic and other baseline characteristics: in part 3, most participants were white, non-hispanic/non-latino, with a median age of 36.0 years exposure: there were 114 participants who received 2 doses of lyophilized bnt162b2 30 g and received dose 3 of bnt162b2 (frozen-liquid mdv). the gmc at 1 month after dose 3 was approximately 3-fold of those observed at 1 month after dose 2, and the gmfr from before dose 3 to 1 month after dose 3 was 16.0. safety results:  pain at the injection site was the most frequently reported local reaction after dose 3 of frozen-liquid mdv bnt162b2. conclusions: immune responses were observed after administration of 2 doses of the lyophilized sdv, frozen-liquid mdv, or rtu formulations of bnt162b2 30 g, although the lyophilized formulation did not meet noninferiority criterion compared with the frozen-liquid mdv formulation. participants who received 2 doses of the lyophilized formulation and received dose 3 of the frozen-liquid mdv had a boosted response based on gmcs and gmfrs."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. in part a, there were no medical problems reported by participants. in part b, 18 out of 19 (95%) participants had at least 1 medical problem. a total of 2 (11%) participants left the study because of medical problems (due to testing positive for covid-19). the most common medical problems  those reported by more than 30% of participants overall  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during part b of the study. all medical problems reported by more than 30% of participants are listed.  the 2nd column tells how many of the 19 participants taking 300 mg ervogastat reported each medical problem. next to this number is the percentage of the 19 participants taking 300 mg ervogastat who reported the medical problem.  the 3rd column tells how many of the 19 participants taking danuglipron titrated up to 200 mg twice a day reported each medical problem. next to this number is the percentage of the 19 participants taking danuglipron titrated up to 200 mg twice a day who reported the medical problem.  the 4th column tells how many of the 16 participants taking 300 mg ervogastat with up to 200 mg danuglipron twice a day reported each medical problem. next to this number is the percentage of the 16 participants taking 300 mg ervogastat with up to 200 mg danuglipron twice a day who reported the medical problem.  the 5th column tells how many of the 16 participants taking 300 mg ervogastat twice a day with up to 200 mg danuglipron twice a day reported each medical problem. next to this number is the percentage of the 16 participants taking 300 mg ervogastat twice a day with up to 200 mg danuglipron twice a day who reported the medical problem.  using these instructions, you can see that 12 out of 19 participants (63%) taking danuglipron titrated up to 200 mg twice a day reported a feeling of sickness compared with 6 out of 16 participants (38%) taking 300 mg ervogastat twice a day and up to 200 mg danuglipron twice a day, 1 out of 19 participants (5%) taking ervogastat 300 mg, and 1 out of the 16 participants (6%) taking 300 mg ervogastat twice a day and up to 200 mg danuglipron twice a day.  ","  most frequently occurred (reported by over 50% of the participants) all-causality aes were nausea, vomiting, and decreased appetite, all of which were considered treatment-related.  most teaes reported were mild in severity, except 1 moderate ae of nausea was reported by 1 participant during treatment of pf-06882961 titration up to 200 mg bid.  a total of 2 participants had dose reductions during the study: o one participant had a pf-06882961 dose reduction from 180 mg bid to 160 mg bid from day 42 through the end of study treatment due to aes of constipation (mild) and nausea (mild), both were treatment-related. o one participant had a pf-06882961 dose reduction from 200 mg bid to 180 mg bid at the second dose on day 59 and further reduced from 180 mg bid to 160 mg bid from day 60 through the end of study treatment due to aes of nausea (moderate), vomiting (mild) and dizziness (mild), all were treatment-related.  a total of 2 participants discontinued from study due to the same reason: ae of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) test positive, both occurred during pf-06882961 titration up to 200 mg bid. hypoglycemic adverse events: one (5.3%) participant reported symptomatic hypoglycemia during titration of pf-06882961 up to 200 mg bid. in part b, laboratory test abnormalities were reported in 16 (84.2%) and 15 (93.8%) participants during treatment of pf-06882961 titration up to 200 mg bid, and pf-06865571 300 mg bid + pf-06882961 200 mg bid, respectively.  the mean (standard deviation [sd]) body weight change from baseline was -5.39 (2.599) kg at period 2 day 41 (study day 43), with pf-06882961 titrated to 200 mg bid, with the mean (sd) percent change of -6.05% (2.999). in part b, 1 (6.3%) participant had pr interval value 300 msec during treatment of pf-06865571 300 mg bid + pf-06882961 200 mg bid. max part b:  there was no clinically relevant change in pf-06882961 exposure after multiple doses of pf-06882961 was co-administered with multiple doses of pf-06865571 compared to that observed when pf-06882961 was administered alone with a 19% increase in auc12 (118.64% [94.05%, 149.66%]) and a 15% increase in c (115.30% [85.37%, max 155.73%]).  pf-06865571 exposure was lower after a single dose of pf-06865571 was co-administered with multiple doses of pf-06882961 compared to that observed when pf-06865571 was administered alone with a 27% decrease in auc (73.20% [66.82%, inf 80.18%]), a 26% decrease in auc (73.91% [67.95%, 80.40%]), and a 61% decrease in last c (38.73% [32.80%, 45.74%])."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by the study drug or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. during period 1, 4 out of the 6 (67%) participants in this study had at least 1 medical problem. no medical problems occurred during period 2. no participants left the study because of medical problems. the medical problems reported by the participants are described below. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were reported during the study. all medical problems reported by the participants are listed.  the 2nd column tells how many of the participants taking the study medication reported each medical problem in period 1. next to this number is the percentage of the participants taking the study medication who reported the medical problem.  the 3rd column tells how many of the participants reported each medical problem in period 2.  using these instructions, you can see that 2 out of the 6 (33%) participants taking the study medication reported diarrhea in period 1. a total of 0 out of the 6 (0%) participants in period 2 reported diarrhea. ","  safety results: in period 1, 4 (66.7%) participants experienced 9 all-causality treatment-emergent adverse events (teaes). two treatment-related teaes of pruritus and flushing were reported by 1 participant in period 1. all teaes resolved by the end of the study. pharmacokinetic results: mass balance in period 1, following a single oral dose of pf-06865571 300 mg (containing 300 nci [14c]pf-06865571), the mean  standard deviation (sd) total recovery of the period 1 orally administered radioactive dose over a period of up to 264 hours post-dose was 79.0  16.7%, with 48.9  16.3% in the urine and 30.1  2.9% in the feces. metabolic profiling and identification after oral dosing of [14c]pf-06865571 in period 1, the major drug-related components detected in circulation were [14c]pf-06865571, m2, and m6 (representing 43.8%, 36.6%, and 11.3 % of circulating radioactivity, respectively). the major drug-related components detected in urine were m2 and coeluting m6, m7, and 584 (representing 24.9% and collectively 11.4% of administered dose, respectively). following administration of a single oral dose of pf-06865571 300 mg, f was 75.06% (90% ci: 71.06%, 79.29%), as measured by the ratio (oral [po]/iv) of adjusted geometric mean dose normalized (to 1 mg equivalent) auc (auc [dn]) values. based on the geometric mean ratio (po/iv) of dose-normalized total 14c_urine values for 6 participants in po and iv treatment with complete urine data, f was 92.78% (90% ci: a 62.07%, 138.68%). taste assessment results: across the 6 participants dosed in this study, none of the mean assessment scores of taste for all 6 domains were above 50 after 5 minutes post-dose, suggesting that none of the characteristics assessed reported a strong intensity (ie, above 75). conclusions: mass balance  following a single oral [14c]pf-06865571 dose to healthy male participants, recovery of radioactivity was incomplete, but within the range observed in similar studies, with approximately 79% of dose recovered (~30% in feces; ~49% in urine). two major metabolites (>10% of radioactivity in circulation) were identified, representing 36.6% (m2) and 11.3% (m6) of radioactivity in plasma.  the plasma pf-06865571 exposures were comparable after 300 mg oral dose in period 1 and period 2. safety and taste assessment  pf-06865571 was generally safe and well-tolerated following either oral or simultaneous oral/iv administration.  administration of a single, oral dose of pf-06865571 did not result in reporting of strong taste across the 6 domains of taste tested."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an unknown underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. in part a, 6 out of the 18 (33%) participants had at least 1 medical problem after taking abrocitinib tablets, 8 out of the 18 (44%) participants had at least 1 medical problem after taking abrocitinib liquid, and 6 out of out of the 18 (33%) participants had at least 1 medical problem after taking abrocitinib after famotidine tablets. in part b, 5 out of the 9 (56%) participants had at least 1 medical problem after taking the 6 abrocitinib liquids and 2 out of the 10 (20%) participants had at least 1 medical problem after taking abrocitinib after famotidine tablets. note: information on medical problems experienced by participants was not available for all the participants who were treated in part b. no participants left the study because of medical problems. the most common medical problems  those reported by more than 1 participant in any group  are described in table 1 for part a and in table 2 for part b. below are instructions on how to read table 1, which shows the medical problems reported in part a. these instructions can also be used to help explain table 2, which shows the medical problems in part b. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 1 participant in any group are listed.  the 2nd column tells how many of the 18 participants taking abrocitinib tablets reported each medical problem. next to this number is the percentage of the 18 participants taking abrocitinib tablets who reported the medical problem.  the 3rd column tells how many of the 18 participants taking abrocitinib liquid (liquid 1) reported each medical problem. next to this number is the percentage of the 18 participants taking abrocitinib liquid (liquid 1) who reported the medical problem.  the 4th column tells how many of the 18 participants taking abrocitinib tablets after famotidine tablets reported each medical problem. next to this number is the percentage of the 18 participants taking abrocitinib tablets after famotidine tablets who reported the medical problem.  using these instructions, you can see that 3 out of the 18 (17%) participants taking abrocitinib tablets and 5 out of the 18 (28%) participants taking abrocitinib liquid (liquid 1) reported nausea. a total of 0 out of the 18 (0%) participants taking abrocitinib tablets after famotidine tablets reported nausea.  ","  safety results: brief summary of aes: in part a, 11 all-causality teaes were reported in 6 (33.3%) participants who received abrocitinib 200 mg commercial tablets; 5 teaes reported in 3 (16.7%) participants were considered treatment-related. a total of 14 all-causality teaes were reported in 8 (44.4%) participants who received abrocitinib 200 mg oral suspension formulation 1; 7 teaes reported in 5 (27.8%) participants were considered treatment-related. a total of 3 all-causality teaes were reported in 2 (20%) participants who received famotidine 40 mg + abrocitinib 200 mg oral suspension formulations (1-6), none of teaes were considered treatment-related. no saes, severe aes, study discontinuations due to aes, dose reductions nor temporary discontinuations were reported during the study. nausea aes in total, of all 45 evaluable participants administrated with abrocitinib alone, 12 (26.7%) participants reported nausea, comparing to 0 out of 28 participants administrated with abrocitinib + famotidine. conclusions:  for abrocitinib 200 mg given as suspension (test) versus tablet (reference), the ratios of adjusted geometric means (90% ci) were 96.96% (85.43%, 110.03%) for aucinf and 100.07% (80.28%, 124.74%) for c with the 90% cis for both auc and c max inf max ratios contained within the bioequivalence limits of (80%, 125%).  co-administration of a single 40 mg dose of famotidine decreased abrocitinib aucinf and c by approximately 37% and 84%, respectively, relative to a single 200 mg max abrocitinib dose given alone. the auc and c of the metabolites pf-06471658 inf max (m1), pf-07055087 (m2), and pf-07054874 (m4) decreased between 13%-29% and 74%-78%, respectively, when abrocitinib was co-administration with famotidine compared to when abrocitinib was given alone.  the auc and c of the active moiety decreased following co-administration of inf,u max,u abrocitinib with famotidine by approximately 20% and 82%, respectively, relative to when abrocitinib was given alone.  increasing sucralose concentration to 3 mg/ml in formulation 4 did not appear to flavor to sucralose (formulation 1) showed similar preference from study participants compared to formulation 3 without strawberry flavor.  single doses of abrocitinib 200 mg, administrated with or without ara (famotidine), was generally safe and well-tolerated in healthy adult participants in this study. there were no deaths or saes in this study, and all teaes were mild in severity, except for one teae which was moderate in severity.  no clinically significant findings in vital signs, ecg or physical examinations were observed."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. for treatment a (bosutinib mixed with applesauce), 11 out of 16 (69%) participants had at least 1 medical problem. for treatment b (bosutinib mixed with yogurt), 14 out of 17 (82%) participants had at least 1 medical problem. for treatment c (bosutinib swallowed intact), 15 out of 18 (83%) participants had at least 1 medical problem. no participants left the study because of a medical problem. the table below shows the most common medical problems that happened during the study (at least 3 participants in any treatment group). below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. medical problems reported by at least 3 participants in any treatment group are listed.  the 2nd column tells how many of the 16 participants reported each medical problem with treatment a. next to this number is the percentage of the 16 participants who reported each medical problem with treatment a.  the 3rd column tells how many of the 17 participants reported each medical problem with treatment b. next to this number is the percentage of the 17 participants who reported each medical problem with treatment b.  the 4th column tells how many of the 18 participants reported each medical problem with treatment c. next to this number is the percentage of the 18 participants who reported each medical problem with treatment c.  using these instructions, you can see that 7 out of 16 (44%) participants reported diarrhea with treatment a, 11 out of 17 (65%) participants reported diarrhea with treatment b, and 10 out of 18 (56%) participants reported diarrhea with treatment c.  ","  safety results: the number of treatment-emergent adverse events (teaes) were comparable between the 3 treatments, the majority were considered as treatment-related. eleven participants (out of 16) experienced teaes (24 total) when dosed with bosutinib 500 mg capsule contents mixed with applesauce; 20 teaes reported by 9 participants were determined to be treatment-related by the investigator. fourteen participants (out of 17) experienced teaes (38 total) when dosed with bosutinib 500 mg capsule contents mixed with yogurt; 27 teaes reported by 12 participants were determined to be treatment-related by the investigator. fifteen participants (out of 18) experienced teaes (39 total) when dosed with bosutinib 500 mg intact capsule; 35 teaes reported by 15 participants were determined to be treatment-related by the investigator. the most frequently reported (3 participants) all-causality teaes in participants receiving bosutinib 500 mg capsule contents mixed with applesauce were diarrhoea, abdominal discomfort, and fatigue. the most frequently reported (3 participants) all-causality teaes in participants receiving bosutinib 500 mg capsule contents mixed with yogurt were diarrhoea, nausea, abdominal discomfort, and fatigue. the most frequently reported (3 participants) all-causality teaes in participants receiving bosutinib 500 mg intact capsule were diarrhoea, nausea, abdominal discomfort, abdominal pain. the most frequently reported (3 participants) treatment-related teaes across the 3 treatments were similar to the all-causality teaes described above. no clinically meaningful trends were observed with the treatment of bosutinib 500 mg intact capsule or bosutinib 500 mg capsule contents mixed with applesauce or yogurt in laboratory data. no clinically meaningful findings in vital signs measurements, ecgs or other observations related to safety were observed in this study. pharmacokinetic results: following administration of single oral doses of 500 mg bosutinib to healthy adult participants under fed condition, median bosutinib plasma concentration-time profiles were nearly identical between the reference intact capsule formulation and the test formulations of capsule contents mixed with applesauce or yogurt. mean elimination t were nearly identical (approximately  36 hours) regardless of whether opened capsule contents were mixed with soft foods (applesauce or yogurt) or administered intact. variability in bosutinib plasma exposure based on geometric %cv were similar between all treatments and ranged from 27% to 33% for c and 23% to 32% for auc . conclusions: pk: bosutinib 500 mg capsule contents mixed with applesauce or yogurt (test treatments) exhibit comparable pharmacokinetics to the 500 mg bosutinib intact capsule under fed condition in healthy adult participants. safety: bosutinib was generally well tolerated in healthy participants in all treatments, and all teaes were mild or moderate in severity. taste assessment: the sensory attributes (overall liking, mouth feel, bitterness and tongue/mouth burn) for bosutinib mixed with applesauce and bosutinib mixed with yogurt, were considered good/like (mean vas score <60) for each sensory attribute at each of the 4 time points."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. the researchers reviewed the medical problems in 2224 participants who got at least 1 dose of nirmatrelvir/ritonavir or placebo. overall, 526 out of 2224 (24%) participants had at least 1 medical problem by day 34 of the study. this included 256 participants who took nirmatrelvir/ritonavir and 270participants who took placebo. table 1 shows the most common medical problems  those reported by 2% or more of participants in either treatment group. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by more than 2% of participants are listed.  the 2nd column tells how many of the 1109 participants taking nirmatrelvir/ritonavir reported each medical problem. next to this number is the percentage of the 1109 participants taking nirmatrelvir/ritonavir who reported the medical problem.  the 3rd column tells how many of the 1115 participants taking a placebo reported each medical problem. next to this number is the percentage of the 1115 participants taking a placebo who reported the medical problem.  using these instructions, you can see that 62 out of the 1109 (6%) participants taking nirmatrelvir/ritonavir had a change in their sense of taste. a total of 3 out of the 1115 (less than 1%) participants taking a placebo had a change in their sense of taste.  ","  safety results:  the proportion of participants with all-causality treatment-emergent adverse events (teaes) that started on or prior to the day 34 visit was comparable between the nirmatrelvir/ritonavir (23.1%) and placebo (24.2%) groups.  most of the all-causality teaes experienced by participants in both treatment groups were mild (grade 1) to moderate (grade 2) in severity.  of the most frequently reported teaes in the nirmatrelvir/ritonavir group (1%), dysgeusia (5.6%), diarrhoea (3.1%), headache (1.4%), and vomiting (1.1%) were reported at a higher frequency than in the placebo group (0.3%, 1.6%, 1.3%, and 0.8%, respectively). in the nirmatrelvir/ritonavir group, dysgeusia, diarrhoea, headache, and vomiting led to few discontinuations from study intervention: 2 participants, 1 participant, 1 participant, and 4 participants, respectively.  the overall incidence of participants with all-causality treatment-emergent serious adverse events (saes) that started on or prior to the day 34 visit was lower in the nirmatrelvir/ritonavir treatment group (1.7%) compared with placebo (6.6%). the most frequently reported saes in the nirmatrelvir/ritonavir group (2 participants) were covid-19 pneumonia, covid-19, and creatinine renal clearance decreased and were reported more frequently in the placebo group than in the nirmatrelvir/ritonavir group.  fewer participants in the nirmatrelvir/ritonavir group compared to the placebo group discontinued study intervention due to an ae (2.1% and 4.2%, respectively) or discontinued the study due to an ae (0% and 1.2% [all due to death], respectively). all-causality teaes that led to discontinuation of study intervention in more than 1 participant in either treatment group were covid-19 pneumonia, nausea, creatinine renal clearance decreased, vomiting, covid-19, glomerular filtration rate decreased, pneumonia, pneumonitis, white blood cell count decreased, and dysgeusia.  no participants in the nirmatrelvir/ritonavir group experienced an ae resulting in death (grade 5) through day 34, compared to 13 (1.2%) in the placebo group, all of which were related to the disease under study. conclusions:  based on the sequential design and prespecified interim analysis specifications, the primary analysis result was statistically significant (p<0.0001) and the primary objective of the study was met and confirmed in the final analysis.  in participants who were treated within 5 days of symptom onset and no mab treatment, nirmatrelvir/ritonavir also significantly reduced the proportion of participants with covid-19-related hospitalization or death from any cause through day 28 by 86.3% (0.878% vs 6.400%, p<0.0001) compared to placebo.  treatment with nirmatrelvir/ritonavir significantly shortened the median time to sustained alleviation of all targeted covid-related signs and symptoms from 15 days to 12 days, and shortened the median time to sustained resolution of these symptoms from 18 days to 16 days."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. in group 1, 11 out of 34 (32%) participants who took treatment a, 5 out of 33 (15%) participants who took treatment b and 6 out of 33 (18%) participants who took treatment c, had at least 1 medical problem. one (1) participant from group 1 left the study due to their death in a road traffic accident. in group 2, 17 out of 33 (52%) participants who took treatment d and 18 out of 34 (53%) participants who took treatment e, had at least 1 medical problem. no participants from group 2 left the study because of medical problems. the most common medical problems  those reported by more than 5% of participants in each group  are described below. below are instructions on how to read tables 1 and 2. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported in group 1 during the study. all medical problems reported by more than 5% of participants are listed.  the 2nd column tells how many of the 34 participants taking treatment a reported each medical problem. next to this number is the percentage of the 34 participants taking treatment a who reported the medical problem.  the 3rd column tells how many of the 33 participants taking treatment b reported each medical problem. next to this number is the percentage of the 33 participants taking treatment b who reported the medical problem.  the 4th column tells how many of the 33 participants taking treatment c reported each medical problem. next to this number is the percentage of the 33 participants taking treatment c who reported the medical problem.  using these instructions, you can see that 2 out of the 34 participants (6%) taking treatment a, 1 out of 33 participants (3%) taking treatment b, and 1 out of 33 participants (3%) reported feeling like about to vomit. instructions for understanding table 2  the 1st column of table 2 lists medical problems that were commonly reported in group 2 during the study. all medical problems reported by more than 5% of participants are listed.  the 2nd column tells how many of the 33 participants taking treatment d reported each medical problem. next to this number is the percentage of the 33 participants taking treatment d who reported the medical problem.  the 3rd column tells how many of the 34 participants taking treatment e reported each medical problem. next to this number is the percentage of the 34 participants taking treatment e who reported the medical problem.  using these instructions, you can see that 1 out of the 33 participants (3%) taking treatment d and 4 out of 34 participants (12%) reported heartbeats faster than 100 beats per minute.   ","  safety results: safety cohort 1: prazosin hcl 1  2 mg (barceloneta) vs. prazosin hcl 1  2 mg and 2  1 mg capsules (ascoli) one death occurred in 1 participant assigned to sequence 1. the event was not related to study treatment. among 34 participants who received prazosin hcl 1  2 mg (barceloneta), a total of 13 all-causality teaes were reported in 11 participants (32.4%), and 9 of the teaes were treatment-related. among 33 participants who received prazosin hcl 1  2 mg (ascoli), a total of 6 all-causality teaes were reported in 5 participants (15.2%), and 4 of the teaes were treatment-related and reported as mild. among 33 participants who received prazosin hcl 2  1 mg (ascoli), a total of 6 all-causality teaes were reported in 6 participants (18.2%), and 5 of the teaes were treatment-related and reported as mild. among 34, 33 and 33 participants who received prazosin hcl 1  2 mg (barceloneta), prazosin hcl 1  2 mg (ascoli), and prazosin hcl 2  1 mg (ascoli), the most frequently reported preferred terms (pts) of teaes were orthostatic hypotension, headache, and orthostatic hypotension and headache, respectively. among 33 participants who received prazosin hcl 1  5 mg (barceloneta), a total of 31 all-causality teaes were reported in 17 participants (51.5%), and 29 of the teaes were treatment-related. among 34 participants who received prazosin hcl 1  5 mg (ascoli), a total of 34 all-causality teaes were reported in 18 participants (52.9%), and 32 of the teaes were treatment-related. among 33 and 34 participants who received prazosin hcl 1  5 mg (barceloneta) and prazosin hcl 1  5 mg (ascoli), the most frequently reported pt of teaes was dizziness and nausea, respectively. similarly, for prazosin hcl 2  1 mg manufactured at ascoli (test) vs. prazosin hcl 1  2 mg manufactured at barceloneta (reference), the test/reference ratios of adjusted geometric means (90% ci) of auc and auc , were 102.08% (95.97%, 108.57%) and 104.87%, inf last (98.68%, 111.44%), respectively. between-participant variability in area under the curve (auc) values were similar between the three treatments in cohort 1, with geometric mean percent coefficient of variation (%cv) values ranging from 31-34%. pk cohort 2: prazosin hcl 15 mg (barceloneta) vs. prazosin hcl 15 mg capsules (ascoli) following administration of single oral dose of prazosin hcl 1  5 mg capsule (barceloneta) and 1  5 mg capsule (ascoli), median t was 2.50 hours and 2.00 hours, respectively."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an unknown underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. in this study, 3 out of 8 (38%) healthy participants with normal liver function and 4 out of 8 (50%) participants with moderate abnormal liver function had at least 1 medical problem. no participants left the study because of medical problems. medical problems reported by 1 or more participant are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were reported during the study. all medical problems reported by 1 or more participant are listed.  the 2nd column tells how many of the 8 healthy participants with normal liver function taking the study medication reported each medical problem. next to this number is the percentage of the 8 healthy participants with normal liver function taking the study medication who reported the medical problem.  the 3rd column tells how many of the 8 participants with moderate abnormal liver function taking the study medication reported each medical problem. next to this number is the percentage of the 8 participants with moderate abnormal liver function taking the study medication who reported the medical problem.  using these instructions, you can see that 0 out of the 8 (0%) healthy participants with normal liver function taking the study medication reported bad taste in mouth. a total of 2 out of the 8 (25%) participants with moderate abnormal liver function taking the study medication reported bad taste in mouth.  ","  safety results: in the normal hepatic function group, 3 aes were reported by 3 participants, including 1 injection site pruritus, 1 dizziness, and 1 ecchymosis. none of the events were considered related to pf-07321332 or ritonavir. in the moderate hepatic impairment group, 8 aes were reported by 4 participants, among which 3 aes (2 dysgeusia and 1 somnolence, all mild in severity) were considered treatment related. other aes included 1 nausea, 1 urinary tract infection, 1 back pain, 1 chromaturia, and 1 dermatitis contact. no deaths, saes, severe aes, discontinuations or dose reductions due to aes were reported during this study. none of the laboratory abnormalities, vital sign parameters, or ecg changes were considered clinically significant. conclusions:  pf-07321332 systemic exposure based on geometric mean auc and c values was inf max comparable between the moderate hepatic impairment group and the normal hepatic function group. pf-07321332 adjusted geometric mean ratios (90% cis) of auc and inf c comparing moderate hepatic impairment (test) to normal hepatic function max (reference) were 98.78% (70.65%, 138.12%) and 101.96% (74.20%, 140.11%), respectively.  pf-07321332/ritonavir has an acceptable safety and tolerability profile in adult participants with normal hepatic function as well as those with moderate hepatic or ecg parameters were observed in the study after single dose of pf-07321332, pharmacokinetically enhanced by ritonavir."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. four (4) out of 12 participants (33%) in this study had at least 1 medical problem. none of the participants left the study because of medical problems. the medical problems reported by 1 or more participants are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 1 or more participants are listed.  the 2ndto 4th column tells how many of the 12 participants taking treatment a, treatment b, and treatment c, respectively, reported each medical problem. next to this number is the percentage of the 12 participants taking the study medication who reported the medical problem.  using these instructions, you can see that 2 out of the 12 participants (17%) taking study treatment a reported pain at the site where a needle or catheter is inserted into a vein.  ","  safety results: none of the teaes were treatment-related. no participant had an sae, severe ae, dose reduction, permanent or temporary discontinuation due to aes. none of the lab abnormalities were considered by the principal investigator as aes. no clinically meaningful findings in the vital signs measurements, electrocardiograms (ecgs), physical examination assessments, or other observations related to safety were observed in this study. pharmacokinetic results: the time to reach maximum plasma concentrations following single oral doses of ritlecitinib hours for the 30 mg intact adult capsules, 3  10 mg pediatric capsules, and the 30 mg spray congealed beads, respectively. for 3  10 mg pediatric capsules formulation of ritlecitinib relative to 30 mg intact adult capsules, the test/reference ratios (90% confidence interval [ci]) of adjusted geometric means of auc and c values were 102.50% (94.21%, 111.51%) and 101.12% (88.25%, inf max 115.87%), respectively. similarly, the 30 mg spray congealed beads formulation of ritlecitinib relative to 30 mg intact adult capsules the test/reference ratios (90% ci) of adjusted geometric means of auc and c were 106.65% (100.07%, 113.66%) and inf max 90.11% (78.49%, 103.44%), respectively. taste assessment: responses to the taste assessment questionnaire that document overall liking, mouth feel, bitterness, sourness, saltiness and tongue/mouth burn of sensory attributes were collected. conclusions: pk:  in comparison to adult capsule formulation of ritlecitinib, both 3  10 mg pediatric capsules formulation and 30 mg spray congealed beads formulation had similar exposures based on geometric mean auc , auc and c values. for 3  10 mg inf last max pediatric capsules formulation of ritlecitinib, relative to 30 mg intact adult capsules, the test/reference ratios (90% ci) of adjusted geometric means of auc and c values inf max were 102.50% (94.21%, 111.51%) and 101.12% (88.25%, 115.87%), respectively. similarly, for 30 mg spray congealed beads formulation of ritlecitinib relative to 30 mg intact adult capsules, the test/reference ratios (90% ci) of adjusted geometric means of auc and c were 106.65% (100.07%, 113.66%) and 90.11% (78.49%, 103.44%), inf max respectively.  the t , t , cl/f, and v /f values were similar following single doses of 30 mg intact max  z adult capsules, 3  10 mg pediatric capsules, and 30 mg spray congealed beads. safety:  the 10 mg capsules, 30 mg capsules and spray congealed beads at the 30 mg dose of ritlecitinib were safe and well tolerated in healthy adult participants. taste assessment:  the taste of ritlecitinib 30 mg spray congealed beads was acceptable in healthy adult"
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. three out of 10 (30%) participants in this study had at least 1 medical problem. none of these medical problems were considered by the study doctor to be caused by the study medication. no participants left the study because of medical problems. all the medical problems are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were reported during the study. all medical problems reported are listed.  the 2nd column tells how many of the 10 participants reported each medical problem after taking the single dose of oc. below this number is the percentage of the 10 participants taking the oc who reported the medical problem.  the 3rd column tells how many of the 10 participants reported each medical problem after taking multiple doses of zimlovisertib. below this number is the percentage of the 10 participants taking multiple doses of zimlovisertib who reported the medical problem.  the 4th column tells how many of the 10 participants reported each medical problem after taking the oc and zimlovisertib together on the same day. below this number is the percentage of the 10 participants taking the oc and zimlovisertib together who reported the medical problem.  using these instructions, you can see that 2 out of the 10 (20%) participants taking multiple doses of zimlovisertib reported itchy skin. none of the participants taking the single dose of oc reported itchy skin, and no participants taking the oc and zimlovisertib on the same day reported itchy skin. ","  safety results: a total of 4 all-causality aes were reported in 2 participants following multiple doses of zimlovisertib 400 mg qd, and 1 all-causality ae was reported in 1 participant following multiple doses of zimlovisertib 400 mg qd co-administered with a single dose oc. no aes were reported following the administration of a single dose oc. no saes, severe aes, discontinuations or dose reductions due to aes were reported in this study. following the administration of multiple doses of zimlovisertib 400 mg qd, a mild nausea and a mild headache was reported in 1 participant each, a mild pruritus was reported in 2 participants. following the administration of multiple doses of zimlovisertib 400 mg qd co-administered with a single dose oc, a mild toothache was reported in 1 participant. following the administration of multiple doses of zimlovisertib 400 mg qd co-administered with a single dose oc, urine hemoglobin positive was reported in 5 participants and leukocyte esterase positive was reported in 2 participants in the urinalysis. no participants with laboratory abnormalities that met the pre-defined criteria for hematology and clinical chemistry analyses. no laboratory abnormalities were considered clinically significant or reported as aes by the investigator or the sponsor. plasma ee pharmacokinetics the median plasma concentration-time profiles of ee were similar when a single dose oc was administered alone or co-administered with zimlovisertib 400 mg qd. the ratio of the adjusted geometric mean (90% ci) auc , auc and c of ee following administration of oc with inf last max zimlovisertib relative to oc administered alone were 99.76% (88.15%, 112.90%), 101.43% (93.01%, 110.61%), and 95.07% (84.44%, 107.04%), respectively. plasma ln pharmacokinetics following single oral administration of oc the median plasma ln concentration-time profile was similar when compared to oc co-administered with zimlovisertib. the terminal phase was not well characterized (auc % >20) for all participants and therefore auc , cl/f and t were not reported. the ratio of the adjusted geometric mean (90% ci) auc and c of ln following last max administration of oc with zimlovisertib relative to oc administered alone were 108.51% (98.85%, 119.11%) and 117.99% (101.82%, 136.73%). conclusions: pk  zimlovisertib did not appear to have a notable impact on the plasma exposure of either ee or ln.  the adjusted geometric mean ratio (%) of test/reference for auc , auc and c last inf max values of ee following co-administration with multiple doses of zimlovisertib were 101.43%, 99.76% and 95.07%, respectively.  the adjusted geometric mean ratio (%) of test/reference for auc and c values of last max ln following co-administration with multiple doses of zimlovisertib were 108.51% and 117.99%, respectively."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an unknown underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. seven out of 26 (27%) participants in this study had at least 1 medical problem. none of the participants left the study because of medical problems. the most common medical problems  those reported by at least 2 out of 26 participants (8%)  are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by at least 2 participants (8%) are listed.  the 2nd column tells how many of the 26 participants taking caffeine, efavirenz, and omeprazole reported each medical problem. next to this number is the percentage of the 26 participants taking caffeine, efavirenz, and omeprazole who reported the medical problem.  the 3rd column tells how many of the 26 participants taking caffeine, efavirenz, and omeprazole after abrocitinib reported each medical problem. next to this number is the percentage of the 26 participants taking caffeine, efavirenz, and omeprazole after abrocitinib who reported the medical problem.  using these instructions, you can see that 0 out of 26 (0%) participants taking caffeine, efavirenz, and omeprazole reported increased blood pressure. a total of 2 out of 26 (8%) participants taking caffeine, efavirenz, and omeprazole after abrocitinib reported increased blood pressure. ","  safety results: seven participants experienced 11 all-causality treatment-emergent adverse events (teaes), out of which 5 were treatment-related. the most frequently reported all-causality teaes by preferred term (pt) were tremor and blood pressure increased (reported by 2 [7.7%] participants each) on treatment of caffeine 100 mg + efavirenz 50 mg + omeprazole 10 mg (days 1 - 3 of period 1) and abrocitinib 200 mg qd + caffeine 100 mg + efavirenz 50 mg + omeprazole 10 mg (days 8  11 of period 2), respectively. the most frequently reported treatment-related teae by pt was tremor on treatment of caffeine 100 mg + efavirenz 50 mg + omeprazole 10 mg (days 1 - 3 of period 1). max tmax (hr) 1.00 (0.50 - 2.00) 0.92 (0.42 - 2.92)  efavirenz: efavirenz pk parameters are summarized descriptively in table s5. efavirenz inf exposure as assessed by auc cr and c cr were similar when co-administered with last max multiple doses of abrocitinib compared to when efavirenz was dosed alone (table s6). conclusions: safety:  abrocitinib, when co-administered with caffeine, efavirenz, and omeprazole, was generally safe and well-tolerated in healthy adult participants. pharmacokinetics:  caffeine exposure as assessed by auc was higher when co-administered with multiple doses of abrocitinib compared to when caffeine was dosed alone, whereas c was similar between both treatments. the ratios of the adjusted geometric means max (90% ci) auc cr, auc cr, and c cr of caffeine were 139.59% (121.98%, inf last max 159.74%), 132.64% (119.25%, 147.53%), and 101.22% (92.21%, 111.12%), respectively, when caffeine was co-administered with multiple doses of abrocitinib (test) as compared to administered alone (reference). the ratios of the adjusted geometric means (90% ci) auc cr and last c cr of efavirenz were 110.10% (103.45%, 117.17%) and 97.26% (83.25%, max 113.62%), respectively, when efavirenz was co-administered with multiple doses of abrocitinib (test) as compared to administered alone (reference), indicating that abrocitinib is not an inducer of cyp2b6.  omeprazole exposure as assessed by both auc and c increased when max co-administrated with multiple doses of abrocitinib compared to when omeprazole was dosed alone. the ratios of the adjusted geometric means (90% ci) auc , inf auc , and c of omeprazole were 288.81% (240.56%, 346.73%), 291.31% last max (241.95%, 350.75%), and 234.16% (170.19%, 322.17%), respectively, when omeprazole was co-administered with multiple doses of abrocitinib (test) as compared to administered alone (reference)."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. five out of 16 (31%) participants in this study had at least 1 medical problem. none of the participants left the study because of medical problems. the most common medical problems  those reported by one or more participants are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists medical problems that were commonly reported during the study. all medical problems reported by 1 or more participants are listed.  the 2nd to 3rd column tells how many of the 16 participants taking the study medication treatment sequence 1 and treatment sequence 2 reported each medical problem. next to this number is the percentage of the 16 participants taking the study medication who reported the medical problem.  using these instructions, for example you can see that 1 out of the 8 (13%) participants taking the treatment sequence 1 of study medication reported swelling of the abdomen. ","  safety results: a total of 6 adverse events (aes) were reported; 4 aes for 3 participants in the ritlecitinib 50 mg group and 2 aes for 2 participants in the ritlecitinib 200 mg group. no serious adverse events (saes), severe aes, discontinuations from study or treatment due to aes, dose reductions or temporary discontinuations due to aes were reported in this study. ae preferred term each was reported in 1 participant (table s3). pharmacokinetic results: the following plasma ritlecitinib pk parameters (table s4) were calculated for each participant and treatment, as applicable, using noncompartmental analysis of plasma concentration-time data. lower levels of jak3 to at 1 h post dose for the ritlecitinib 200 mg dose compared to 50 mg were observed and the mechanism for this lower jak3 to could be either assay technical issues or biological, however a clear rationale has not been identified. the maximal jak3 to for the 200 mg ritlecitinib group was observed at 2 h post dose, and there was a dose-dependent increase in the duration of jak3 to by ritlecitinib. there was notably minimal jak3 to observed after 2 h post dose for the ritlecitinib 50 mg dose group, compared to sustained moderate jak3 to (30-50%) observed through 48 h post dose at the 200 mg dose. for the 5 tec kinases there was a dose-dependent increase in to by ritlecitinib for the magnitude of occupancy, and the maximal median to for the 50 mg dose >94% was observed in all tec kinases except bmx (to of 87% observed in the 50 mg group). there were similar dose-dependent effects on the duration of to for the tec kinases, although biological variability in the duration of to was observed due to differences in individual tec family member target turnover. bmx, btk and tec had notably sustained to through 24-48 h post dose, compared to itk and txk which demonstrated a more rapid return to minimal to.  txk: median %to for txk rapidly increased from 0 h to 1 h post dose and peaked at 1 h, followed by a decrease until 48 h, with greater rapidity of to declination observed in the 50 mg group (minimal to by 48 h). there was a dose-dependent increase in inhibition of cd69 upregulation by ritlecitinib, and the maximum median inhibition was 48% and 70% for the ritlecitinib 50 mg and 200 mg treatment groups, respectively. for the ritlecitinib 200 mg group, cd69 inhibition was observed at 8 h, but had returned to baseline or lower by 24 h and remained low at 48 h conclusions: pd:  ritlecitinib demonstrated dose-dependent target occupancy of all 5 tec kinases, with varying levels of occupancy magnitude and duration for these 5 different kinases due to target turnover."
" the researchers recorded any medical problems the participants had during the study. participants could have had medical problems for reasons not related to the study (for example, caused by an unknown underlying disease or by chance). or, medical problems could also have been caused by a study treatment or by another medicine the participant was taking. sometimes the cause of a medical problem is unknown. by comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant. eleven (11) out of the 12 (92%) participants in this study had at least 1 medical problem. none of participants left the study because of medical problems. medical problems seen in this study are described below. below are instructions on how to read table 1. instructions for understanding table 1.  the 1st column of table 1 lists the medical problems reported during the study. all medical problems are listed.  the 2nd column tells how many of the 12 participants had medical problems after treatment a, which was nirmatrelvir/ritonavir taken on an empty stomach. next to this number is the percentage of the 12 participants in the study who reported the medical problem.  the 3rd column tells how many of the 12 participants had medical problems after treatment b, which was nirmatrelvir/ritonavir taken after a high fat meal. next to this number is the percentage of the 12 participants in the study who reported the medical problem.  using these instructions, you can see that 1 out of the 12 (8%) participants in the study had stomach discomfort after treatment a and none of the 12 (0%) participants had stomach discomfort after treatment b. ","  safety results: no participant had a serious adverse event (sae), severe adverse event (ae), dose reduction or temporary discontinuation due to aes. the most frequently reported teae was dysgeusia in both treatment groups, detected in 5 (41.7%) and 3 (25.0%) participants during the fed and fasted treatment periods, respectively. the numbers of participants with laboratory abnormalities were similar between the fed and fasted treatment groups (0-2 participants in either group). no clinically meaningful changes in vital signs measurements, ecgs or other observations related to safety were observed in this study. overall, food had a minimum impact on the systemic exposure of pf-07321332 with an approximately 1.2-fold increase in geometric mean auc for the fed treatment compared to inf the fasted treatment. peak exposure was higher in the fed treatment with a 1.6-fold increase in geometric mean c compared to the fasted treatment. the test/reference (fed/fasted) max ratios of the adjusted geometric means (90% confidence interval [ci]) for pf-07321332 auc , and c were 119.67% (108.75%, 131.68%) and 161.01% (139.05%, 186.44%), inf max respectively. mean terminal t was 7.390 hours for the fed treatment compared to 8.673 hours for the  fasted treatment. mean apparent clearance (cl/f) and apparent volume of distribution (v /f) values were 6.812 l/hr and 68.77 l, respectively, for the fed treatment compared to z 8.148 l/hr and 96.88 l, respectively, for the fasted treatment. inter-individual variability for pf-07321332 auc and c geometric means were similar inf max between the fed and fasted treatments. the geometric coefficient of variation (cv%) was 31% for both auc and c in the fed treatment period and 36% and 44%, respectively, in inf max the fasted treatment period. the test/reference (fed/fasted) ratios of the adjusted geometric means (90% ci) for pf-07321332 auc , and c were 119.67% (108.75%, 131.68%) and 161.01% inf max (139.05%, 186.44%), respectively. safety:  the safety data, including aes, laboratory abnormalities, vital signs, and ecgs indicate that pf-07321332/ritonavir has an acceptable safety profile in healthy adult participants when administered under both fed and fasted conditions."
